WO2018113201A1 - 一类色满-6-磺酰胺RORγ调节剂及其用途 - Google Patents

一类色满-6-磺酰胺RORγ调节剂及其用途 Download PDF

Info

Publication number
WO2018113201A1
WO2018113201A1 PCT/CN2017/087263 CN2017087263W WO2018113201A1 WO 2018113201 A1 WO2018113201 A1 WO 2018113201A1 CN 2017087263 W CN2017087263 W CN 2017087263W WO 2018113201 A1 WO2018113201 A1 WO 2018113201A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
group
optionally substituted
cycloalkyl
compound
Prior art date
Application number
PCT/CN2017/087263
Other languages
English (en)
French (fr)
Inventor
金秋
秦引林
苏梅
马瑞
仇亚男
Original Assignee
南京柯菲平盛辉制药有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 南京柯菲平盛辉制药有限公司 filed Critical 南京柯菲平盛辉制药有限公司
Publication of WO2018113201A1 publication Critical patent/WO2018113201A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the present invention relates to novel retinoic acid-related orphan receptor gamma (ROR ⁇ ) modulators, preparation methods thereof, pharmaceutical compositions containing the same, and their use in the treatment of ROR ⁇ -mediated inflammatory, metabolic and autoimmune diseases use.
  • ROR ⁇ retinoic acid-related orphan receptor gamma
  • RORs Retinoic acid receptor-related orphan receptors
  • RORs are a class of ligand-dependent transcription factors that are involved in reproductive development, circadian rhythm regulation, metabolic disorders, inflammation, and immune system regulation. Play an important role in the physiological and pathological process.
  • RORs are a member of the nuclear receptor superfamily, including ROR ⁇ , ROR ⁇ , and ROR ⁇ .
  • ROR ⁇ is mainly distributed in liver, skeletal muscle, skin, lung, adipose tissue, kidney, thymus, brain and blood, and is related to physiological and pathological processes such as hepatic gluconeogenesis, lipid metabolism and atherosclerosis.
  • ROR ⁇ is mainly distributed in the central nervous system, including the brain, retina and pineal gland, and is mainly related to the treatment of sensitive information in the spinal cord, thalamus and cerebellum.
  • ROR ⁇ is highly expressed in the thymus and is also distributed in the kidney, liver, heart, skeletal muscle, adipose tissue, testis, prostate, and pancreas, and is associated with autoimmune diseases such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
  • ROR ⁇ includes two subtypes of ROR ⁇ 1 and ROR ⁇ 2 (ROR ⁇ t).
  • ROR ⁇ 1 is expressed in a variety of tissues including thymus, muscle, kidney, and liver;
  • ROR ⁇ t is uniquely expressed only in cells of the immune system and plays a key role in thymus production, development of several secondary lymphoid tissues, and differentiation of Th17 lineage.
  • Th17 cells are subtypes of T helper cells that produce IL-17 and other pro-inflammatory cytokines.
  • Th17 cells play a key role in several mouse autoimmune disease models including: encephalomyelitis (EAE) and collagen-induced arthritis (CIA).
  • EAE encephalomyelitis
  • CIA collagen-induced arthritis
  • Th17 cells or their products are involved in the pathology of various human inflammation and autoimmune diseases including multiple sclerosis, rheumatoid arthritis, psoriasis, Crohn's disease, and asthma.
  • the main cause of the onset of autoimmune diseases is the intolerance of autoantigens and the development of autoinvasive effector T cells in infiltrating tissues.
  • Th17 cells are one of the important driving factors in the inflammatory process of tissue-specific autoimmunity.
  • Th17 cells are activated and are responsible for recruiting other inflammatory cells (neutrophils), which mediate the pathological changes of the target tissues. .
  • ROR ⁇ t has been reported to be a key regulator of Th17 cell differentiation, and Th17 cells have recently been found to be a subset of T helper cells that preferentially produce the cytokines IL-17A, IL-17F, IL-21 and IL-22. ROR ⁇ t induces transcription of genes encoding IL-17A and IL-17F in naive CD4+ T helper cells. ROR ⁇ t-deficient mice showed very few Th17 cells. The inhibition and deletion of ROR ⁇ t resulted in an improvement in EAE.
  • ROR ⁇ In view of the role of ROR ⁇ in the pathogenesis of disease, it is desirable to prepare compounds that modulate ROR ⁇ activity and are therefore useful in the treatment of ROR ⁇ -mediated inflammatory, metabolic and autoimmune diseases, such as respiratory diseases, asthma, chronic Obstructive pulmonary disease (COPD) and bronchitis, allergic diseases including allergic rhinitis and atopic dermatitis, cystic fibrosis, and lung allograft rejection.
  • COPD chronic Obstructive pulmonary disease
  • bronchitis allergic diseases including allergic rhinitis and atopic dermatitis, cystic fibrosis, and lung allograft rejection.
  • novel retinoic acid-related orphan receptor gamma (ROR ⁇ ) modulators a process for the preparation thereof, a pharmaceutical composition comprising the same, and their use in the treatment of ROR ⁇ -mediated inflammatory, metabolic and autoimmune The use in diseases.
  • ROR ⁇ retinoic acid-related orphan receptor gamma
  • the invention relates to a compound of the formula (I), or a stereoisomer, tautomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate or prodrug thereof:
  • R 1 and R 2 are each independently selected from the group consisting of hydrogen, halogen, hydroxy, amino, C 1 -C 6 alkyl, C 1 -C 6 alkylamino, C 1 -C 6 alkoxy, C 3 -C 8 a cycloalkyloxy group, or R 1 , R 2 combined into an oxo group;
  • R 4 is selected from hydrogen, optionally substituted C 1 -C 6 alkyl, optionally substituted C 3 -C 8 cycloalkyl, optionally substituted C 2 -C 8 heterocycloalkyl, optionally substituted -CH 2 C 3 a -C 8 cycloalkyl group, an optionally substituted C 6 -C 10 aryl group or an optionally substituted C 2 -C 10 heteroaryl group, the substituent being selected from the group consisting of hydrogen, halogen, hydroxy, amino, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl or C 3 -C 8 cycloalkyl;
  • R 5 is selected from an optionally substituted C 6 -C 10 aryl group, an optionally substituted -CH 2 C 6 -C 10 aryl group, an optionally substituted C 2 -C 10 heteroaryl group or an optionally substituted -CH 2 C 2 - a C 10 heteroaryl group, the substituent being selected from the group consisting of hydrogen, halogen, cyano, C 1 -C 6 alkyl, amino, C 1 -C 3 alkylamino, C 2 -C 8 heterocycloalkyl, C 1 - C 2 alkyl C 4 -C 8 heterocycloalkyl, C 3 -C 8 cycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, hydroxy C 1 -C 6 haloalkyl or S(O 2 )C 1 -C 6 alkyl;
  • R 6 is selected from the group consisting of hydrogen, halogen, hydroxy, amino, optionally substituted C 1 -C 6 alkyl, and the substituent is selected from hydrogen, halogen, hydroxy, amino or C 1 -C 6 alkyl;
  • R 3 is a group -(CHR 7 ) s -(Y) t -(CHR 8 ) u -R 9 ;
  • R 7 and R 8 are independently selected from the group consisting of hydrogen, C 1 -C 6 alkyl, and hydroxy;
  • Y is selected from C 1 -C 6 alkyl, NH or O;
  • R 9 is selected from optionally substituted C 2 -C 8 heterocycloalkyl, optionally substituted C 3 -C 8 cycloalkyl, optionally substituted C 6 -C 10 aryl or optionally substituted C 2 -C 10 heteroaryl a substituent selected from H, C 1 -C 6 alkyl, halogen-substituted C 1 -C 6 alkyl, hydroxy-substituted C 1 -C 6 alkyl, C 2 -C 8 heterocycloalkyl, C 3 -C 8 cycloalkyl, -S(O 2 )C 1 -C 6 alkyl, -S(O 2 )(CH 2 ) m C 3 -C 8 cycloalkyl, -S(O 2 )(CH 2 m C 2 -C 8 heterocycloalkyl, -C(O)C 1 -C 6 alkyl, -C(O)(CH 2 ) m C 3 -C 8
  • n 0, 1, 2;
  • s, t, u are independently selected from 0, 1, 2;
  • X is selected from O, NR 10 , CR 10 ;
  • R 10 is selected from the group consisting of hydrogen, C 1 -C 6 alkyl, C 2 -C 8 heterocycloalkyl, C 3 -C 8 cycloalkyl;
  • n is selected from 0 and 1.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising: a compound of formula (I), or a stereoisomer, tautomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate or prodrug thereof; One or more pharmaceutically acceptable excipients.
  • the present invention provides a compound of formula (I), or a stereoisomer, tautomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof or prodrug thereof, for use in the treatment of a ROR ⁇ -mediated disease, Use in inflammatory, metabolic or autoimmune diseases.
  • the present invention provides a compound of formula (I), or a stereoisomer, tautomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof or prodrug thereof, for use in the treatment of asthma, chronic obstructive pulmonary disease (COPD), bronchitis, allergic diseases (eg allergic rhinitis), atopic dermatitis, cystic fibrosis, lung allograft rejection, multiple sclerosis, rheumatoid arthritis, juvenile rheumatoid Arthritis, osteoarthritis, ankylosing spondylitis, systemic lupus erythematosus, psoriasis, Hashimoto's disease, pancreatitis, autoimmune diabetes, autoimmune eye disease, ulcerative colitis, Crohn's disease Inflammatory bowel disease (IBS), inflammatory bowel syndrome (IBD), Sjogren's syndrome, optic neuritis, type I diabetes, optic neuromyelitis, myas
  • the present invention provides a compound of formula (I), or a stereoisomer, tautomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof or prodrug thereof, for use in the treatment of asthma, rheumatoid joints Use in inflammation, psoriasis, ulcerative colitis or Crohn's disease.
  • the invention relates to a compound of the formula (I), or a stereoisomer, tautomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate or prodrug thereof,
  • R 5 is selected from the group consisting of benzene ring, pyridine ring, benzothiophene, pyrimidine ring, pyridazine ring, pyrazine ring, quinoline, isoquinoline, pyrrole ring, pyrazole ring, imidazole ring, a thiophene ring, a thiazole ring, a furan ring or an oxazole ring; the substituent is selected from the group consisting of hydrogen, halogen, cyano, C 1 -C 6 alkyl, C 2 -C 8 heterocycloalkyl, C 3 -C 8 cycloalkyl a C 1 -C 6 alkoxy group, a C 1 -C 6
  • R 5 is selected from an optionally substituted benzene ring, an optionally substituted benzothiophene or an optionally substituted pyridine ring; the substituent is selected from the group consisting of hydrogen, halogen, cyano, C 1 -C 6 alkyl, C 2 -C 8 Heterocycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, C 1 -C 3 alkylamino or -S(O 2 )C 1 -C 6 alkyl; further preferably, The substituent is selected from the group consisting of hydrogen, halogen, cyano, C 1 -C 4 alkyl, C 2 -C 6 heterocycloalkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, C 1 -C 3 alkylamino or -S(O 2 )C 1 -C 3 alkyl.
  • the invention relates to a compound of the formula (I), or a stereoisomer, tautomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate or prodrug thereof,
  • R 9 is selected from the group consisting of oxacyclopropane, oxetane, cyclobutane, isoxazole, tetrahydrofuran, tetrahydro-2H-pyran, azetidine, pyrrolidine, Piperidine, morpholine, pyridine, morpholin-3-one or thiomorpholine 1,1-dioxide; substituents selected from H, C 1 -C 6 alkyl, C 2 -C 8 heterocycloalkyl , C 3 -C 8 cycloalkyl, -S(O 2 )C 1 -C 6 alkyl, -S(O 2 )(CH 2 ) m C 3 -C 8 cycloalkyl,
  • R 3 is -CH 2 R 9 or -R 9 ;
  • R 9 is selected from the group of any of the following substitutions: oxirane, oxetane, cyclobutane, isoxazole, tetrahydrofuran, tetrahydrogen -2H-pyran, azetidine, pyrrolidine, piperidine, morpholine, pyridine, morpholin-3-one or thiomorpholine 1,1-dioxide; substituent selected from H, C 1 -C 6 alkyl, C 2 -C 8 heterocycloalkyl, C 3 -C 8 cycloalkyl, -S(O 2 )C 1 -C 6 alkyl, -S(O 2 )(CH 2 ) m C 3 -C 8 cycloalkyl, -S(O 2 )(CH 2 ) m C 2 -C 8 heterocycloalkyl, -C(O)C 1 -C
  • R 9 is selected from the group consisting of oxetane, cyclobutane, isoxazole, tetrahydrofuran, tetrahydro-2H-pyran, pyrrolidine, piperidine, morpholine, pyridine;
  • the substituent is selected from H, C 1 -C 6 alkyl, halogen-substituted C 1 -C 6 alkyl, C 2 -C 8 heterocycloalkyl, C 3 -C 8 cycloalkyl, -S(O 2 ) C 1 -C 6 alkyl, -S(O 2 )(CH 2 ) m C 3 -C 8 cycloalkyl, -S(O 2 )(CH 2 ) m C 2 -C 8 heterocycloalkyl, - C(O)C 1 -C 6 alkyl, -C(O)(CH 2 ) m C 3 -C 8 cycloalkyl, - C
  • the present invention relates to a compound of the formula (I), or a stereoisomer, tautomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate or prodrug thereof, wherein X is selected from O, NH or CH 2 ; more preferably X is selected from O or NH, and further preferably X is O.
  • the present invention relates to a compound of the formula (I) or a stereoisomer, tautomer thereof or a pharmaceutically acceptable salt thereof or a solvate or prodrug thereof
  • R 1 , R 2 are each independently selected from hydrogen, hydroxy, halogen, amino, C 1-3 alkyl, C 1 -C 3 alkoxy, C 3 -C 6 cycloalkyloxy or R 1 , R 2 combined It is an oxo group.
  • the present invention relates to a compound of the formula (I) or a stereoisomer, tautomer thereof or a pharmaceutically acceptable salt thereof or a solvate or prodrug thereof
  • R 4 is selected from the group consisting of hydrogen, optionally substituted C 1 -C 6 alkyl, optionally substituted C 3 -C 8 cycloalkyl, optionally substituted C 2 -C 6 heterocycloalkyl, optionally substituted -CH 2 C 3 - C 6 cycloalkyl, optionally substituted C 6 -C 10 aryl or optionally substituted C 2 -C 8 heteroaryl, the substituent being selected from hydrogen, halogen, hydroxy, amino, C 1 -C 6 alkyl or C 3- C 6 cycloalkyl; further preferably, R 4 is selected from hydrogen, optionally substituted C 1 -C 4 alkyl, optionally substituted C 3 -C 6 cycloalkyl, optionally substituted C 2 -C 6 heteroaryl, the substitu
  • the present invention relates to a compound of the formula (I) or a stereoisomer, tautomer thereof or a pharmaceutically acceptable salt thereof or a solvate or prodrug thereof
  • R 6 is selected from the group consisting of hydrogen, halogen, optionally substituted C 1 -C 6 alkyl, the substituent is selected from hydrogen, halogen, hydroxy, amino or C 1 -C 6 alkyl; further preferably R 6 is selected from hydrogen, halogen, optionally Substituted C 1 -C 3 alkyl, the substituent is selected from hydrogen, halogen, hydroxy, amino or C 1 -C 3 alkyl.
  • the invention relates to a compound of the formula (I), or a stereoisomer, tautomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate or prodrug thereof
  • X is O
  • n is 0 or 1
  • R 1 and R 2 are each independently selected from hydrogen, hydroxy, halogen, amino, C 1 -C 3 alkyl, C 1 -C 3 alkoxy, or R 1 , R 2 is combined into an oxo group
  • R 4 is selected from hydrogen, optionally substituted C 1 -C 6 alkyl, optionally substituted C 3 -C 6 cycloalkyl, optionally substituted C 4 -C 8 heterocycloalkane Any optionally substituted -CH 2 C 3 -C 8 cycloalkyl or optionally substituted C 6 -C 10 aryl group, the substituent being selected from the group consisting of hydrogen, halogen, hydroxy, amino, C 1 -C 3 alkyl or C 3
  • the present invention also provides a compound of any one of Formulas Ia-Ij, or a stereoisomer, tautomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof
  • Subgroup of drugs :
  • R 3 , R 4 , R 5 , R 6 and n are as defined above.
  • R 3 is selected from the group -(CHR 7 ) s -(Y) t -(CHR 8 ) u -R 9 ;
  • R 7 , R 8 are independently selected from hydrogen, C 1 -C 6 alkyl, hydroxy;
  • Y is selected from C 1 -C 6 alkyl, NH or O;
  • s, t, u are independently selected from 0, 1, 2;
  • R 9 is selected from the group consisting of the following substituted oxirane, oxetane, cyclobutane Alkane, isoxazole, tetrahydrofuran, tetrahydro-2H-pyran, azetidine, pyrrolidine, piperidine, morpholine, pyridine, morpholin-3-one or thiomorpholine 1,1-dioxide Substituent selected from H, C 1 -C 6 alkyl, C 2 -C 8 heterocycloalkyl, C 3 -C
  • R 4 is selected from hydrogen, optionally substituted C 1 -C 6 alkyl, optionally substituted C 3 -C 8 cycloalkyl, optionally substituted C 2 -C 6 heterocycloalkyl, optionally substituted -CH 2 C 3 a -C 8 cycloalkyl group, an optionally substituted C 6 -C 10 aryl group or an optionally substituted C 2 -C 8 heteroaryl group, the substituent group being selected from the group consisting of hydrogen, halogen, hydroxy, amino, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl or C 3 -C 6 cycloalkyl;
  • R 5 is selected from the group optionally substituted: benzene ring, pyridine ring, benzothiophene, pyrimidine ring, pyridazine ring, pyrazine ring, quinoline, isoquinoline, pyrrole ring, pyrazole ring, imidazole ring, thiophene a ring, a thiazole ring, a furan ring or an oxazole ring; the substituent is selected from the group consisting of hydrogen, halogen, cyano, C 1 -C 6 alkyl, C 2 -C 8 heterocycloalkyl, C 3 -C 8 cycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, C 1 -C 3 alkylamino or -S(O 2 )C 1 -C 6 alkyl; R 6 is selected from hydrogen, halogen, optionally Substituted C 1 -
  • the present invention provides a compound of the formula (Ia-Ie, Ih, Ii, Ij), or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof or Subgroup of solvates or prodrugs:
  • R 3 , R 4 , R 5 , R 6 and n are as defined above.
  • the present invention provides a compound of the formula (Ia-Ie, Ij), or a stereoisomer, tautomer thereof or a pharmaceutically acceptable salt thereof or a solvate thereof or Subgroup of prodrugs:
  • R 3 , R 4 , R 5 , R 6 and n are as defined above.
  • R 5 is selected from an optionally substituted benzene ring, an optionally substituted benzothiophene or an optionally substituted pyridine ring;
  • the substituent is selected from the group consisting of hydrogen, halogen, cyano, C 1 -C 6 alkyl, C 1 -C 6 alkoxy , C 1 -C 6 haloalkyl, C 1 -C 3 alkylamino or -S(O 2 )C 1 -C 6 alkyl, further preferably, the substituent is selected from the group consisting of hydrogen, halogen, cyano, C 1 -C 3 alkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkyl, C 1 -C 3 alkylamino or -S(O 2 )C 1 -C 3 alkyl;
  • R 3 is -CH 2 R 9 or -R 9 ;
  • R 9 is selected from the group optionally substituted: oxetane, cyclobutane, tetrahydrofuran, tetrahydro-2H-pyran, azetidine, Pyrrolidine, piperidine, morpholine, pyridine; substituents selected from H, C 1 -C 6 alkyl, halogen-substituted C 1 -C 6 alkyl, C 2 -C 8 heterocycloalkyl, C 3 -C 8 -cycloalkyl, -S(O 2 )C 1 -C 6 alkyl, hydroxy or halogen.
  • R 9 is selected from optionally substituted tetrahydro-2H-pyran, optionally substituted piperidine, optionally substituted oxetane or optionally substituted cyclobutane; the substituent is selected from H, C 1 -C 6 alkyl , C 2 -C 8 heterocycloalkyl, C 3 -C 8 cycloalkyl, -S(O 2 )C 1 -C 6 alkyl, hydroxy or halogen.
  • the present invention relates to a compound having the structure shown below, or a stereoisomer, tautomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate or prodrug thereof:
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising: a compound of formula (I), or a stereoisomer, tautomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate or prodrug thereof; One or more pharmaceutically acceptable excipients.
  • the present invention provides a compound of formula (I), or a stereoisomer, tautomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof or prodrug thereof, for use in the treatment of a ROR ⁇ mediated disease Use, as well as in the preparation of a medicament for the treatment of a disease mediated by ROR ⁇ .
  • diseases mediated by ROR ⁇ include, but are not limited to, inflammatory, metabolic or autoimmune diseases.
  • the present invention provides a compound of formula (I), or a stereoisomer, tautomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof or prodrug thereof, for use in the treatment of asthma, chronic obstructive pulmonary disease (COPD), bronchitis, allergic diseases (eg allergic rhinitis), atopic dermatitis, cystic fibrosis, lung allograft rejection, multiple sclerosis, rheumatoid arthritis, juvenile rheumatoid Arthritis, osteoarthritis, ankylosing spondylitis, systemic lupus erythematosus, psoriasis, Hashimoto's disease, pancreatitis, autoimmune diabetes, autoimmune eye disease, ulcerative colitis, Crohn's disease Inflammatory bowel disease (IBS), inflammatory bowel syndrome (IBD), Sjogren's syndrome, optic neuritis, type I diabetes, optic neuromyelitis, myas
  • the invention also provides a process for the preparation of a compound of the invention.
  • the compounds of the invention can be prepared by methods as shown in the synthetic scheme below.
  • all groups are as defined above unless otherwise stated.
  • TW Greene and PGM Wuts (1991) Protecting Groups in Organic Synthesis, John Wiley &Sons are used as necessary.
  • these groups are removed using methods readily apparent to those skilled in the art; the choice of such methods, as well as the reaction conditions and their order of execution, are considered to be consistent with the preparation of the compounds of the invention.
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , X and n are as defined above.
  • the present invention relates to a compound of the formula (I) or a stereoisomer, tautomer thereof or a pharmaceutically acceptable salt thereof or a solvate or prodrug thereof:
  • R 6 is H
  • R 1 and R 2 are each independently selected from the group consisting of hydrogen, halogen, hydroxy, amino, C 1 -C 6 alkyl, C 1 -C 6 alkylamino, C 1 -C 6 alkoxy, or R 1 ,R 2 combined into an oxo group;
  • R 4 is selected from hydrogen, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl or -CH 2 C 3 -C 8 cycloalkyl, wherein the alkyl or cycloalkyl group may be one or more a substituent selected from the group consisting of hydrogen, halogen, hydroxy, amino, C 1 -C 6 alkyl;
  • R 5 is selected from C 6 -C 10 aryl or C 2 -C 10 heteroaryl; wherein C 6 -C 10 aryl, C 2 -C 10 heteroaryl may be selected from one or more selected from the group consisting of hydrogen, halogen, Cyano, C 1 -C 6 alkyl, C 2 -C 8 heterocycloalkyl, C 3 -C 8 cycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, C 1 - Substituent substitution of a C 6 alkylsulfonyl group;
  • R 3 is a group -(CHR 7 ) s -(Y) t -(CHR 8 ) u -R 9 ;
  • R 7 and R 8 are independently selected from the group consisting of hydrogen, C 1 -C 6 alkyl, and hydroxy;
  • Y is selected from C 1 -C 6 alkyl, NH or O;
  • R 9 is selected from C 2 -C 8 heterocycloalkyl, C 3 -C 8 cycloalkyl, C 6 -C 10 aryl, C 2 -C 10 heteroaryl, wherein said C 2 -C 8 heterocyclic ring
  • An alkyl group, a C 3 -C 8 cycloalkyl group, a C 6 -C 10 aryl group, a C 2 -C 10 heteroaryl group may be selected from one or more selected from the group consisting of H, C 1 -C 6 alkyl, C 2 -C 8- heterocycloalkyl, C 3 -C 8 cycloalkyl, -S(O 2 )C 1 -C 6 alkyl, -S(O 2 )(CH 2 ) m C 3 -C 8 cycloalkyl, - S(O 2 )(CH 2 ) m C 2 -C 8 heterocycloalkyl, -C(O)C 1 -C 6 al
  • n 0, 1, 2;
  • s, t, u are independently selected from 0, 1, 2;
  • X is selected from O, NR 10 , CR 10 ;
  • R 10 is selected from the group consisting of hydrogen, C 1 -C 6 alkyl, C 2 -C 8 heterocycloalkyl, C 3 -C 8 cycloalkyl;
  • n is selected from 0 and 1.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising: a compound of formula (I), or a stereoisomer, tautomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate or prodrug thereof; One or more pharmaceutically acceptable excipients.
  • the present invention provides a compound of formula (I), or a stereoisomer, tautomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof or prodrug thereof, for use in the treatment of a ROR ⁇ -mediated disease, Use in inflammatory, metabolic or autoimmune diseases.
  • the present invention provides a compound of formula (I), or a stereoisomer, tautomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof or prodrug thereof, for use in the treatment of asthma, chronic obstructive pulmonary disease (COPD), bronchitis, allergic diseases (eg allergic rhinitis), atopic dermatitis, cystic fibrosis, lung allograft rejection, multiple Sclerosis, rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, systemic lupus erythematosus, psoriasis, Hashimoto's disease, pancreatitis, autoimmune diabetes, autoimmune Eye disease, ulcerative colitis, Crohn's disease, inflammatory bowel disease (IBS), inflammatory bowel syndrome (IBD), Sjogren's syndrome, optic neuritis, type I diabetes, optic neuromyelitis, severe Use in myasth
  • the present invention provides a compound of formula (I), or a stereoisomer, tautomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof or prodrug thereof, for use in the treatment of asthma, rheumatoid joints Use in inflammation, psoriasis, ulcerative colitis or Crohn's disease.
  • the present invention relates to a compound of the formula (I) or a stereoisomer, tautomer thereof or a pharmaceutically acceptable salt thereof or a solvate or prodrug thereof:
  • R 6 is H
  • R 1 and R 2 are each independently selected from the group consisting of hydrogen, halogen, hydroxy, amino, C 1 -C 6 alkyl, C 1 -C 6 alkylamino, C 1 -C 6 alkoxy, or R 1 ,R 2 combined into an oxo group;
  • R 4 is selected from hydrogen, optionally substituted C 1 -C 6 alkyl, optionally substituted C 3 -C 8 cycloalkyl or optionally substituted -CH 2 C 3 -C 8 cycloalkyl, the substituent being selected from hydrogen, Halogen, hydroxy, amino or C 1 -C 6 alkyl;
  • R 5 is selected from: an optionally substituted C 6 -C 10 aryl group or an optionally substituted C 2 -C 10 heteroaryl group, the substituent being selected from the group consisting of hydrogen, halogen, cyano, C 1 -C 6 alkyl, C 2 - C 8 heterocycloalkyl, C 3 -C 8 cycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl or -S(O 2 )C 1 -C 6 alkyl;
  • R 3 is a group -(CHR 7 ) s -(Y) t -(CHR 8 ) u -R 9 ;
  • R 7 and R 8 are independently selected from the group consisting of hydrogen, C 1 -C 6 alkyl, and hydroxy;
  • Y is selected from C 1 -C 6 alkyl, NH or O;
  • R 9 is selected from optionally substituted C 2 -C 8 heterocycloalkyl, optionally substituted C 3 -C 8 cycloalkyl, optionally substituted C 6 -C 10 aryl or optionally substituted C 2 -C 10 heteroaryl a substituent selected from the group consisting of H, C 1 -C 6 alkyl, C 2 -C 8 heterocycloalkyl, C 3 -C 8 cycloalkyl, -S(O 2 )C 1 -C 6 alkyl, - S(O 2 )(CH 2 ) m C 3 -C 8 cycloalkyl, -S(O 2 )(CH 2 ) m C 2 -C 8 heterocycloalkyl, -C(O) C 1 -C 6 Alkyl, -C(O)(CH 2 ) m C 3 -C 8 cycloalkyl, -C(O)(CH 2 ) m C 2 -C 8 heterocycloal
  • n 0, 1, 2;
  • s, t, u are independently selected from 0, 1, 2;
  • X is selected from O, NR 10 , CR 10 ;
  • R 10 is selected from the group consisting of hydrogen, C 1 -C 6 alkyl, C 2 -C 8 heterocycloalkyl, C 3 -C 8 cycloalkyl;
  • n is selected from 0 and 1.
  • the invention relates to a compound of the formula (I), or a stereoisomer, tautomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate or prodrug thereof,
  • R 5 is selected from the group consisting of benzene ring, pyridine ring, pyrimidine ring, pyridazine ring, pyrazine ring, quinoline, isoquinoline, pyrrole ring, pyrazole ring, imidazole ring, thiophene ring, thiazole a ring, a furan ring or an oxazole ring;
  • the substituent is selected from the group consisting of hydrogen, halogen, cyano, C 1 -C 6 alkyl, C 2 -C 8 heterocycloalkyl, C 3 -C 8 cycloalkyl, C 1 - C 6 alkoxy, C 1 -C 6 haloalkyl or C 1 -C 6 al
  • R 5 is selected from an optionally substituted benzene ring or an optionally substituted pyridine ring; the substituent is selected from the group consisting of hydrogen, halogen, cyano, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 - C 6 haloalkyl or C 1 -C 6 alkylsulfonyl; the substituent is more preferably selected from the group consisting of hydrogen, halogen, cyano, C 1 -C 3 alkyl, C 1 -C 3 alkoxy, C 1 -C 3- haloalkyl or -S(O 2 )C 1 -C 3 alkyl.
  • the present invention relates to a compound of the formula (I), or a stereoisomer, tautomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate or prodrug thereof, wherein R 9 is selected from the group optionally substituted: oxirane, oxetane, tetrahydrofuran, tetrahydro-2H-pyran, azetidine, pyrrolidine, piperidine, morpholine, pyridine, Oroxazinone or thiomorpholine 1,1-dioxide; substituent selected from H, C 1 -C 6 alkyl, C 2 -C 8 heterocycloalkyl, C 3 -C 8 cycloalkyl , -S(O 2 )C 1 -C 6 alkyl, -S(O 2 )(CH 2 ) m C 3 -C 8 cycloalkyl, -S(O 2 )(CH 2 ) m C 2 -C 8 cycl
  • R 3 is -CH 2 R 9 or -R 9 .
  • R 9 is selected from the group optionally substituted: oxirane, oxetane, tetrahydrofuran, tetrahydro-2H-pyran, azetidine, pyrrolidine, piperidine, morpholine, pyridine, Oroxazinone or thiomorpholine 1,1-dioxide; substituent selected from H, C 1 -C 6 alkyl, C 2 -C 8 heterocycloalkyl, C 3 -C 8 cycloalkyl , -S(O 2 )C 1 -C 6 alkyl, -S(O 2 )(CH 2 ) m C 3 -C 8 cycloalkyl, -S(O 2 )(CH 2 ) m C 2 -C 8- heterocycloalkyl, -C(O)C 1 -C 6 alkyl, -C(O)(CH 2 )(
  • R 9 is selected from the group consisting of oxetane, tetrahydrofuran, tetrahydro-2H-pyran, pyrrolidine, piperidine, morpholine, pyridine; the substituent is selected from H, C 1 -C 6 alkyl, C 2 -C 8 heterocycloalkyl, C 3 -C 8 cycloalkyl, -S(O 2 )C 1 -C 6 alkyl, -S(O 2 )(CH 2 ) m C 3 -C 8 cycloalkyl, -S(O 2 )(CH 2 ) m C 2 -C 8 heterocycloalkyl, -C(O)C 1 -C 6 alkyl, -C(O)(CH 2 ) m C 3 -C 8 cycloalkyl, -C(O)(CH 2 ) m C 2 -C 8 heterocycloalkyl, hydroxy or halogen, the substituent is
  • the present invention relates to a compound of the formula (I), or a stereoisomer, tautomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate or prodrug thereof, wherein X is selected from O, NH or CH 2 ; more preferably X is selected from O or NH, and further preferably X is O.
  • the present invention relates to a compound of the formula (I) or a stereoisomer, tautomer thereof or a pharmaceutically acceptable salt thereof or a solvate or prodrug thereof,
  • R 1 ⁇ R 2 is independently selected from hydrogen, hydroxy, halogen, amino, C 1 -C 3 alkyl, C 1 -C 3 alkoxy, or R 1 and R 2 are combined to form an oxo group.
  • the present invention relates to a compound of the formula (I) or a stereoisomer, tautomer thereof or a pharmaceutically acceptable salt thereof or a solvate or prodrug thereof,
  • R 4 is selected from the group consisting of hydrogen, optionally substituted C 1 -C 6 alkyl or optionally substituted C 3 -C 8 cycloalkyl, the substituent being selected from hydrogen, halogen, hydroxy, amino or C 1 -C 6 alkyl.
  • the invention relates to a compound of the formula (I), or a stereoisomer, tautomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate or prodrug thereof
  • X is selected from O or NH
  • R 5 is selected from an optionally substituted benzene ring or an optionally substituted pyridine ring
  • the substituent is selected from the group consisting of hydrogen, halogen, cyano, C 1 -C 6 alkyl, C 1 -C 6 Alkoxy, C 1 -C 6 haloalkyl or C 1 -C 6 alkylsulfonyl
  • R 3 is -CH 2 R 9 or -R 9
  • R 9 is selected from the group optionally substituted: oxirane , oxetane, tetrahydrofuran, tetrahydro-2H-pyran, pyrrolidine, piperidine, morpholine, pyridine, morpholin-3-one or
  • the invention relates to a compound of the formula (I), or a stereoisomer, tautomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate or prodrug thereof
  • X is selected from O
  • R 5 is selected from an optionally substituted benzene ring or an optionally substituted pyridine ring
  • the substituent is selected from the group consisting of hydrogen, halogen, cyano, C 1 -C 6 alkyl, C 1 -C 6 alkoxy a C 1 -C 6 haloalkyl group or a C 1 -C 6 alkylsulfonyl group
  • R 3 is -CH 2 R 9 or -R 9
  • R 9 is selected from the following groups optionally substituted: oxirane, oxygen Heterocyclobutane, tetrahydrofuran, tetrahydro-2H-pyran, pyrrolidine, piperidine, morpholine, pyridine, morpholin
  • the invention relates to a compound of the formula (I), or a stereoisomer, tautomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate or prodrug thereof
  • X is O
  • n is 0 or 1
  • R 1 and R 2 are each independently selected from the group consisting of hydrogen, hydroxy, halogen, amino, C 1-3 alkyl, C 1 -C 3 alkoxy, or R 1 And R 2 is bonded to an oxo group
  • R 4 is selected from hydrogen, optionally substituted C 1 -C 6 alkyl or optionally substituted C 3 -C 6 cycloalkyl, and the substituent is selected from hydrogen, halogen, hydroxy, amino or C 1 -C 3 alkyl
  • R 5 is selected from an optionally substituted benzene ring or an optionally substituted pyridine ring
  • the substituent is selected from the group consisting of hydrogen, halogen, cyano, C 1 -C 3 alkyl
  • the present invention further provides a compound of the formula (I aj j), or a stereoisomer, tautomer thereof or a pharmaceutically acceptable salt thereof, or a solvate thereof or a prodrug thereof Subgroup:
  • R 3 , R 4 , R 5 and n are as defined above.
  • R 3 is selected from the group -(CHR 7 ) s -(Y) t -(CHR 8 ) u -R 9 .
  • R 7 , R 8 are independently selected from hydrogen, C 1 -C 6 alkyl, hydroxy;
  • Y is selected from C 1 -C 6 alkyl, NH or O;
  • s, t, u are independently selected from 0, 1, 2;
  • R 9 is selected from the group optionally substituted: oxirane, oxetane, tetrahydrofuran, tetrahydro-2H-pyran, azetidine, pyrrolidine, piperidine, morpholine, pyridine, Oroxazinone or thiomorpholine 1,1-dioxide; substituent selected from H, C 1 -C 6 alkyl, C 2 -C 8 heterocycloalkyl, C 3 -C 8 cycloalkyl , -S(O 2 )C 1 -
  • R 4 is selected from hydrogen, optionally substituted C 1 -C 6 alkyl, optionally substituted C 3 -C 8 cycloalkyl or optionally substituted -CH 2 C 3 -C 8 cycloalkyl, the substituent being selected from hydrogen, Halogen, hydroxy, amino or C 1 -C 6 alkyl;
  • R 5 is selected from the group consisting of benzene ring, pyridine ring, pyrimidine ring, pyridazine ring, pyrazine ring, quinoline, isoquinoline, pyrrole ring, pyrazole ring, imidazole ring, thiophene ring, thiazole ring a furan ring or an oxazole ring; the substituent is selected from the group consisting of hydrogen, halogen, cyano, C 1 -C 6 alkyl, C 2 -C 8 heterocycloalkyl, C 3 -C 8 cycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl or C 1 -C 6 alkylsulfonyl.
  • the present invention provides a compound of the formula (Ia-Ie, Ih, Ii, Ij), or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof or Subgroup of solvates or prodrugs:
  • R 3 , R 4 , R 5 and n are as defined above.
  • the present invention provides a compound of the formula (Ia-Ie, Ij), or a stereoisomer, tautomer thereof or a pharmaceutically acceptable salt thereof or a solvate thereof or Subgroup of prodrugs:
  • R 3 , R 4 , R 5 and n are as defined above.
  • R 5 is selected from an optionally substituted benzene ring or an optionally substituted pyridine ring; the substituent is selected from the group consisting of hydrogen, halogen, cyano, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkane Or a C 1 -C 6 alkylsulfonyl group;
  • R 3 is -CH 2 R 9 or -R 9 .
  • R 9 is selected from the group optionally substituted: oxetane, tetrahydrofuran, tetrahydro-2H-pyran, azetidine, pyrrolidine, piperidine, morpholine, pyridine; the substituent is selected from H, C 1 -C 6 alkyl, C 2 -C 8 heterocycloalkyl, C 3 -C 8 cycloalkyl, -S(O 2 )C 1 -C 6 alkyl, hydroxy or halogen.
  • R 5 is selected from an optionally substituted benzene ring or an optionally substituted pyridine ring; the substituent is selected from the group consisting of hydrogen, halogen, cyano, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkane Or a C 1 -C 6 alkylsulfonyl group;
  • R 3 is -CH 2 R 9 or -R 9 .
  • R 9 is selected from optionally substituted tetrahydro-2H-pyran or optionally substituted piperidine; the substituent is selected from H, C 1 -C 6 alkyl, C 2 -C 8 heterocycloalkyl, C 3 -C 8 Cycloalkyl, -S(O 2 )C 1 -C 6 alkyl, hydroxy or halogen.
  • the present invention relates to a compound having the structure shown below or a stereoisomer thereof, and a mutual transformation
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising: a compound of formula (I), or a stereoisomer, tautomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate or prodrug thereof; One or more pharmaceutically acceptable excipients.
  • the present invention provides a compound of formula (I), or a stereoisomer, tautomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof or prodrug thereof, for use in the treatment of a ROR ⁇ mediated disease Use, as well as in the preparation of a medicament for the treatment of a disease mediated by ROR ⁇ .
  • diseases mediated by ROR ⁇ include, but are not limited to, inflammatory, metabolic or autoimmune diseases.
  • the present invention provides a compound of formula (I), or a stereoisomer, tautomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof or prodrug thereof, for use in the treatment of asthma, chronic obstructive pulmonary disease (COPD), bronchitis, allergic diseases (eg allergic rhinitis), atopic dermatitis, cystic fibrosis, lung allograft rejection, multiple sclerosis, rheumatoid arthritis, juvenile rheumatoid Arthritis, osteoarthritis, ankylosing spondylitis, systemic lupus erythematosus, psoriasis, Hashimoto's disease, pancreatitis, autoimmune diabetes, autoimmune eye disease, ulcerative colitis, Crohn's disease Inflammatory bowel disease (IBS), inflammatory bowel syndrome (IBD), Sjogren's syndrome, optic neuritis, type I diabetes, optic neuromyelitis, myas
  • the invention also provides a process for the preparation of a compound of the invention.
  • the compounds of the invention can be prepared by methods as shown in the synthetic scheme below.
  • all groups are as defined above unless otherwise stated.
  • TW Greene and PGM Wuts (1991) Protecting Groups in Organic Synthesis, John Wiley &Sons are used as necessary.
  • these groups are removed using methods readily apparent to those skilled in the art; the choice of such methods, as well as the reaction conditions and their order of execution, are considered to be consistent with the preparation of the compounds of the invention.
  • R 1 , R 2 , R 3 , R 4 , R 5 , X and n are as defined above.
  • the present invention relates to a compound of the formula (I) or a stereoisomer, tautomer thereof or a pharmaceutically acceptable salt thereof or a solvate or prodrug thereof:
  • R 6 is H
  • R 1 and R 2 are each independently selected from the group consisting of hydrogen, halogen, hydroxy, amino, C 1 -C 6 alkyl, C 1 -C 6 alkylamino, C 1 -C 6 alkoxy, or R 1 ,R 2 combined into an oxo group;
  • R 4 is selected from an optionally substituted C 1 -C 6 alkyl group, an optionally substituted C 3 -C 8 cycloalkyl group or an optionally substituted —CH 2 C 3 -C 8 cycloalkyl group, and the substituent is selected from C 1 -C 6 haloalkyl or C 3 -C 8 cycloalkyl;
  • R 5 is selected from an optionally substituted C 6 -C 10 aryl group or an optionally substituted C 2 -C 10 heteroaryl group selected from hydrogen, halogen, cyano, C 1 -C 6 alkyl, C 2 -C 8 heterocycloalkyl, C 3 -C 8 cycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl or -S(O 2 )C 1 -C 6 alkyl;
  • R 3 is a group -(CHR 7 ) s -(Y) t -(CHR 8 ) u -R 9 ;
  • R 7 and R 8 are independently selected from the group consisting of hydrogen, C 1 -C 6 alkyl, and hydroxy;
  • Y is selected from C 1 -C 6 alkyl, NH or O;
  • R 9 is selected from optionally substituted C 2 -C 8 heterocycloalkyl, optionally substituted C 3 -C 8 cycloalkyl, optionally substituted C 6 -C 10 aryl or optionally substituted C 2 -C 10 heteroaryl a substituent selected from the group consisting of H, C 1 -C 6 alkyl, C 2 -C 8 heterocycloalkyl, C 3 -C 8 cycloalkyl, -S(O 2 )C 1 -C 6 alkyl, - S(O 2 )(CH 2 ) m C 3 -C 8 cycloalkyl, -S(O 2 )(CH 2 ) m C 2 -C 8 heterocycloalkyl, -C(O)C 1 -C 6 Alkyl, -C(O)(CH 2 ) m C 3 -C 8 cycloalkyl, -C(O)(CH 2 ) m C 2 -C 8 heterocycloal
  • n 0, 1, 2;
  • s, t, u are independently selected from 0, 1, 2;
  • X is selected from O, NR 10 , CR 10 ;
  • R 10 is selected from the group consisting of hydrogen, C 1 -C 6 alkyl, C 2 -C 8 heterocycloalkyl, C 3 -C 8 cycloalkyl;
  • n is selected from 0 and 1.
  • the present invention relates to a compound of the formula (I) or a stereoisomer, tautomer thereof or a pharmaceutically acceptable salt thereof or a solvate or prodrug thereof:
  • R 6 is H
  • R 1 and R 2 are each independently selected from the group consisting of hydrogen, halogen, hydroxy, amino, C 1 -C 6 alkyl, C 1 -C 6 alkylamino, C 1 -C 6 alkoxy, or R 1 ,R 2 combined into an oxo group;
  • R 4 is selected from hydrogen, optionally substituted C 1 -C 6 alkyl, optionally substituted C 3 -C 8 cycloalkyl or optionally substituted -CH 2 C 3 -C 8 cycloalkyl, the substituent being selected from hydrogen, Halogen, hydroxy, amino or C 1 -C 6 alkyl;
  • R 5 is selected from: an optionally substituted C 6 -C 10 aryl group or an optionally substituted C 2 -C 10 heteroaryl group, the substituent group being selected from the group consisting of an amino group, a C 1 -C 3 alkylamino group, a C 1 -C 2 alkane a C 4 -C 8 heterocycloalkyl group or a hydroxy C 1 -C 6 haloalkyl group;
  • R 3 is a group -(CHR 7 ) s -(Y) t -(CHR 8 ) u -R 9 ;
  • R 7 and R 8 are independently selected from the group consisting of hydrogen, C 1 -C 6 alkyl, and hydroxy;
  • Y is selected from C 1 -C 6 alkyl, NH or O;
  • R 9 is selected from optionally substituted C 2 -C 8 heterocycloalkyl, optionally substituted C 3 -C 8 cycloalkyl, optionally substituted C 6 -C 10 aryl or optionally substituted C 2 -C 10 heteroaryl a substituent selected from the group consisting of H, C 1 -C 6 alkyl, C 2 -C 8 heterocycloalkyl, C 3 -C 8 cycloalkyl, -S(O 2 )C 1 -C 6 alkyl, - S(O 2 )(CH 2 ) m C 3 -C 8 cycloalkyl, -S(O 2 )(CH 2 ) m C 2 -C 8 heterocycloalkyl, -C(O)C 1 -C 6 Alkyl, -C(O)(CH 2 ) m C 3 -C 8 cycloalkyl, -C(O)(CH 2 ) m C 2 -C 8 heterocycloal
  • n 0, 1, 2;
  • s, t, u are independently selected from 0, 1, 2;
  • X is selected from O, NR 10 , CR 10 ;
  • R 10 is selected from the group consisting of hydrogen, C 1 -C 6 alkyl, C 2 -C 8 heterocycloalkyl, C 3 -C 8 cycloalkyl;
  • n is selected from 0 and 1.
  • the present invention relates to a compound of the formula (I) or a stereoisomer, tautomer thereof or a pharmaceutically acceptable salt thereof or a solvate or prodrug thereof:
  • R 6 is H
  • R 1 and R 2 are each independently selected from the group consisting of hydrogen, halogen, hydroxy, amino, C 1 -C 6 alkyl, C 1 -C 6 alkylamino, C 1 -C 6 alkoxy, or R 1 ,R 2 combined into an oxo group;
  • R 4 is selected from hydrogen, optionally substituted C 1 -C 6 alkyl, optionally substituted C 3 -C 8 cycloalkyl or optionally substituted -CH 2 C 3 -C 8 cycloalkyl, the substituent being selected from hydrogen, Halogen, hydroxy, amino or C 1 -C 6 alkyl;
  • R 5 is selected from: an optionally substituted C 6 -C 10 aryl group or an optionally substituted C 2 -C 10 heteroaryl group, the substituent being selected from the group consisting of hydrogen, halogen, cyano, C 1 -C 6 alkyl, C 2 - C 8 heterocycloalkyl, C 3 -C 8 cycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl or -S(O 2 )C 1 -C 6 alkyl;
  • R 3 is a group -(CHR 7 ) s -(Y) t -(CHR 8 ) u -R 9 ;
  • R 7 and R 8 are independently selected from the group consisting of hydrogen, C 1 -C 6 alkyl, and hydroxy;
  • Y is selected from C 1 -C 6 alkyl, NH or O;
  • R 9 is selected from optionally substituted C 2 -C 8 heterocycloalkyl, optionally substituted C 3 -C 8 cycloalkyl, optionally substituted C 6 -C 10 aryl or optionally substituted C 2 -C 10 heteroaryl a substituent selected from a halogen-substituted C 1 -C 6 alkyl group or a hydroxy-substituted C 1 -C 6 alkyl group;
  • n 0, 1, 2;
  • s, t, u are independently selected from 0, 1, 2;
  • X is selected from O, NR 10 , CR 10 ;
  • R 10 is selected from the group consisting of hydrogen, C 1 -C 6 alkyl, C 2 -C 8 heterocycloalkyl, C 3 -C 8 cycloalkyl;
  • n is selected from 0 and 1.
  • the compound of the present invention having the structure of the formula (I), or a stereoisomer, tautomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate or prodrug thereof, may also be:
  • R 6 is H
  • R 1 and R 2 are each independently selected from a C 3 -C 8 cycloalkyloxy group
  • R 4 is selected from hydrogen, optionally substituted C 1 -C 6 alkyl, optionally substituted C 3 -C 8 cycloalkyl, optionally substituted C 2 -C 8 heterocycloalkyl, optionally substituted -CH 2 C 3 a -C 8 cycloalkyl group, an optionally substituted C 6 -C 10 aryl group or an optionally substituted C 2 -C 10 heteroaryl group, the substituent being selected from the group consisting of hydrogen, halogen, hydroxy, amino, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl or C 3 -C 8 cycloalkyl;
  • R 5 is selected from an optionally substituted C 6 -C 10 aryl group, an optionally substituted -CH 2 C 6 -C 10 aryl group, an optionally substituted C 2 -C 10 heteroaryl group or an optionally substituted -CH 2 C 2 - a C 10 heteroaryl group, the substituent being selected from the group consisting of hydrogen, halogen, cyano, C 1 -C 6 alkyl, amino, C 1 -C 3 alkylamino, C 2 -C 8 heterocycloalkyl, C 1 - C 2 alkyl C 4 -C 8 heterocycloalkyl, C 3 -C 8 cycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, hydroxy C 1 -C 6 haloalkyl or S(O 2 )C 1 -C 6 alkyl;
  • R 3 is a group -(CHR 7 ) s -(Y) t -(CHR 8 ) u -R 9 ;
  • R 7 and R 8 are independently selected from the group consisting of hydrogen, C 1 -C 6 alkyl, and hydroxy;
  • Y is selected from C 1 -C 6 alkyl, NH or O;
  • R 9 is selected from optionally substituted C 2 -C 8 heterocycloalkyl, optionally substituted C 3 -C 8 cycloalkyl, optionally substituted C 6 -C 10 aryl or optionally substituted C 2 -C 10 heteroaryl a substituent selected from H, C 1 -C 6 alkyl, halogen-substituted C 1 -C 6 alkyl, hydroxy-substituted C 1 -C 6 alkyl, C 2 -C 8 heterocycloalkyl, C 3 -C 8 cycloalkyl, -S(O 2 )C 1 -C 6 alkyl, -S(O 2 )(CH 2 ) m C 3 -C 8 cycloalkyl, -S(O 2 )(CH 2 m C 2 -C 8 heterocycloalkyl, -C(O)C 1 -C 6 alkyl, -C(O)(CH 2 ) m C 3 -C 8
  • n 0, 1, 2;
  • s, t, u are independently selected from 0, 1, 2;
  • X is selected from O, NR 10 , CR 10 ;
  • R 10 is selected from the group consisting of hydrogen, C 1 -C 6 alkyl, C 2 -C 8 heterocycloalkyl, C 3 -C 8 cycloalkyl;
  • n is selected from 0 and 1.
  • the compound of the present invention having the structure of the formula (I), or a stereoisomer, tautomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate or prodrug thereof, may also be:
  • R 6 is H
  • R 1 and R 2 are each independently selected from the group consisting of hydrogen, halogen, hydroxy, amino, C 1 -C 6 alkyl, C 1 -C 6 alkylamino, C 1 -C 6 alkoxy, C 3 -C 8 a cycloalkyloxy group, or R 1 , R 2 combined into an oxo group;
  • R 4 is selected from optionally substituted C 2 -C 8 heterocycloalkyl, optionally substituted C 6 -C 10 aryl or optionally substituted C 2 -C 10 heteroaryl, the substituent being selected from the group consisting of hydrogen, halogen, hydroxy, An amino group, a C 1 -C 6 alkyl group, a C 1 -C 6 haloalkyl group or a C 3 -C 8 cycloalkyl group;
  • R 5 is selected from an optionally substituted C 6 -C 10 aryl group, an optionally substituted -CH 2 C 6 -C 10 aryl group, an optionally substituted C 2 -C 10 heteroaryl group or an optionally substituted -CH 2 C 2 - a C 10 heteroaryl group, the substituent being selected from the group consisting of hydrogen, halogen, cyano, C 1 -C 6 alkyl, amino, C 1 -C 3 alkylamino, C 2 -C 8 heterocycloalkyl, C 1 - C 2 alkyl C 4 -C 8 heterocycloalkyl, C 3 -C 8 cycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, hydroxy C 1 -C 6 haloalkyl or S(O 2 )C 1 -C 6 alkyl;
  • R 3 is a group -(CHR 7 ) s -(Y) t -(CHR 8 ) u -R 9 ;
  • R 7 and R 8 are independently selected from the group consisting of hydrogen, C 1 -C 6 alkyl, and hydroxy;
  • Y is selected from C 1 -C 6 alkyl, NH or O;
  • R 9 is selected from optionally substituted C 2 -C 8 heterocycloalkyl, optionally substituted C 3 -C 8 cycloalkyl, optionally substituted C 6 -C 10 aryl or optionally substituted C 2 -C 10 heteroaryl a substituent selected from H, C 1 -C 6 alkyl, halogen-substituted C 1 -C 6 alkyl, hydroxy-substituted C 1 -C 6 alkyl, C 2 -C 8 heterocycloalkyl, C 3 -C 8 cycloalkyl, -S(O 2 )C 1 -C 6 alkyl, -S(O 2 )(CH 2 ) m C 3 -C 8 cycloalkyl, -S(O 2 )(CH 2 m C 2 -C 8 heterocycloalkyl, -C(O)C 1 -C 6 alkyl, -C(O)(CH 2 ) m C 3 -C 8
  • n 0, 1, 2;
  • s, t, u are independently selected from 0, 1, 2;
  • X is selected from O, NR 10 , CR 10 ;
  • R 10 is selected from the group consisting of hydrogen, C 1 -C 6 alkyl, C 2 -C 8 heterocycloalkyl, C 3 -C 8 cycloalkyl;
  • n is selected from 0 and 1.
  • the compound of the present invention having the structure of the formula (I), or a stereoisomer, tautomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate or prodrug thereof, may also be:
  • R 6 is H
  • R 1 and R 2 are each independently selected from the group consisting of hydrogen, halogen, hydroxy, amino, C 1 -C 6 alkyl, C 1 -C 6 alkylamino, C 1 -C 6 alkoxy, C 3 -C 8 a cycloalkyloxy group, or R 1 , R 2 combined into an oxo group;
  • R 4 is selected from hydrogen, optionally substituted C 1 -C 6 alkyl, optionally substituted C 3 -C 8 cycloalkyl, optionally substituted C 2 -C 8 heterocycloalkyl, optionally substituted -CH 2 C 3 a -C 8 cycloalkyl group, an optionally substituted C 6 -C 10 aryl group or an optionally substituted C 2 -C 10 heteroaryl group, the substituent being selected from the group consisting of hydrogen, halogen, hydroxy, amino, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl or C 3 -C 8 cycloalkyl;
  • R 5 is selected from optionally substituted -CH 2 C 6 -C 10 aryl, optionally substituted -CH 2 C 2 -C 10 heteroaryl, the substituent is selected from the group consisting of hydrogen, halogen, cyano, C 1 -C 6 alkane a base, an amino group, a C 1 -C 3 alkylamino group, a C 2 -C 8 heterocycloalkyl group, a C 1 -C 2 alkyl C 4 -C 8 heterocycloalkyl group, a C 3 -C 8 cycloalkyl group, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, hydroxy C 1 -C 6 haloalkyl or -S(O 2 )C 1 -C 6 alkyl;
  • R 3 is a group -(CHR 7 ) s -(Y) t -(CHR 8 ) u -R 9 ;
  • R 7 and R 8 are independently selected from the group consisting of hydrogen, C 1 -C 6 alkyl, and hydroxy;
  • Y is selected from C 1 -C 6 alkyl, NH or O;
  • R 9 is selected from optionally substituted C 2 -C 8 heterocycloalkyl, optionally substituted C 3 -C 8 cycloalkyl, optionally substituted C 6 -C 10 aryl or optionally substituted C 2 -C 10 heteroaryl a substituent selected from H, C 1 -C 6 alkyl, halogen-substituted C 1 -C 6 alkyl, hydroxy-substituted C 1 -C 6 alkyl, C 2 -C 8 heterocycloalkyl, C 3 -C 8 cycloalkyl, -S(O 2 )C 1 -C 6 alkyl, -S(O 2 )(CH 2 ) m C 3 -C 8 cycloalkyl, -S(O 2 )(CH 2 m C 2 -C 8 heterocycloalkyl, -C(O)C 1 -C 6 alkyl, -C(O)(CH 2 ) m C 3 -C 8
  • n 0, 1, 2;
  • s, t, u are independently selected from 0, 1, 2;
  • X is selected from O, NR 10 , CR 10 ;
  • R 10 is selected from the group consisting of hydrogen, C 1 -C 6 alkyl, C 2 -C 8 heterocycloalkyl, C 3 -C 8 cycloalkyl;
  • n is selected from 0 and 1.
  • the compound of the present invention having the structure of the formula (I), or a stereoisomer, tautomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate or prodrug thereof, may also be:
  • R 1 and R 2 are each independently selected from the group consisting of hydrogen, halogen, hydroxy, amino, C 1 -C 6 alkyl, C 1 -C 6 alkylamino, C 1 -C 6 alkoxy, C 3 -C 8 a cycloalkyloxy group, or R 1 , R 2 combined into an oxo group;
  • R 4 is selected from hydrogen, optionally substituted C 1 -C 6 alkyl, optionally substituted C 3 -C 8 cycloalkyl, optionally substituted C 2 -C 8 heterocycloalkyl, optionally substituted -CH 2 C 3 a -C 8 cycloalkyl group, an optionally substituted C 6 -C 10 aryl group or an optionally substituted C 2 -C 10 heteroaryl group, the substituent being selected from the group consisting of hydrogen, halogen, hydroxy, amino, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl or C 3 -C 8 cycloalkyl;
  • R 5 is selected from an optionally substituted C 6 -C 10 aryl group, an optionally substituted -CH 2 C 6 -C 10 aryl group, an optionally substituted C 2 -C 10 heteroaryl group or an optionally substituted -CH 2 C 2 - a C 10 heteroaryl group, the substituent being selected from the group consisting of hydrogen, halogen, cyano, C 1 -C 6 alkyl, amino, C 1 -C 3 alkylamino, C 2 -C 8 heterocycloalkyl, C 1 - C 2 alkyl C 4 -C 8 heterocycloalkyl, C 3 -C 8 cycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, hydroxy C 1 -C 6 haloalkyl or S(O 2 )C 1 -C 6 alkyl;
  • R 6 is selected from the group consisting of halogen, hydroxy, amino, optionally substituted C 1 -C 6 alkyl, and the substituent is selected from hydrogen, halogen, hydroxy, amino or C 1 -C 6 alkyl;
  • R 3 is a group -(CHR 7 ) s -(Y) t -(CHR 8 ) u -R 9 ;
  • R 7 and R 8 are independently selected from the group consisting of hydrogen, C 1 -C 6 alkyl, and hydroxy;
  • Y is selected from C 1 -C 6 alkyl, NH or O;
  • R 9 is selected from optionally substituted C 2 -C 8 heterocycloalkyl, optionally substituted C 3 -C 8 cycloalkyl, optionally substituted C 6 -C 10 aryl or optionally substituted C 2 -C 10 heteroaryl a substituent selected from H, C 1 -C 6 alkyl, halogen-substituted C 1 -C 6 alkyl, hydroxy-substituted C 1 -C 6 alkyl, C 2 -C 8 heterocycloalkyl, C 3 -C 8 cycloalkyl, -S(O 2 )C 1 -C 6 alkyl, -S(O 2 )(CH 2 ) m C 3 -C 8 cycloalkyl, -S(O 2 )(CH 2 m C 2 -C 8 heterocycloalkyl, -C(O)C 1 -C 6 alkyl, -C(O)(CH 2 ) m C 3 -C 8
  • n 0, 1, 2;
  • s, t, u are independently selected from 0, 1, 2;
  • X is selected from O, NR 10 , CR 10 ;
  • R 10 is selected from the group consisting of hydrogen, C 1 -C 6 alkyl, C 2 -C 8 heterocycloalkyl, C 3 -C 8 cycloalkyl;
  • n is selected from 0 and 1.
  • R 3 , R 4 , R 5 , R 6 and n may be as described above.
  • Alkyl means a saturated aliphatic hydrocarbon group. A straight or branched chain group of 1 to 20 carbon atoms is included.
  • C 1 -C 6 alkyl means a medium-sized alkyl group having 1 to 6 carbon atoms, such as methyl, ethyl, propyl, 2-propyl, n-butyl, isobutyl, tert-butyl, pentyl Wait.
  • the alkyl group may be substituted or unsubstituted, and when substituted, preferred groups are: halogen, C 2 -C 6 alkenyl, C 6 -C 10 aryl, C 5 -C 10 heteroaryl, halogen C 1 -C 6 alkyl, 4 to 8 membered heteroalicyclic, hydroxy, C 1 -C 6 alkoxy, C 6 -C 10 aryloxy.
  • Alkylamino refers to a group in which one or two hydrogen atoms of the amino group are replaced by an alkyl group. Including an amino group substituted with a straight, branched or cyclic alkyl group, such as methylamino, dimethylamino, ethylamino, n-propylamino, isopropylamino, n-butylamino, isobutylamino, tert-butylamino, ring Propylamino, cyclobutylamino, pentylamino and the like. Preferred are lower straight, branched or cyclic alkyl substituted amino groups containing from 1 to 4 carbon atoms.
  • Cycloalkyl means a 3 to 8 membered all-carbon monocyclic, all-carbon 5/6 or 6/6-membered fused or polycyclic fused ring ("thickened” ring means each in the system The ring shares an adjacent pair of carbon atoms) with other rings in the system, one of which Or a plurality of rings having a fully connected ⁇ -electron system, examples of which are not limited to cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, adamantane, cyclohexadiene, Cycloheptane or cycloheptatriene. Cycloalkyl groups are substitutable and unsubstituted.
  • the substituent is preferably one or more groups each selected from the group consisting of hydrogen, hydroxy, thiol, oxo, lower alkyl, lower alkoxy, lower cycloalkyl, lower heterocycloalkane , lower haloalkoxy, alkylthio, halogen, lower haloalkyl, lower hydroxyalkyl, lower cycloalkylalkylene, lower heterocycloalkylene, aryl, heteroaryl, alkoxycarbonyl, Amino, alkylamino, alkylsulfonyl, arylsulfonyl, alkylaminosulfonyl, arylaminosulfonyl, alkylsulfonylamino, arylsulfonylamino, alkylaminocarbonyl, arylaminocarbonyl, Alkylcarbonylamino, arylcarbonylamino.
  • Aryl means an all-carbon monocyclic or fused polycyclic group of 6 to 14 carbon atoms having a fully conjugated pi-electron system. “Aryl” includes:
  • a six-membered carbon aromatic ring such as benzene
  • a bicyclic ring in which at least one ring is a carbon aromatic ring such as naphthalene, anthracene or 1,2,3,4-tetrahydroquinoline;
  • an aryl group includes a six-membered carbon aromatic ring and a six-membered heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, provided that the point of attachment is on the carbon aromatic ring.
  • the aryl group does not contain, nor does it overlap in any way with the heterocyclic aryl groups respectively defined below.
  • the resulting ring system is a heteroaryl group rather than an aryl group.
  • Non-limiting examples of aryl groups are phenyl, naphthyl.
  • the aryl group can be substituted or unsubstituted.
  • preferred groups are: hydrogen, hydroxy, nitro, cyano, oxo, lower alkyl, lower alkoxy, lower cycloalkyl, lower heterocycloalkyl, lower haloalkoxy, alkane Sulfur, halogen, lower haloalkyl, lower hydroxyalkyl, lower cycloalkylalkylene, lower heterocycloalkylene, aryl, heteroaryl, alkoxycarbonyl, amino, alkylamino, alkyl Sulfonyl, arylsulfonyl, alkylaminosulfonyl, arylaminosulfonyl, alkylsulfonylamino, arylsulfonylamino, alkylaminocarbonyl, arylaminocarbonyl, alkylcarbonylamino, arylcarbonyl Amino group.
  • Heteroaryl means a monocyclic or fused ring radical of 5 to 14 ring atoms containing one, two, three or four ring heteroatoms selected from N, O or S, the remaining ring atoms being C In addition, it has a fully conjugated ⁇ -electron system. Heteroaryl refers to:
  • N N
  • O organic radical
  • S sulfur
  • a heteroaryl group includes a 5-6 membered heteroaromatic ring and a 5-6 membered cycloalkyl group.
  • one of the rings contains one or more heteroatoms and the attachment sites are on the heteroaromatic ring.
  • the total number of sulfur and oxygen atoms on the heteroaryl group exceeds 1, these heteroatoms are not adjacent one another. In some embodiments, the total number of sulfur and oxygen atoms in the heteroaryl group does not exceed two. In some embodiments, the total number of sulfur and oxygen atoms in the heteroaryl group does not exceed one.
  • heteroaryl groups include, but are not limited to, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, triazole, pyrimidine, pyridine, pyridone, imidate, pyrazine, pyridazine, anthracene, Azaindene, benzimidazole, benzotriazole, porphyrin, anthrone, quinoline, isoquinoline, quinazoline, thienopyridine, thienopyrimidine, and the like.
  • Preferred examples of such groups are benzene rings, pyridine, pyrimidine, pyridazine, pyrazine, quinoline, isoquinoline, pyrrole, pyrazole, imidazole, thiophene, thiazole, furan or oxazole.
  • One or all of the hydrogen atoms in the heteroaryl group may be substituted with hydrogen, hydroxy, nitro, cyano, oxo, lower alkyl, lower alkoxy, lower cycloalkyl, lower heterocycloalkyl, Lower haloalkoxy, alkylthio, halogen, lower haloalkyl, lower hydroxyalkyl, lower cycloalkylalkylene, lower heterocycloalkylene, aryl, heteroaryl, alkoxycarbonyl, amino, Alkylamino, alkylsulfonyl, arylsulfonyl, alkylaminosulfonyl, arylaminosulfonyl, alkylsulfonylamino, arylsulfonylamino, alkylaminocarbonyl, arylaminocarbonyl, alkyl Carbonylamino, arylcarbonylamino.
  • Heterocycloalkyl means a monovalent saturated cyclic group consisting of one or more rings, preferably 1 to 2 rings, including a spiro ring system, each ring having 3 to 8 atoms in combination with one or a plurality of ring heteroatoms (selected from N, O or S(O) 0-2 ), and which may be optionally substituted independently by one or more, preferably one or two substituents, said substituents being selected From: hydrogen, hydroxy, mercapto, oxo, lower alkyl, lower alkoxy, lower cycloalkyl, lower heterocycloalkyl, lower haloalkoxy, alkylthio, halogen, lower haloalkyl, lower hydroxyalkyl , lower cycloalkylalkylene, lower heterocycloalkylene, aryl, heteroaryl, alkoxycarbonyl, amino, alkylamino, alkylsulfonyl, arylsulfonyl
  • heterocycloalkyl groups include, but are not limited to, oxirane, aziridine, pyridine, morpholin-3-one, thiomorpholine 1,1-dioxide, morpholinyl, piperazinyl, piperidine Pyridyl, azetidinyl, pyrrolidinyl, hexahydroazain, oxetanyl, tetrahydrofuranyl, tetrahydrothiophenyl, oxazolidinyl, thiazolidinyl, isoxazolidinyl , tetrahydro-2H-pyranyl, thio-allinyl, quinuclidinyl and imidazolinyl, preferably W is selected from O, S or NR 12 , and each group is as described above, and the examples may also be bicyclic, such as, for example, 3,8-diaza-bicyclo[3.2.1]octane, 2,5- Dia
  • Alkoxy means -O-(unsubstituted alkyl) and -O-(unsubstituted cycloalkyl). Representative examples include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy, and the like.
  • Aryloxy means -O-aryl and -O-heteroaryl. Representative examples include, but are not limited to, phenoxy, pyridyloxy, furanoxy, thienyloxy, pyrimidinyloxy, pyrazinyloxy, and the like, and derivatives thereof.
  • Arylalkylene means an alkyl group, preferably a lower alkyl group as defined above, which is substituted by an aryl group as described above, for example -CH 2 phenyl, -(CH 2 ) 2 phenyl, -(CH 2 3 phenyl, CH 3 CH(CH 3 )CH 2 phenyl and its derivatives.
  • Heteroaryl alkylene denotes a lower alkyl, preferably as defined above, heteroaryl which is substituted as described above, for example, -CH 2 pyridinyl, - (CH 2) 2 pyrimidinyl, - ( CH 2 ) 3 imidazolyl and the like and derivatives thereof.
  • Haldroxy means an -OH group.
  • Indexl means a -SH group.
  • Halogen means fluoro, chloro, bromo or iodo, preferably fluoro or chloro.
  • Haloalkyl means an alkyl group substituted by a halogen, preferably a lower alkyl group as defined above, which is substituted by one or more of the same or different halogen atoms, for example -CH 2 Cl, -CF 3 , -CCl 3 , - CH 2 CF 3 , -CH 2 CCl 3 and the like.
  • Cyano means a -CN group.
  • Amino means a -NH 2 group.
  • Niro means a -NO 2 group.
  • Alkylsulfonyl means a -S(O 2 )C 1 -C 6 alkyl group wherein alkyl is as defined above.
  • Cycloalkyloxy means that H in the -OH group is substituted by a cycloalkyl group, wherein cycloalkyl is as defined above.
  • Optionally substituted includes both substituted and substituted unsubstituted ones, such as an optionally substituted alkyl group including an unsubstituted alkyl group and an alkyl group substituted with one or more substituents.
  • substituted by one or more groups means that one, two, three or four hydrogen atoms in a given atom or group are each selected from a specified range of groups. Replace the same or different groups.
  • a wavy line indicates a connection site
  • “Pharmaceutically acceptable salt” means those salts which retain the biological effectiveness and properties of the parent compound. Such salts include:
  • a salt with an acid obtained by a reaction of a free base of a parent compound with an inorganic or organic acid includes hydrochloric acid, hydrobromic acid, nitric acid, phosphoric acid, metaphosphoric acid, sulfuric acid, sulfurous acid, perchloric acid, etc.
  • Organic acids include acetic acid, propionic acid, acrylic acid, oxalic acid, (D) or (L) malic acid, fumaric acid, maleic acid, hydroxybenzoic acid, ⁇ -hydroxybutyric acid, methoxybenzoic acid, ortho-benzene Formic acid, methanesulfonic acid, ethanesulfonic acid, naphthalene-1-sulfonic acid, naphthalene-2-sulfonic acid, p-toluenesulfonic acid, salicylic acid, tartaric acid, citric acid, lactic acid, mandelic acid, succinic acid or malonic acid .
  • an organic base such as ethanolamine, diethanolamine, or the like. Ethanolamine, tromethamine, N-methylglucamine, and the like.
  • “Pharmaceutical composition” refers to a combination of one or more of the compounds of the invention, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, with one or more pharmaceutically acceptable excipients.
  • auxiliary is generally selected from other chemical components other than the compounds described herein, such as pharmaceutically acceptable pharmaceutically acceptable carriers, or other pharmaceutical effects. Mixing of compounds and the like. The purpose of the pharmaceutical composition may be to facilitate the administration to the animal or to synergistic effects of the drug.
  • “Pharmaceutically acceptable carrier” refers to an inactive ingredient in a pharmaceutical composition that does not cause significant irritation to the organism and does not interfere with the biological activity and properties of the administered compound, such as, but not limited to, calcium carbonate, calcium phosphate, various Sugar (eg lactose, mannitol, etc.), starch, cyclodextrin, magnesium stearate, cellulose, magnesium carbonate, acrylic polymer or methacrylic acid polymer, gel, water, polyethylene glycol, propylene glycol, B Glycol, castor oil or hydrogenated castor oil or polyethoxylated hydrogenated castor oil, sesame oil, corn oil, peanut oil and the like.
  • the pharmaceutical composition of the foregoing may include, in addition to a pharmaceutically acceptable carrier and the like, an adjuvant commonly used in medicine, such as an antibacterial agent, an antifungal agent, an antimicrobial agent, a shelf life agent, A toner, a solubilizer, a thickener, a surfactant, a complexing agent, a protein, an amino acid, a fat, a saccharide, a vitamin, a mineral, a trace element, a sweetener, a coloring matter, a flavor, or a combination thereof.
  • an adjuvant commonly used in medicine such as an antibacterial agent, an antifungal agent, an antimicrobial agent, a shelf life agent, A toner, a solubilizer, a thickener, a surfactant, a complexing agent, a protein, an amino acid, a fat, a saccharide, a vitamin, a mineral, a trace element, a sweetener, a coloring matter, a flavor, or a combination thereof
  • the compounds of formula (I) according to the invention have a significant inhibitory effect on ROR ⁇ t, while ROR ⁇ t plays a very important role in inflammatory, metabolic and autoimmune diseases, and inhibition of ROR ⁇ t will result in the alleviation or effective treatment of these diseases.
  • Example 1 N-(4-ethylphenyl)-N-isobutyl-4-oxo-2-(tetrahydro-2H-pyran-4-yl)chroman-6-sulfonamide compound EXP Preparation of 1
  • the Exp1 (40mg, 0.09mmol, 1.0eq) was dissolved in MeOH (5mL), was added the compound NaBH 4 (10mg, 0.25mmol, 3.0eq ), stirred at room temperature for 2 hours. TLC showed the reaction was complete, the solvent was evaporated, and the solid compound Exp 2 (21 mg, yield: 52%) was obtained by prep-HPLC separation.
  • Hydroxylamine hydrochloride (20 mg, 0.29 mmol, 2.7 eq) was dissolved in 5 mL of dry ethanol, sodium acetate (50 mg, 0.61 mmol, 5.7 eq) was added at room temperature, stirred at room temperature for 15 min, then Exp 1 (50 mg, 0.11) Methyl, 1.0 eq) was dissolved in 1.0 mL of absolute ethanol and added to the reaction mixture. Stir overnight at room temperature and TLC showed approximately 30% of the starting material remained.
  • SR1001 is an inverse agonist of ROR ⁇ t, and as a positive reference, its structure is:
  • the first day of cell seed plate The 293T adherent cells were digested with 1 mL of trypsin for about 5 minutes. The digested cells were pipetted, transferred to a 15 mL centrifuge tube, and centrifuged at 1000 rpm for 5 min. Discard the old medium, resuspend the cells in fresh medium and dilute to the desired density.
  • the cell suspension was prepared at a cell density of 15,000 cells/well. Plate, 100 ⁇ L of cells per well. To prevent edge effects, 96-well cell culture plates were only plated with 60 wells in the middle of the plate, and 36 wells were filled with 100 ⁇ L of PBS per well. The cells were cultured at 37 ° C in a 5% CO 2 incubator.
  • transient transfection experiments were performed 24 hours after cell seed plating.
  • a transient plasmid ie, Gal4-ROR ⁇ -LBD: 25 ng/well; PgL4.3-luc: 25 ng/well
  • transfection reagent liposome 2000 concentration of 3 times DNA
  • a small molecule compound (a compound of SR1001 or Exp1-Exp34) can be added by transient transfection for more than 5 hours.
  • the cells were then cultured in a 5% CO 2 incubator at 37 °C. After about 24 hours, the cells were taken out, and the growth of the cells was observed under a microscope, and the cell culture plates were taken out of the cells. Then do the luciferase double reporter gene assay.
  • the cell culture medium was first aspirated, and then about 100 ⁇ L of PBS was added to wash the residual medium. After the mother liquor 5 ⁇ cell lysate was diluted to 1 ⁇ , 20 ⁇ L was added per well, and then the cells were lysed by shaking for about 20 min.
  • ++++ means IC 50 ⁇ 50 nM; +++ means IC 50 range is 50-200 nM; ++ means IC 50 range is 200-1000 nM; + means IC 50 >1000 nM; NA means undetected.
  • reaction buffer DTT and KF were dissolved in 1x buffer D. Final concentration: DTT 5 mM, KF 50 mM.
  • Detection plate wavelengths 665 nm and 615 nm; instrument: multi-label microplate detector.
  • IC 50 of the compound is calculated and dose-response curve: log inhibition rate was calculated by the compounds and compound concentration using Graphpad 5.0, to obtain dose-response curve and IC50 of the compound.
  • ROR ⁇ t plays a very important role in inflammatory, metabolic and autoimmune diseases, and inhibition of ROR ⁇ t will cause these diseases to be alleviated or Effective treatment.
  • respiratory diseases such as asthma, COPD
  • autoimmune diseases such as rheumatoid arthritis, psoriasis, ulcerative colitis, Crohn's disease

Abstract

一种如式(I)所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药、其制备方法、含有这些调节剂的药物组合物及其在治疗RORγ介导的炎性、代谢性和自身免疫性疾病中的用途。所述化合物对RORγ具有抑制活性，可以用于炎性、代谢性和自身免疫性疾病的治疗。

Description

一类色满-6-磺酰胺RORγ调节剂及其用途 技术领域
本发明涉及新颖的维甲酸相关孤儿受体γ(RORγ)调节剂、其制备方法、含有这些调节剂的药物组合物及其在治疗RORγ介导的炎性、代谢性和自身免疫性疾病中的用途。
背景技术
维甲酸受体相关的孤儿受体(retinoic acid receptor-related orphan receptors，RORs)是一类配体依赖的转录因子，在生殖发育、生理节律调节、新陈代谢紊乱、炎症发生以及免疫***调节等一系列生理病理过程中扮演重要角色。RORs是核受体超家族中的一员，包括RORα、RORβ、RORγ。RORα主要分布在肝脏、骨骼肌、皮肤、肺、脂肪组织、肾脏、胸腺、大脑和血液中，与肝糖原异生、脂代谢、动脉粥样硬化等生理病理过程有关。RORβ主要分布在中枢神经***中，包括大脑、视网膜和松果腺，主要与脊髓、丘脑、小脑皮质对敏感信息的处理方面有关。RORγ高表达于胸腺中，在肾脏、肝脏、心脏、骨骼肌、脂肪组织、睾丸、***、胰腺中也有分布，与类风湿性关节炎、牛皮癣、多发性硬化症等自身免疫病有关。
RORγ包括RORγ1和RORγ2(RORγt)两个亚型。RORγ1在包括胸腺、肌肉、肾和肝在内的多种组织中表达；RORγt仅在免疫***细胞中唯一表达，并在胸腺生成、若干二级淋巴组织的发育和Th17谱系分化中起关键作用。研究显示，RORγt为Th17细胞分化的关键调节剂。Th17细胞是T辅助细胞的亚型，其产生IL-17和其他促炎细胞因子。Th17细胞在若干种小鼠自身免疫性疾病模型(包括：脑脊髓炎(EAE)和胶原诱导的关节炎(CIA))中具有关键作用。此外，研究显示，Th17细胞或其产物与多发性硬化病、类风湿关节炎、银屑病、克罗恩病、哮喘在内的多种人类炎症和自身免疫性疾病的病理有关。自身免疫性疾病发病的主要原因是对自体抗原的不耐受和浸润组织的自动侵袭性效应子T细胞的发展。Th17细胞是组织特异性自身免疫中炎症性过程中重要的驱动因子之一，在疾病发展过程中，Th17细胞被激活并负责募集其他炎症细胞(中性粒细胞)，从而介导靶组织的病变。
据报道，RORγt为Th17细胞分化的关键调节剂，最近发现Th17细胞是优先产生细胞因子IL-17A、IL-17F、IL-21和IL-22的T辅助细胞的亚组。RORγt诱导编码IL-17A和IL-17F的基因在初始CD4+T辅助细胞中的转录。RORγt缺陷的小鼠显示非常少的Th17细胞。RORγt的抑制、缺失使得EAE得到改善。
在哮喘患者中，已显示RORγt和IL-17A表达水平在唾液、肺、支气管肺泡灌洗(BAL)液和外周血中增加，且水平与疾病严重程度直接相关。除IL-17A以外，最近研究已显示IL-17家族的另一细胞因子IL-17F可在过敏性气道炎症中具有重要作用，且因此在气道疾病例如哮喘中具有重要影响。IL-17F基因在小鼠气道中的过度表达与气道中性白细胞增多症、细胞因子诱导、气道高反应性的增加和粘液分泌过多相关。
鉴于RORγ在疾病的发病机制中所起的作用，期望制备调节RORγ活性并因此用于治疗RORγ介导的炎性、代谢性和自身免疫性疾病的化合物，所述疾病例如呼吸***疾病哮喘、慢性阻塞性肺病(COPD)和支气管炎、包括过敏性鼻炎和异位性皮肤炎的过敏性疾病、囊性纤维化和肺同种异体移植排斥。
发明内容
根据本发明，提供新颖的维甲酸相关孤儿受体γ(RORγ)调节剂、其制备方法、包含有这些调节剂的药物组合物及其在治疗RORγ介导的炎性、代谢性和自身免疫性等疾病中的用途。
更具体地，一方面，本发明涉及结构如式(I)所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药：
Figure PCTCN2017087263-appb-000001
其中，
R1、R2各自独立的选自氢、卤素、羟基、氨基、C1-C6烷基、C1-C6烷基胺基、C1-C6烷氧基、C3-C8环烷基氧基，或者R1、R2合并为氧代基；
R4选自氢、任意取代的C1-C6烷基、任意取代的C3-C8环烷基、任意取代的C2-C8杂环烷基、任意取代的-CH2C3-C8环烷基、任意取代的C6-C10芳基或任意取代的C2-C10杂芳基，取代基选自氢、卤素、羟基、氨基、C1-C6烷基、C1-C6卤代烷基或C3-C8环烷基；
R5选自任意取代的C6-C10芳基、任意取代的-CH2C6-C10芳基、任意取代的C2-C10杂芳基或任意取代的-CH2C2-C10杂芳基，取代基选自氢、卤素、氰基、C1-C6烷基、氨基、C1-C3烷基胺基、C2-C8杂环烷基、C1-C2烷基C4-C8杂环烷基、C3-C8环烷基、C1-C6烷氧基、C1-C6卤代烷基、羟基C1-C6卤代烷基或-S(O2)C1-C6烷基；
R6选自氢、卤素、羟基、氨基、任意取代的C1-C6烷基，取代基选自氢、卤素、羟基、氨基或C1-C6烷基；
R3为基团-(CHR7)s-(Y)t-(CHR8)u-R9；
R7、R8独立选自氢、C1-C6烷基、羟基；
Y选自C1-C6烷基、NH或O；
R9选自任意取代的C2-C8杂环烷基、任意取代的C3-C8环烷基、任意取代的C6-C10芳基或任意取代的C2-C10杂芳基，取代基选自H、C1-C6烷基、卤素取代的C1-C6烷基、羟基取代的C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基、-S(O2)C1-C6烷基、-S(O2)(CH2)mC3-C8环烷基、-S(O2)(CH2)m C2-C8杂环烷基、-C(O)C1-C6烷基、-C(O)(CH2)mC3-C8环烷基、-C(O)(CH2)m C2-C8杂环烷基、C2-C10杂芳基、C6-C10芳基、羟基或卤素；
m选自0、1、2；
s、t、u独立地选自0、1、2；
X选自O、NR10、CR10；
R10选自氢、C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基；
n选自0、1。
另一方面，本发明提供一种药物组合物，其包含：式(I)化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药；一种或多种药学上可接受的辅料。
另一方面，本发明提供式(I)化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药其用于治疗RORγ介导的疾病，如炎性、代谢性或自身免疫性疾病中的用途。
另一方面，本发明提供式(I)化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药其用于治疗哮喘、慢性阻塞性肺病(COPD)、支气管炎、过敏性疾病(如：过敏性鼻炎)、异位性皮肤炎、囊性纤维化、肺同种异体移植排斥、多发性硬化症、类风湿性关节炎、青少年类风湿性关节炎、骨关节炎、强直性脊柱炎、***性红斑狼疮、银屑病、桥本氏病、胰腺炎、自身免疫性糖尿病、自身免疫性眼病、溃疡性结肠炎、克罗恩氏病、炎性肠病(IBS)、炎性肠综合征(IBD)、斯耶格伦氏综合征、视神经炎、I型糖尿病、视神经脊髓炎、重症肌无力、葡萄膜炎、格林-巴利综合征、银屑病关节炎、格雷氏病或巩膜炎等中的用途。
另一方面，本发明提供式(I)化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药其用于治疗哮喘、类风湿性关节炎、银屑病、溃疡性结肠炎或克罗恩氏病中的用途。
在一种优选方案中，本发明涉及的结构如式(I)所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药，其中R5选自任意取代的以下基团：苯环、吡啶环、苯并噻吩、嘧啶环、哒嗪环、吡嗪环、喹啉、异喹啉、吡咯环、吡唑环、咪唑环、噻吩环、噻唑环、呋喃环或噁唑环；取代基选自氢、卤素、氰基、C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基、C1-C6烷氧基、C1-C6卤代烷基、C1-C3烷基胺基或-S(O2)C1-C6烷基；进一步优选的，取代基选自氢、卤素、氰基、C1-C4烷基、C2-C6杂环烷基、C3-C6环烷基、C1-C3烷氧基、C1-C3卤代烷基、C1-C3烷基胺基或-S(O2)C1-C3烷基。
优选的，R5选自任意取代的苯环、任意取代的苯并噻吩或任意取代的吡啶环；取代基选自氢、卤素、氰基、C1-C6烷基、C2-C8杂环烷基、C1-C6烷氧基、C1-C6卤代烷基、C1-C3烷基胺基或-S(O2)C1-C6烷基；进一步优选的，取代基选自氢、卤素、氰基、C1-C4烷基、C2-C6杂环烷基、C1-C4烷氧基、C1-C4卤代烷基、C1-C3烷基胺基或-S(O2)C1-C3烷基。
在一种优选方案中，本发明涉及的结构如式(I)所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药，其中R9选自任意取代的以下基团：氧杂环丙烷、氧杂环丁烷、环丁烷、异噁唑、四氢呋喃、四氢-2H-吡喃、氮杂环丁烷、吡咯烷、哌啶、吗啉、吡啶、吗啉-3-酮或硫代吗啉1,1-二氧化物；取代基选自H、C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基、-S(O2)C1-C6烷基、-S(O2)(CH2)mC3-C8环烷基、-S(O2)(CH2)m C2-C8杂环烷基、-C(O)C1-C6烷基、-C(O)(CH2)mC3-C8环烷基、-C(O)(CH2)m C2-C8杂环烷基、C2-C10杂芳基、C6-C10芳基、羟基取代的C1-C6烷基、羟基或卤素；进一步优选的，取代基选自H、C1-C4烷基、C2-C6杂环烷基、C3-C6环烷基、-S(O2)C1-C3烷基、-S(O2)(CH2)mC3-C6环烷基、-S(O2)(CH2)m C2-C6杂环烷基、-C(O)C1-C4烷基、-C(O)(CH2)mC3-C6环烷基、-C(O)(CH2)m C2-C6杂环烷基、C2-C6杂芳基、C6-C8芳基、羟基取代的C1-C4烷基、羟基或卤素。
优选的，R3为-CH2R9或-R9；R9选自任意取代的以下基团：氧杂环丙烷、氧杂环丁烷、环丁烷、异噁唑、四氢呋喃、四氢-2H-吡喃、氮杂环丁烷、吡咯烷、哌啶、吗啉、吡啶、吗啉-3-酮或硫代吗啉1,1-二氧化物；取代基选自H、C1-C6烷基、C2-C8杂环烷基、C3-C8 环烷基、-S(O2)C1-C6烷基、-S(O2)(CH2)mC3-C8环烷基、-S(O2)(CH2)m C2-C8杂环烷基、-C(O)C1-C6烷基、-C(O)(CH2)mC3-C8环烷基、-C(O)(CH2)m C2-C8杂环烷基、C2-C10杂芳基、C6-C10芳基、羟基取代的C1-C6烷基、羟基或卤素。更优选的，R9选自任意取代的以下基团：氧杂环丁烷、环丁烷、异噁唑、四氢呋喃、四氢-2H-吡喃、吡咯烷、哌啶、吗啉、吡啶；取代基选自H、C1-C6烷基、卤素取代的C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基、-S(O2)C1-C6烷基、-S(O2)(CH2)mC3-C8环烷基、-S(O2)(CH2)m C2-C8杂环烷基、-C(O)C1-C6烷基、-C(O)(CH2)mC3-C8环烷基、-C(O)(CH2)m C2-C8杂环烷基、羟基取代的C1-C6烷基、羟基或卤素；进一步优选的，取代基选自H、C1-C4烷基、卤素取代的C1-C3烷基、C2-C6杂环烷基、C3-C6环烷基、-S(O2)C1-C3烷基、-S(O2)(CH2)mC3-C6环烷基、-S(O2)(CH2)m C2-C6杂环烷基、-C(O)C1-C3烷基、-C(O)(CH2)mC3-C6环烷基、-C(O)(CH2)m C2-C6杂环烷基、羟基取代的C1-C3烷基、羟基或卤素。
在一种优选方案中，本发明涉及结构如式(I)所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药，其中X选自O、NH或CH2；更优选的X选自O或NH，进一步优选的X为O。
在一种优选方案中，本发明涉及结构如式(I)所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药，R1、R2各自独立的选自氢、羟基、卤素、氨基、C1-3烷基、C1-C3烷氧基、C3-C6环烷基氧基或者R1、R2合并为氧代基。
在一种优选方案中，本发明涉及结构如式(I)所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药，R4选自氢、任意取代的C1-C6烷基、任意取代的C3-C8环烷基、任意取代的C2-C6杂环烷基、任意取代的-CH2C3-C6环烷基、任意取代的C6-C10芳基或任意取代的C2-C8杂芳基，取代基选自氢、卤素、羟基、氨基、C1-C6烷基或C3-C6环烷基；进一步优选的，R4选自氢、任意取代的C1-C4烷基、任意取代的C3-C6环烷基、任意取代的C2-C6杂环烷基、任意取代的-CH2C3-C6环烷基、任意取代的C6-C8芳基或任意取代的C2-C6杂芳基，取代基选自氢、卤素、羟基、氨基、C1-C3烷基或C3-C6环烷基。
在一种优选方案中，本发明涉及结构如式(I)所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药，R6选自氢、卤素、任意取代的C1-C6烷基，取代基选自氢、卤素、羟基、氨基或C1-C6烷基；进一步优选的R6选自氢、卤素、任意取代的C1-C3烷基，取代基选自氢、卤素、羟基、氨基或C1-C3烷基。
应当理解，本发明还涉及上述优选方案的任意组合。下文中给出组合的一些实例。然而，本发明不限于这些组合。
在一种优选的实施方案中：本发明涉及结构如式(I)所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药，其中：X为O；n为0或1；R1、R2各自独立的选自氢、羟基、卤素、氨基、C1-C3烷基、C1-C3烷氧基，或者R1、R2合并为氧代基；R4选自氢、任意取代的C1-C6烷基、任意取代的C3-C6环烷基、任意取代的C4-C8杂环烷基、任意取代的-CH2C3-C8环烷基或任意取代的C6-C10芳基，取代基选自氢、卤素、羟基、氨基、C1-C3烷基或C3-C8环烷基；R5选自任意取代的苯环、任意取代的苯并噻吩或任意取代的吡啶环；取代基选自氢、卤素、氰基、C1-C3烷基、C1-C3烷氧基、C1-C3卤代烷基、C1-C3烷基胺基或-S(O2)C1-C3烷基；R6选自氢、卤素、任意取代的C1-C6烷基，取代基选自氢、卤素、羟基、氨基或C1-C6烷基；R3为-CH2R9或-R9；R9选自任意取代的以下基团：氧杂环丁烷、环丁烷、四氢呋喃、四氢-2H-吡喃、吡咯烷、哌啶、吗啉、吡啶；取代基选自H、C1-C6烷基、卤素取代的C1-C3烷基、C2-C8杂环烷基、C3-C8环烷基、-S(O2)C1-C3烷基、羟基或卤素。
在一种优选方案中，本发明还提供了式Ia-Ij任一结构所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药的亚组：
Figure PCTCN2017087263-appb-000002
其中：R3、R4、R5、R6和n的定义如上所述。
在一种优选组合方案中，式(Ia-Ij)的化合物，或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药的亚组，其中：
R3选自基团-(CHR7)s-(Y)t-(CHR8)u-R9；R7、R8独立选自氢、C1-C6烷基、羟基；Y选自C1-C6烷基、NH或O；s、t、u独立地选自0、1、2；R9选自任意取代的以下基团氧杂环丙烷、氧杂环丁烷、环丁烷、异噁唑、四氢呋喃、四氢-2H-吡喃、氮杂环丁烷、吡咯烷、哌啶、吗啉、吡啶、吗啉-3-酮或硫代吗啉1,1-二氧化物；取代基选自H、C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基、-S(O2)C1-C6烷基、-S(O2)(CH2)mC3-C8环烷基、-S(O2)(CH2)m C2-C8杂环烷基、-C(O)C1-C6烷基、-C(O)(CH2)mC3-C8环烷基、-C(O)(CH2)m C2-C8杂环烷基、C2-C10杂芳基、C6-C10芳基、羟基取代的C1-C6烷基、羟基或卤素；
R4选自氢、任意取代的C1-C6烷基、任意取代的C3-C8环烷基、任意取代的C2-C6杂环烷基、任意取代的-CH2C3-C8环烷基、任意取代的C6-C10芳基或任意取代的C2-C8杂芳基，取代基选自氢、卤素、羟基、氨基、C1-C6烷基、C3-C6环烷基或C3-C6环烷基；
R5选自任意取代的以下基团：苯环、吡啶环、苯并噻吩、嘧啶环、哒嗪环、吡嗪环、喹啉、异喹啉、吡咯环、吡唑环、咪唑环、噻吩环、噻唑环、呋喃环或噁唑环；取代基选自氢、卤素、氰基、C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基、C1-C6烷氧基、C1-C6卤代烷基、C1-C3烷基胺基或-S(O2)C1-C6烷基；R6选自氢、卤素、任意取代的C1-C6烷基，取代基选自氢、卤素、羟基、氨基或C1-C6烷基。
进一步的，在一种优选方案中，本发明提供式(Ia-Ie、Ih、Ii、Ij)的化合物，或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药的亚组：
Figure PCTCN2017087263-appb-000003
Figure PCTCN2017087263-appb-000004
其中，R3、R4、R5、R6和n的定义如上所述。
进一步的，在一种优选方案中，本发明提供式(Ia-Ie，Ij)的化合物，或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药的亚组：
Figure PCTCN2017087263-appb-000005
其中：R3、R4、R5、R6和n的定义如上所述。
下文中给出组合的一些实例。然而，本发明不限于这些组合。
在一种优选组合方案中，式(Ia-Ie，Ij)的化合物，或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药的亚组，其中：
R5选自任意取代的苯环、任意取代的苯并噻吩或任意取代的吡啶环；取代基选自氢、卤素、氰基、C1-C6烷基、C1-C6烷氧基、C1-C6卤代烷基、C1-C3烷基胺基或-S(O2)C1-C6烷基，进一步优选的，取代基选自氢、卤素、氰基、C1-C3烷基、C1-C3烷氧基、C1-C3卤代烷基、C1-C3烷基胺基或-S(O2)C1-C3烷基；
R3为-CH2R9或-R9；R9选自任意取代的以下基团：氧杂环丁烷、环丁烷、四氢呋喃、四氢-2H-吡喃、氮杂环丁烷、吡咯烷、哌啶、吗啉、吡啶；取代基选自H、C1-C6烷基、卤素取代的C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基、-S(O2)C1-C6烷基、羟基或卤素。
在一种优选组合方案中，式(Ia-Ie)的化合物，或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药的亚组，其中：
R9选自任意取代的四氢-2H-吡喃、任意取代的哌啶、任意取代的氧杂环丁烷或任意取代的环丁烷；取代基选自H、C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基、-S(O2)C1-C6烷基、羟基或卤素。
另一方面，更具体的方案，本发明涉及结构如下所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药：
Figure PCTCN2017087263-appb-000006
Figure PCTCN2017087263-appb-000007
Figure PCTCN2017087263-appb-000008
另一方面，本发明提供一种药物组合物，其包含：式(I)化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药；一种或多种药学上可接受的辅料。
另一方面，本发明提供式(I)化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药其用于治疗RORγ介导的疾病中的用途，以及制备治疗RORγ介导的疾病的药物中的应用。其中RORγ介导的疾病包括但不限于炎性、代谢性或自身免疫性疾病等。
另一方面，本发明提供式(I)化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药其用于治疗哮喘、慢性阻塞性肺病(COPD)、支气管炎、过敏性疾病(例如：过敏性鼻炎)、异位性皮肤炎、囊性纤维化、肺同种异体移植排斥、多发性硬化症、类风湿性关节炎、青少年类风湿性关节炎、骨关节炎、强直性脊柱炎、***性红斑狼疮、银屑病、桥本氏病、胰腺炎、自身免疫性糖尿病、自身免疫性眼病、溃疡性结肠炎、克罗恩氏病、炎性肠病(IBS)、炎性肠综合征(IBD)、斯耶格伦氏综合征、视神经炎、I型糖尿病、视神经脊髓炎、重症肌无力、葡萄膜炎、格林-巴利综合征、银屑病关节炎、格雷氏病或巩膜炎等中的用途，优选其用于治疗哮喘、类风湿性关节炎、银屑病、溃疡性结肠炎、克罗恩氏病中的用途。
另一方面，本发明还提供本发明所述化合物的制备方法。
本发明化合物可通过如以下合成路线所示的方法来制备。在以下反应路线和下文中，除非另有说明，所有基团如前述中定义。也认识到，在下文所述的所有路线中，众所周知，根据有机合成的一般原理，必要时采用敏感或反应性基团的保护基(T.W.Greene和P.G.M.Wuts(1991)Protecting Groups in Organic Synthesis，John Wiley&Sons)；在化合物合成的适宜阶段，使用本领域技术人员容易明白的方法除去这些基团；这种方法的选择以及反应条件和它们的执行顺序应认为与本发明化合物的制备方法是一致的。
一般反应路线：
Figure PCTCN2017087263-appb-000009
路线2：
Figure PCTCN2017087263-appb-000010
路线3：
Figure PCTCN2017087263-appb-000011
其中，R1、R2、R3、R4、R5、R6、X和n的定义如前所述。
关于本发明的另一种详细描述：
本发明涉及结构如式(I)所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药：
Figure PCTCN2017087263-appb-000012
其中R6为H，
R1、R2各自独立的选自氢、卤素、羟基、氨基、C1-C6烷基、C1-C6烷基胺基、C1-C6烷氧基，或者R1、R2合并为氧代基；
R4选自氢、C1-C6烷基、C3-C8环烷基或-CH2C3-C8环烷基，其中所述烷基、环烷基可以被一个或多个选自氢、卤素、羟基、氨基、C1-C6烷基的取代基取代；
R5选自C6-C10芳基或C2-C10杂芳基；其中C6-C10芳基、C2-C10杂芳基可以被一个或多个选自氢、卤素、氰基、C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基、C1-C6烷氧基、C1-C6卤代烷基、C1-C6烷基磺酰基的取代基取代；
R3为基团-(CHR7)s-(Y)t-(CHR8)u-R9；
R7、R8独立选自氢、C1-C6烷基、羟基；
Y选自C1-C6烷基、NH或O；
R9选自C2-C8杂环烷基、C3-C8环烷基、C6-C10芳基、C2-C10杂芳基，其中所述C2-C8杂环烷基、C3-C8环烷基、C6-C10芳基、C2-C10杂芳基可以被一个或多个选自H、C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基、-S(O2)C1-C6烷基、-S(O2)(CH2)mC3-C8环烷基、-S(O2)(CH2)m C2-C8杂环烷基、-C(O)C1-C6烷基、-C(O)(CH2)mC3-C8环烷基、-C(O)(CH2)m C2-C8杂环烷基、C2-C10杂芳基、C6-C10芳基、羟基、卤素的取代基取代；
m选自0、1、2；
s、t、u独立地选自0、1、2；
X选自O、NR10、CR10；
R10选自氢、C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基；
n选自0、1。
另一方面，本发明提供一种药物组合物，其包含：式(I)化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药；一种或多种药学上可接受的辅料。
另一方面，本发明提供式(I)化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药其用于治疗RORγ介导的疾病，如炎性、代谢性或自身免疫性疾病中的用途。
另一方面，本发明提供式(I)化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药其用于治疗哮喘、慢性阻塞性肺病(COPD)、支气管炎、过敏性疾病(如：过敏性鼻炎)、异位性皮肤炎、囊性纤维化、肺同种异体移植排斥、多发性 硬化症、类风湿性关节炎、青少年类风湿性关节炎、骨关节炎、强直性脊柱炎、***性红斑狼疮、银屑病、桥本氏病、胰腺炎、自身免疫性糖尿病、自身免疫性眼病、溃疡性结肠炎、克罗恩氏病、炎性肠病(IBS)、炎性肠综合征(IBD)、斯耶格伦氏综合征、视神经炎、I型糖尿病、视神经脊髓炎、重症肌无力、葡萄膜炎、格林-巴利综合征、银屑病关节炎、格雷氏病或巩膜炎等中的用途。
另一方面，本发明提供式(I)化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药其用于治疗哮喘、类风湿性关节炎、银屑病、溃疡性结肠炎或克罗恩氏病中的用途。
发明详述：
本发明涉及结构如式(I)所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药：
Figure PCTCN2017087263-appb-000013
其中R6为H，
R1、R2各自独立的选自氢、卤素、羟基、氨基、C1-C6烷基、C1-C6烷基胺基、C1-C6烷氧基，或者R1、R2合并为氧代基；
R4选自氢、任意取代的C1-C6烷基、任意取代的C3-C8环烷基或任意取代的-CH2C3-C8环烷基，取代基选自氢、卤素、羟基、氨基或C1-C6烷基；
R5选自：任意取代的C6-C10芳基或任意取代的C2-C10杂芳基，取代基选自氢、卤素、氰基、C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基、C1-C6烷氧基、C1-C6卤代烷基或-S(O2)C1-C6烷基；
R3为基团-(CHR7)s-(Y)t-(CHR8)u-R9；
R7、R8独立选自氢、C1-C6烷基、羟基；
Y选自C1-C6烷基、NH或O；
R9选自任意取代的C2-C8杂环烷基、任意取代的C3-C8环烷基、任意取代的C6-C10芳基或任意取代的C2-C10杂芳基，取代基选自H、C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基、-S(O2)C1-C6烷基、-S(O2)(CH2)mC3-C8环烷基、-S(O2)(CH2)m C2-C8杂环烷基、-C(O) C1-C6烷基、-C(O)(CH2)mC3-C8环烷基、-C(O)(CH2)m C2-C8杂环烷基、C2-C10杂芳基、C6-C10芳基、羟基或卤素；
m选自0、1、2；
s、t、u独立地选自0、1、2；
X选自O、NR10、CR10；
R10选自氢、C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基；
n选自0、1。
在一种优选方案中，本发明涉及的结构如式(I)所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药，其中R5选自任意取代的以下基团：苯环、吡啶环、嘧啶环、哒嗪环、吡嗪环、喹啉、异喹啉、吡咯环、吡唑环、咪唑环、噻吩环、噻唑环、呋喃环或噁唑环；取代基选自氢、卤素、氰基、C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基、C1-C6烷氧基、C1-C6卤代烷基或C1-C6烷基磺酰基。
优选的，R5选自任意取代的苯环或任意取代的吡啶环；取代基选自氢、卤素、氰基、C1-C6烷基、C1-C6烷氧基、C1-C6卤代烷基或C1-C6烷基磺酰基；取代基更优选的选自氢、卤素、氰基、C1-C3烷基、C1-C3烷氧基、C1-C3卤代烷基或-S(O2)C1-C3烷基。
在一种优选方案中，本发明涉及结构如式(I)所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药，其中R9选自任意取代的以下基团：氧杂环丙烷、氧杂环丁烷、四氢呋喃、四氢-2H-吡喃、氮杂环丁烷、吡咯烷、哌啶、吗啉、吡啶、吗啉-3-酮或硫代吗啉1,1-二氧化物；取代基选自H、C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基、-S(O2)C1-C6烷基、-S(O2)(CH2)mC3-C8环烷基、-S(O2)(CH2)m C2-C8杂环烷基、-C(O)C1-C6烷基、-C(O)(CH2)mC3-C8环烷基、-C(O)(CH2)m C2-C8杂环烷基、C2-C10杂芳基、C6-C10芳基、羟基或卤素。
优选的，R3为-CH2R9或-R9。R9选自任意取代的以下基团：氧杂环丙烷、氧杂环丁烷、四氢呋喃、四氢-2H-吡喃、氮杂环丁烷、吡咯烷、哌啶、吗啉、吡啶、吗啉-3-酮或硫代吗啉1,1-二氧化物；取代基选自H、C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基、-S(O2)C1-C6烷基、-S(O2)(CH2)mC3-C8环烷基、-S(O2)(CH2)m C2-C8杂环烷基、-C(O)C1-C6烷基、-C(O)(CH2)mC3-C8环烷基、-C(O)(CH2)m C2-C8杂环烷基、C2-C10杂芳基、C6-C10芳基、羟基或卤素。更优选的，R9选自任意取代的以下基团：氧杂环丁烷、四氢呋喃、四氢-2H-吡喃、吡咯烷、哌啶、吗啉、吡啶；取代基选自H、C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基、 -S(O2)C1-C6烷基、-S(O2)(CH2)mC3-C8环烷基、-S(O2)(CH2)m C2-C8杂环烷基、-C(O)C1-C6烷基、-C(O)(CH2)mC3-C8环烷基、-C(O)(CH2)m C2-C8杂环烷基、羟基或卤素，取代基优选自H、C1-C3烷基、C2-C6杂环烷基、C3-C6环烷基、-S(O2)C1-C3烷基、-S(O2)C3-C6环烷基、-S(O2)CH2C3-C6环烷基、-S(O2)C2-C6杂环烷基、-S(O2)CH2C2-C6杂环烷基、-C(O)C1-3烷基、-C(O)C3-C6环烷基、-C(O)CH2C3-C6环烷基、-C(O)C2-C6杂环烷基、-C(O)CH2C2-C6杂环烷基、羟基或卤素；取代基进一步优选自H、C1-3烷基、-S(O2)C1-3烷基、-S(O2)C3-C6环烷基、-S(O2)CH2C3-C6环烷基、-S(O2)C2-C6杂环烷基、-S(O2)CH2C2-C6杂环烷基、-C(O)C1-C3烷基、羟基或卤素；取代基更进一步优选自H、羟基、卤素、C1-C3烷基、-S(O2)C1-C3烷基、-S(O2)C3-C4环烷基、-S(O2)CH2C3-C4环烷基、-S(O2)C2-C4杂环烷基、-S(O2)CH2C2-C4杂环烷基或-C(O)C1-C3烷基。
在一种优选方案中，本发明涉及结构如式(I)所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药，其中X选自O、NH或CH2；更优选的X选自O或NH，进一步优选的X为O。
在一种优选方案中，本发明涉及结构如式(I)所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药，R1、R2各自独立的选自氢、羟基、卤素、氨基、C1-C3烷基、C1-C3烷氧基，或者R1、R2合并为氧代基。
在一种优选方案中，本发明涉及结构如式(I)所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药，R4选自氢、任意取代的C1-C6烷基或任意取代的C3-C8环烷基，取代基选自氢、卤素、羟基、氨基或C1-C6烷基。
应当理解，本发明还涉及上述优选方案的任意组合。下文中给出组合的一些实例。然而，本发明不限于这些组合。
在一种优选的实施方案中：本发明涉及结构如式(I)所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药，其中X选自O或NH；R5选自任意取代的苯环或任意取代的吡啶环；其中取代基选自氢、卤素、氰基、C1-C6烷基、C1-C6烷氧基、C1-C6卤代烷基或C1-C6烷基磺酰基；R3为-CH2R9或-R9；R9选自任意取代的以下基团：氧杂环丙烷、氧杂环丁烷、四氢呋喃、四氢-2H-吡喃、吡咯烷、哌啶、吗啉、吡啶、吗啉-3-酮或硫代吗啉1,1-二氧化物；取代基选自H、C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基、-S(O2)C1-C6烷基、-S(O2)(CH2)mC3-C8环烷基、-S(O2)(CH2)m C2-C8杂环烷基、-C(O)C1-C6烷基、-C(O)(CH2)mC3-C8环烷基、-C(O)(CH2)m C2-C8杂环烷基、C2-C10 杂芳基、C6-C10芳基、羟基或卤素；m选自0、1、2。
在一种优选的实施方案中：本发明涉及结构如式(I)所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药，其中X选自O，R5选自任意取代的苯环或任意取代的吡啶环；其中取代基选自氢、卤素、氰基、C1-C6烷基、C1-C6烷氧基、C1-C6卤代烷基或C1-C6烷基磺酰基；R3为-CH2R9或-R9；R9选自任意取代的以下基团：氧杂环丙烷、氧杂环丁烷、四氢呋喃、四氢-2H-吡喃、吡咯烷、哌啶、吗啉、吡啶、吗啉-3-酮或硫代吗啉1,1-二氧化物；取代基选自H、C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基、-S(O2)C1-C6烷基、-S(O2)(CH2)mC3-C8环烷基、-S(O2)(CH2)m C2-C8杂环烷基、-C(O)C1-C6烷基、-C(O)(CH2)mC3-C8环烷基、-C(O)(CH2)m C2-C8杂环烷基、C2-C10杂芳基、C6-C10芳基、羟基或卤素；m选自0、1、2。
在一种优选的实施方案中：本发明涉及结构如式(I)所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药，其中：X为O；n为0或1；R1、R2各自独立的选自氢、羟基、卤素、氨基、C1-3烷基、C1-C3烷氧基，或者R1、R2合并为氧代基；R4选自氢、任意取代的C1-C6烷基或任意取代的C3-C6环烷基，取代基选自氢、卤素、羟基、氨基或C1-C3烷基；R5选自任意取代的苯环或任意取代的吡啶环；取代基选自氢、卤素、氰基、C1-C3烷基、C1-C3烷氧基、C1-C3卤代烷基或C1-C3烷基磺酰基；R3为-CH2R9或-R9；R9选自任意取代的四氢-2H-吡喃或任意取代的哌啶；取代基选自H、C1-C3烷基、-S(O2)C1-C3烷基、羟基或卤素。
在一种优选方案中，本发明还提供了式(I a-I j)的化合物，或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药的亚组：
Figure PCTCN2017087263-appb-000014
Figure PCTCN2017087263-appb-000015
其中：R3、R4、R5和n的定义如上。
下文中给出组合的一些实例。然而，本发明不限于这些组合。
在一种优选组合方案中，式(Ia-Ij)的化合物，或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药的亚组，其中：
R3选自基团-(CHR7)s-(Y)t-(CHR8)u-R9。R7、R8独立选自氢、C1-C6烷基、羟基；Y选自C1-C6烷基、NH或O；s、t、u独立地选自0、1、2；R9选自任意取代的以下基团：氧杂环丙烷、氧杂环丁烷、四氢呋喃、四氢-2H-吡喃、氮杂环丁烷、吡咯烷、哌啶、吗啉、吡啶、吗啉-3-酮或硫代吗啉1,1-二氧化物；取代基选自H、C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基、-S(O2)C1-C6烷基、-S(O2)(CH2)mC3-C8环烷基、-S(O2)(CH2)m C2-C8杂环烷基、-C(O)C1-C6烷基、-C(O)(CH2)mC3-C8环烷基、-C(O)(CH2)m C2-C8杂环烷基、C2-C10杂芳基、C6-C10芳基、羟基或卤素；
R4选自氢、任意取代的C1-C6烷基、任意取代的C3-C8环烷基或任意取代的-CH2C3-C8环烷基，取代基选自氢、卤素、羟基、氨基或C1-C6烷基；
R5选自任意取代的以下基团：苯环、吡啶环、嘧啶环、哒嗪环、吡嗪环、喹啉、异喹啉、吡咯环、吡唑环、咪唑环、噻吩环、噻唑环、呋喃环或噁唑环；取代基选自氢、卤素、氰基、C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基、C1-C6烷氧基、C1-C6卤代烷基或C1-C6烷基磺酰基。
进一步的，在一种优选方案中，本发明提供式(Ia-Ie、Ih、Ii、Ij)的化合物，或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药的亚组：
Figure PCTCN2017087263-appb-000016
Figure PCTCN2017087263-appb-000017
其中：R3、R4、R5和n的定义如上。
进一步的，在一种优选方案中，本发明提供式(Ia-Ie，Ij)的化合物，或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药的亚组：
Figure PCTCN2017087263-appb-000018
其中：R3、R4、R5和n的定义如上。
下文中给出组合的一些实例。然而，本发明不限于这些组合。
在一种优选组合方案中，式(Ia-Ie，Ij)的化合物，或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药的亚组，其中：
R5选自任意取代的苯环或任意取代的吡啶环；取代基选自氢、卤素、氰基、C1-C6烷基、C1-C6烷氧基、C1-C6卤代烷基或C1-C6烷基磺酰基；
R3为-CH2R9或-R9。R9选自任意取代的以下基团：氧杂环丁烷、四氢呋喃、四氢-2H-吡喃、氮杂环丁烷、吡咯烷、哌啶、吗啉、吡啶；取代基选自H、C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基、-S(O2)C1-C6烷基、羟基或卤素。
在一种优选组合方案中，式(Ia-Ie)的化合物，或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药的亚组，其中：
R5选自任意取代的苯环或任意取代的吡啶环；取代基选自氢、卤素、氰基、C1-C6烷基、C1-C6烷氧基、C1-C6卤代烷基或C1-C6烷基磺酰基；
R3为-CH2R9或-R9。R9选自任意取代的四氢-2H-吡喃或任意取代的哌啶；取代基选自H、C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基、-S(O2)C1-C6烷基、羟基或卤素。
另一方面，更具体的方案，本发明涉及结构如下所示的化合物或其立体异构体、互变 异构体或其药学上可接受的盐或其溶剂合物或者前药：
Figure PCTCN2017087263-appb-000019
Figure PCTCN2017087263-appb-000020
另一方面，本发明提供一种药物组合物，其包含：式(I)化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药；一种或多种药学上可接受的辅料。
另一方面，本发明提供式(I)化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药其用于治疗RORγ介导的疾病中的用途，以及制备治疗RORγ介导的疾病的药物中的应用。其中RORγ介导的疾病包括但不限于炎性、代谢性或自身免疫性疾病等。
另一方面，本发明提供式(I)化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药其用于治疗哮喘、慢性阻塞性肺病(COPD)、支气管炎、过敏性疾病(例如：过敏性鼻炎)、异位性皮肤炎、囊性纤维化、肺同种异体移植排斥、多发性硬化症、类风湿性关节炎、青少年类风湿性关节炎、骨关节炎、强直性脊柱炎、***性红斑狼疮、银屑病、桥本氏病、胰腺炎、自身免疫性糖尿病、自身免疫性眼病、溃疡性结肠炎、克罗恩氏病、炎性肠病(IBS)、炎性肠综合征(IBD)、斯耶格伦氏综合征、视神经炎、I型糖尿病、视神经脊髓炎、重症肌无力、葡萄膜炎、格林-巴利综合征、银屑病关节炎、格雷氏病或巩膜炎等中的用途，优选其用于治疗哮喘、类风湿性关节炎、银屑病、 溃疡性结肠炎、克罗恩氏病中的用途。
另一方面，本发明还提供本发明所述化合物的制备方法。
本发明化合物可通过如以下合成路线所示的方法来制备。在以下反应路线和下文中，除非另有说明，所有基团如前述中定义。也认识到，在下文所述的所有路线中，众所周知，根据有机合成的一般原理，必要时采用敏感或反应性基团的保护基(T.W.Greene和P.G.M.Wuts(1991)Protecting Groups in Organic Synthesis，John Wiley&Sons)；在化合物合成的适宜阶段，使用本领域技术人员容易明白的方法除去这些基团；这种方法的选择以及反应条件和它们的执行顺序应认为与本发明化合物的制备方法是一致的。
一般反应路线：
路线1：
Figure PCTCN2017087263-appb-000021
路线2：
Figure PCTCN2017087263-appb-000022
其中R1、R2、R3、R4、R5、X和n的定义如前所述。
本发明涉及的结构如式(I)所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药：
Figure PCTCN2017087263-appb-000023
其中R6为H，
R1、R2各自独立的选自氢、卤素、羟基、氨基、C1-C6烷基、C1-C6烷基胺基、C1-C6烷氧基，或者R1、R2合并为氧代基；
R4选自任意取代的C1-C6烷基、任意取代的C3-C8环烷基或任意取代的-CH2C3-C8环烷基，取代基选自C1-C6卤代烷基或C3-C8环烷基；
R5选自任意取代的C6-C10芳基或任意取代的C2-C10杂芳基，取代基选自氢、卤素、氰基、C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基、C1-C6烷氧基、C1-C6卤代烷基或-S(O2)C1-C6烷基；
R3为基团-(CHR7)s-(Y)t-(CHR8)u-R9；
R7、R8独立选自氢、C1-C6烷基、羟基；
Y选自C1-C6烷基、NH或O；
R9选自任意取代的C2-C8杂环烷基、任意取代的C3-C8环烷基、任意取代的C6-C10芳基或任意取代的C2-C10杂芳基，取代基选自H、C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基、-S(O2)C1-C6烷基、-S(O2)(CH2)mC3-C8环烷基、-S(O2)(CH2)m C2-C8杂环烷基、-C(O)C1-C6烷基、-C(O)(CH2)mC3-C8环烷基、-C(O)(CH2)m C2-C8杂环烷基、C2-C10杂芳基、C6-C10芳基、羟基或卤素；
m选自0、1、2；
s、t、u独立地选自0、1、2；
X选自O、NR10、CR10；
R10选自氢、C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基；
n选自0、1。
本发明涉及的结构如式(I)所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药：
Figure PCTCN2017087263-appb-000024
其中R6为H，
R1、R2各自独立的选自氢、卤素、羟基、氨基、C1-C6烷基、C1-C6烷基胺基、C1-C6烷氧基，或者R1、R2合并为氧代基；
R4选自氢、任意取代的C1-C6烷基、任意取代的C3-C8环烷基或任意取代的-CH2C3-C8环烷基，取代基选自氢、卤素、羟基、氨基或C1-C6烷基；
R5选自：任意取代的C6-C10芳基或任意取代的C2-C10杂芳基，取代基选自氨基、C1-C3烷基胺基、C1-C2烷基C4-C8杂环烷基、或羟基C1-C6卤代烷基；
R3为基团-(CHR7)s-(Y)t-(CHR8)u-R9；
R7、R8独立选自氢、C1-C6烷基、羟基；
Y选自C1-C6烷基、NH或O；
R9选自任意取代的C2-C8杂环烷基、任意取代的C3-C8环烷基、任意取代的C6-C10芳基或任意取代的C2-C10杂芳基，取代基选自H、C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基、-S(O2)C1-C6烷基、-S(O2)(CH2)mC3-C8环烷基、-S(O2)(CH2)m C2-C8杂环烷基、-C(O)C1-C6烷基、-C(O)(CH2)mC3-C8环烷基、-C(O)(CH2)m C2-C8杂环烷基、C2-C10杂芳基、C6-C10芳基、羟基或卤素；
m选自0、1、2；
s、t、u独立地选自0、1、2；
X选自O、NR10、CR10；
R10选自氢、C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基；
n选自0、1。
本发明涉及的结构如式(I)所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药：
Figure PCTCN2017087263-appb-000025
其中R6为H，
R1、R2各自独立的选自氢、卤素、羟基、氨基、C1-C6烷基、C1-C6烷基胺基、C1-C6烷氧基，或者R1、R2合并为氧代基；
R4选自氢、任意取代的C1-C6烷基、任意取代的C3-C8环烷基或任意取代的-CH2C3-C8环烷基，取代基选自氢、卤素、羟基、氨基或C1-C6烷基；
R5选自：任意取代的C6-C10芳基或任意取代的C2-C10杂芳基，取代基选自氢、卤素、 氰基、C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基、C1-C6烷氧基、C1-C6卤代烷基或-S(O2)C1-C6烷基；
R3为基团-(CHR7)s-(Y)t-(CHR8)u-R9；
R7、R8独立选自氢、C1-C6烷基、羟基；
Y选自C1-C6烷基、NH或O；
R9选自任意取代的C2-C8杂环烷基、任意取代的C3-C8环烷基、任意取代的C6-C10芳基或任意取代的C2-C10杂芳基，取代基选自卤素取代的C1-C6烷基或羟基取代的C1-C6烷基；
m选自0、1、2；
s、t、u独立地选自0、1、2；
X选自O、NR10、CR10；
R10选自氢、C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基；
n选自0、1。
本发明结构如式(I)所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药，还可以：
Figure PCTCN2017087263-appb-000026
其中R6为H，
R1、R2各自独立的选自C3-C8环烷基氧基；
R4选自氢、任意取代的C1-C6烷基、任意取代的C3-C8环烷基、任意取代的C2-C8杂环烷基、任意取代的-CH2C3-C8环烷基、任意取代的C6-C10芳基或任意取代的C2-C10杂芳基，取代基选自氢、卤素、羟基、氨基、C1-C6烷基、C1-C6卤代烷基或C3-C8环烷基；
R5选自任意取代的C6-C10芳基、任意取代的-CH2C6-C10芳基、任意取代的C2-C10杂芳基或任意取代的-CH2C2-C10杂芳基，取代基选自氢、卤素、氰基、C1-C6烷基、氨基、C1-C3烷基胺基、C2-C8杂环烷基、C1-C2烷基C4-C8杂环烷基、C3-C8环烷基、C1-C6烷氧基、C1-C6卤代烷基、羟基C1-C6卤代烷基或-S(O2)C1-C6烷基；
R3为基团-(CHR7)s-(Y)t-(CHR8)u-R9；
R7、R8独立选自氢、C1-C6烷基、羟基；
Y选自C1-C6烷基、NH或O；
R9选自任意取代的C2-C8杂环烷基、任意取代的C3-C8环烷基、任意取代的C6-C10芳基或任意取代的C2-C10杂芳基，取代基选自H、C1-C6烷基、卤素取代的C1-C6烷基、羟基取代的C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基、-S(O2)C1-C6烷基、-S(O2)(CH2)mC3-C8环烷基、-S(O2)(CH2)m C2-C8杂环烷基、-C(O)C1-C6烷基、-C(O)(CH2)mC3-C8环烷基、-C(O)(CH2)m C2-C8杂环烷基、C2-C10杂芳基、C6-C10芳基、羟基或卤素；
m选自0、1、2；
s、t、u独立地选自0、1、2；
X选自O、NR10、CR10；
R10选自氢、C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基；
n选自0、1。
本发明结构如式(I)所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药，还可以：
Figure PCTCN2017087263-appb-000027
其中R6为H，
R1、R2各自独立的选自氢、卤素、羟基、氨基、C1-C6烷基、C1-C6烷基胺基、C1-C6烷氧基、C3-C8环烷基氧基，或者R1、R2合并为氧代基；
R4选自任意取代的C2-C8杂环烷基、任意取代的C6-C10芳基或任意取代的C2-C10杂芳基，取代基选自氢、卤素、羟基、氨基、C1-C6烷基、C1-C6卤代烷基或C3-C8环烷基；
R5选自任意取代的C6-C10芳基、任意取代的-CH2C6-C10芳基、任意取代的C2-C10杂芳基或任意取代的-CH2C2-C10杂芳基，取代基选自氢、卤素、氰基、C1-C6烷基、氨基、C1-C3烷基胺基、C2-C8杂环烷基、C1-C2烷基C4-C8杂环烷基、C3-C8环烷基、C1-C6烷氧基、C1-C6卤代烷基、羟基C1-C6卤代烷基或-S(O2)C1-C6烷基；
R3为基团-(CHR7)s-(Y)t-(CHR8)u-R9；
R7、R8独立选自氢、C1-C6烷基、羟基；
Y选自C1-C6烷基、NH或O；
R9选自任意取代的C2-C8杂环烷基、任意取代的C3-C8环烷基、任意取代的C6-C10芳基或任意取代的C2-C10杂芳基，取代基选自H、C1-C6烷基、卤素取代的C1-C6烷基、羟基取代的C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基、-S(O2)C1-C6烷基、-S(O2)(CH2)mC3-C8环烷基、-S(O2)(CH2)m C2-C8杂环烷基、-C(O)C1-C6烷基、-C(O)(CH2)mC3-C8环烷基、-C(O)(CH2)m C2-C8杂环烷基、C2-C10杂芳基、C6-C10芳基、羟基或卤素；
m选自0、1、2；
s、t、u独立地选自0、1、2；
X选自O、NR10、CR10；
R10选自氢、C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基；
n选自0、1。
本发明结构如式(I)所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药，还可以：
Figure PCTCN2017087263-appb-000028
其中R6为H，
R1、R2各自独立的选自氢、卤素、羟基、氨基、C1-C6烷基、C1-C6烷基胺基、C1-C6烷氧基、C3-C8环烷基氧基，或者R1、R2合并为氧代基；
R4选自氢、任意取代的C1-C6烷基、任意取代的C3-C8环烷基、任意取代的C2-C8杂环烷基、任意取代的-CH2C3-C8环烷基、任意取代的C6-C10芳基或任意取代的C2-C10杂芳基，取代基选自氢、卤素、羟基、氨基、C1-C6烷基、C1-C6卤代烷基或C3-C8环烷基；
R5选自任意取代的-CH2C6-C10芳基、任意取代的-CH2C2-C10杂芳基，取代基选自氢、卤素、氰基、C1-C6烷基、氨基、C1-C3烷基胺基、C2-C8杂环烷基、C1-C2烷基C4-C8杂环烷基、C3-C8环烷基、C1-C6烷氧基、C1-C6卤代烷基、羟基C1-C6卤代烷基或-S(O2)C1-C6烷基；
R3为基团-(CHR7)s-(Y)t-(CHR8)u-R9；
R7、R8独立选自氢、C1-C6烷基、羟基；
Y选自C1-C6烷基、NH或O；
R9选自任意取代的C2-C8杂环烷基、任意取代的C3-C8环烷基、任意取代的C6-C10芳基或任意取代的C2-C10杂芳基，取代基选自H、C1-C6烷基、卤素取代的C1-C6烷基、羟基取代的C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基、-S(O2)C1-C6烷基、-S(O2)(CH2)mC3-C8环烷基、-S(O2)(CH2)m C2-C8杂环烷基、-C(O)C1-C6烷基、-C(O)(CH2)mC3-C8环烷基、-C(O)(CH2)m C2-C8杂环烷基、C2-C10杂芳基、C6-C10芳基、羟基或卤素；
m选自0、1、2；
s、t、u独立地选自0、1、2；
X选自O、NR10、CR10；
R10选自氢、C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基；
n选自0、1。
本发明结构如式(I)所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药，还可以：
Figure PCTCN2017087263-appb-000029
其中，
R1、R2各自独立的选自氢、卤素、羟基、氨基、C1-C6烷基、C1-C6烷基胺基、C1-C6烷氧基、C3-C8环烷基氧基，或者R1、R2合并为氧代基；
R4选自氢、任意取代的C1-C6烷基、任意取代的C3-C8环烷基、任意取代的C2-C8杂环烷基、任意取代的-CH2C3-C8环烷基、任意取代的C6-C10芳基或任意取代的C2-C10杂芳基，取代基选自氢、卤素、羟基、氨基、C1-C6烷基、C1-C6卤代烷基或C3-C8环烷基；
R5选自任意取代的C6-C10芳基、任意取代的-CH2C6-C10芳基、任意取代的C2-C10杂芳基或任意取代的-CH2C2-C10杂芳基，取代基选自氢、卤素、氰基、C1-C6烷基、氨基、C1-C3烷基胺基、C2-C8杂环烷基、C1-C2烷基C4-C8杂环烷基、C3-C8环烷基、C1-C6烷氧基、C1-C6卤代烷基、羟基C1-C6卤代烷基或-S(O2)C1-C6烷基；
R6选自卤素、羟基、氨基、任意取代的C1-C6烷基，取代基选自氢、卤素、羟基、氨基或C1-C6烷基；
R3为基团-(CHR7)s-(Y)t-(CHR8)u-R9；
R7、R8独立选自氢、C1-C6烷基、羟基；
Y选自C1-C6烷基、NH或O；
R9选自任意取代的C2-C8杂环烷基、任意取代的C3-C8环烷基、任意取代的C6-C10芳基或任意取代的C2-C10杂芳基，取代基选自H、C1-C6烷基、卤素取代的C1-C6烷基、羟基取代的C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基、-S(O2)C1-C6烷基、-S(O2)(CH2)mC3-C8环烷基、-S(O2)(CH2)m C2-C8杂环烷基、-C(O)C1-C6烷基、-C(O)(CH2)mC3-C8环烷基、-C(O)(CH2)m C2-C8杂环烷基、C2-C10杂芳基、C6-C10芳基、羟基或卤素；
m选自0、1、2；
s、t、u独立地选自0、1、2；
X选自O、NR10、CR10；
R10选自氢、C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基；
n选自0、1。
进一步优选的，所述的R3、R4、R5、R6和n的定义可以如上所述。
本发明在说明书和权利要求中的术语具有下述含义。
“烷基”指饱和的脂族烃基团。包括1至20个碳原子的直链或支链基团。C1-C6烷基指含有1至6个碳原子的中等大小烷基，例如甲基、乙基、丙基、2-丙基、正丁基、异丁基、叔丁基、戊基等。优选的是含有1至4个碳原子的低级烷基，更优选是含有1至4个碳原子的低级烷基，例如甲基、乙基、丙基、2-丙基、正丁基、异丁基或叔丁基等。烷基可以是取代的或未取代的，当被取代时，优选的基团为：卤素、C2-C6烯基、C6-C10芳基、C5-C10杂芳基、卤代C1-C6烷基、4至8元杂脂环基、羟基、C1-C6烷氧基、C6-C10芳氧基。
“烷基胺基”是指氨基中的一个或两个氢原子被烷基取代的基团。包括被直连、支链或环状烷基取代的氨基基团，如甲氨基、二甲氨基、乙氨基、正丙氨基、异丙氨基、正丁氨基、异丁氨基、叔丁氨基、环丙氨基、环丁氨基、戊氨基等。优选的是含有1至4个碳原子的低级直连、支链或环状烷基取代的氨基。
“环烷基”指3至8元全碳单环、全碳5元/6元或6元/6元稠和环或多环稠和环(“稠和”环意味着***中的每个环与***中的其它环共享毗邻的一对碳原子)基团，其中一个 或多个环具有完全连接的π电子***，环烷基的实例(不局限于)为环丙烷、环丁烷、环戊烷、环戊烯、环己烷、金刚烷、环己二烯、环庚烷或环庚三烯。环烷基为可取代的和未取代的。当被取代时，取代基优选为一个或多个各自选自以下的基团，包括：氢、羟基、巯基、氧代、低级烷基、低级烷氧基、低级环烷基、低级杂环烷基、低级卤代烷氧基、烷硫基、卤素、低级卤代烷基、低级羟烷基、低级环烷基亚烷基、低级杂环烷基亚烷、芳基、杂芳基、烷氧基羰基、氨基、烷基氨基、烷基磺酰基、芳基磺酰基、烷基氨基磺酰基、芳基氨基磺酰基、烷基磺酰基氨基、芳基磺酰基氨基、烷基氨基羰基、芳基氨基羰基、烷基羰基氨基、芳基羰基氨基。
“芳基”表示6至14个碳原子的全碳单环或稠合多环基团，具有完全共轭的π电子***。“芳基”包括：
六元的碳芳香环，如，苯；
双环，其中至少有一个环是碳芳香环，如，萘，茚或1,2,3,4-四氢喹啉；以及
三环，其中至少有一个环是碳芳香环，如，芴。
例如，芳基包括含六元的碳芳香环并一个六元杂环，这个杂环包含一个或多个选自氮、氧和硫的杂原子，条件是连接点在碳芳香环上。但是，芳基不包含、也不通过任何方式与下面分别定义的杂环芳基重叠。因此，在此定义，如果一个或多个碳芳香环与一个杂芳香环并环，由此产生的环***是杂芳基，而不是芳基。芳基的非限制性实例有苯基、萘基。芳基可以是取代的或未取代的。当被取代时，优选的基团为：氢、羟基、硝基、氰基、氧代、低级烷基、低级烷氧基、低级环烷基、低级杂环烷基、低级卤代烷氧基、烷硫基、卤素、低级卤代烷基、低级羟烷基、低级环烷基亚烷基、低级杂环烷基亚烷、芳基、杂芳基、烷氧基羰基、氨基、烷基氨基、烷基磺酰基、芳基磺酰基、烷基氨基磺酰基、芳基氨基磺酰基、烷基磺酰基氨基、芳基磺酰基氨基、烷基氨基羰基、芳基氨基羰基、烷基羰基氨基、芳基羰基氨基。
“杂芳基”表示5至14个环原子的单环或稠合环基团，含有一个、两个、三个或四个选自N、O或S的环杂原子，其余环原子是C，另外具有完全共轭的π电子***。杂芳基指的是：
5-8元的单环芳烃，含一个或多个选自N、O和S的杂原子，如1-4个杂原子，在一些实施方案中，1-3个杂原子，环上其他原子是碳原子；
8-12元的双环芳烃，含一个或多个选自N、O和S的杂原子，如1-4个杂原子，在一些实施方案中，1-3个杂原子，环上其他原子是碳原子；其中至少有一个环是芳香环；以及
11-14元的三环芳烃，含一个或多个选自N、O和S的杂原子，如1-4个杂原子，在一些实施方案中，1-3个杂原子，环上其他原子是碳原子；其中至少有一个环是芳香环。
例如，杂芳基包括一个5-6元的杂芳香环并一个5-6元的环烷基。对于这样的双环并起来的杂芳基，其中只有一个环含有一个或多个杂原子，连接位点在杂芳香环上。
当杂芳基上的硫原子和氧原子总数超过1时，这些杂原子不会一一相邻。在一些实施方案中，硫原子和氧原子在杂芳基中的总数不超过2。在一些实施方案中，硫原子和氧原子在杂芳基中的总数不超过1。
杂芳基的例子，包括但不限于，吡咯、呋喃、噻吩、咪唑、噁唑、噻唑、吡唑、三氮唑、嘧啶、吡啶、吡啶酮、咪啶、吡嗪、哒嗪、吲哚、氮杂吲哚、苯并咪唑、苯并三氮唑、吲哚啉、吲哚酮、喹啉、异喹啉、喹唑啉、噻吩并吡啶、噻吩并嘧啶等。此类基团的优选实施例为苯环、吡啶、嘧啶、哒嗪、吡嗪、喹啉、异喹啉、吡咯、吡唑、咪唑、噻吩、噻唑、呋喃或噁唑。杂芳基中的一个或全部氢原子可被下列基团取代：氢、羟基、硝基、氰基、氧代、低级烷基、低级烷氧基、低级环烷基、低级杂环烷基、低级卤代烷氧基、烷硫基、卤素、低级卤代烷基、低级羟烷基、低级环烷基亚烷基、低级杂环烷基亚烷、芳基、杂芳基、烷氧基羰基、氨基、烷基氨基、烷基磺酰基、芳基磺酰基、烷基氨基磺酰基、芳基氨基磺酰基、烷基磺酰基氨基、芳基磺酰基氨基、烷基氨基羰基、芳基氨基羰基、烷基羰基氨基、芳基羰基氨基。
“杂环烷基”表示由一个或多个环，优选1至2个环(包括螺环***)组成的一价饱和环状基团，每个环3至8个原子，其结合有一个或多个环杂原子(选自N，O或S(O)0-2)，并且其可以任选独立地被一个或多个，优选1个或2个取代基取代，所述的取代基选自:氢、羟基、巯基、氧代、低级烷基、低级烷氧基、低级环烷基、低级杂环烷基、低级卤代烷氧基、烷硫基、卤素、低级卤代烷基、低级羟烷基、低级环烷基亚烷基、低级杂环烷基亚烷、芳基、杂芳基、烷氧基羰基、氨基、烷基氨基、烷基磺酰基、芳基磺酰基、烷基氨基磺酰基、芳基氨基磺酰基、烷基磺酰基氨基、芳基磺酰基氨基、烷基氨基羰基、芳基氨 基羰基、烷基羰基氨基、芳基羰基氨基。除非另外指出。
杂环烷基的实例包括但不限于氧杂环丙烷，氮杂环丙烷，吡啶，吗啉-3-酮，硫代吗啉1,1-二氧化物，吗啉基，哌嗪基，哌啶基，氮杂环丁烷基，吡咯烷基，六氢氮杂草基，氧杂环丁烷基，四氢呋喃基，四氢噻吩基，噁唑烷基，噻唑烷基，异噁唑烷基，四氢-2H-吡喃基，硫代吗琳基，奎宁环基和咪唑啉基，优选
Figure PCTCN2017087263-appb-000030
Figure PCTCN2017087263-appb-000031
Figure PCTCN2017087263-appb-000032
W选自O、S或NR12，各基团如前所述，实例还可以是双环的，诸如，例如，3，8-二氮杂-双环[3.2.1]辛烷、2，5-二氮杂双环[2.2.2]辛烷或八氢-吡嗪并[2，1-c][1,4]噁嗪；优选氧杂环丙烷、氧杂环丁烷、四氢呋喃、四氢-2H-吡喃、氮杂环丙烷、氮杂环丁烷、吡咯烷、哌啶、吗啉、吡啶、吗啉-3-酮或硫代吗啉1,1-二氧化物；其杂环烷基(和衍生物)包括其离子形式。
“烷氧基”表示-O-(未取代的烷基)和-O-(未取代的环烷基)。代表性的实例包括但不限于甲氧基、乙氧基、丙氧基、丁氧基、环丙氧基、环丁氧基、环戊氧基、环己氧基等。
“芳氧基”表示-O-芳基和-O-杂芳基。代表性实例包括但不限于苯氧基、吡啶氧基、呋喃氧基、噻吩氧基、嘧啶氧基、吡嗪氧基等及其衍生物。
“芳基亚烷基”表示烷基，优选如上所定义的低级烷基，它被如上所述的芳基取代，例如-CH2苯基、-(CH2)2苯基、-(CH2)3苯基、CH3CH(CH3)CH2苯基及其衍生物。
“杂芳基亚烷基”表示烷基，优选如上所定义的低级烷基，它被如上所述的杂芳基取代，例如-CH2吡啶基、-(CH2)2嘧啶基、-(CH2)3咪唑基等及其衍生物。
“氧代基”表示＝O基团。
“羟基”表示-OH基团。
“巯基”表示-SH基团。
“卤素”表示氟、氯、溴或碘，优选为氟或氯。
“卤代烷基”表示被卤素取代的烷基，优选如上所定义的低级烷基，它被一个或多个相 同或不同的卤原子取代，例如-CH2Cl、-CF3、-CCl3、-CH2CF3、-CH2CCl3等。
“氰基”表示-CN基团。
“氨基”表示-NH2基团。
“硝基”表示-NO2基团。
“四氢-2H-吡喃”表示
Figure PCTCN2017087263-appb-000033
“烷基磺酰基”表示-S(O2)C1-C6烷基，其中烷基定义如上。
“环烷基氧基”表示-OH基团中的H被环烷基取代，其中环烷基的定义如上。
“任意取代的”包括一个或多个取代基取代的情况和未取代的情况，如任意取代的烷基包括未取代的烷基和被一个或多个取代基取代的烷基。
所谓“任选地”的意思是指后续描述的事件或情形可能会也可能不会发生，并且该描述包括事物或情形可能会也可能不会发生，并且该描述包括事物或情形发生和不发生两种情况。
在一些实施方案中，“被一个或多个基团取代”是指在指定的原子或基团中的一个、两个、三个或四个氢原子分别被指定范围的基团中选出的相同或不同的基团替换。
波浪线表示连接位点；
“药学上可接受的盐”表示保留母体化合物的生物有效性和性质的那些盐。这类盐包括：
(1)与酸成盐，通过母体化合物的游离碱与无机酸或有机酸的反应而得，无机酸包括盐酸、氢溴酸、硝酸、磷酸、偏磷酸、硫酸、亚硫酸和高氯酸等，有机酸包括乙酸、丙酸、丙烯酸、草酸、(D)或(L)苹果酸、富马酸、马来酸、羟基苯甲酸、γ-羟基丁酸、甲氧基苯甲酸、邻苯二甲酸、甲磺酸、乙磺酸、萘-1-磺酸、萘-2-磺酸、对甲苯磺酸、水杨酸、酒石酸、柠檬酸、乳酸、扁桃酸、琥珀酸或丙二酸等。
(2)存在于母体化合物中的酸性质子被金属离子代替或者与有机碱配位化合所生成的盐，金属例子例如碱金属离子、碱土金属离子或铝离子，有机碱例如乙醇胺、二乙醇胺、三乙醇胺、氨丁三醇、N-甲基葡糖胺等。
“药物组合物”指将本发明中的化合物中的一个或多个或其药学上可接受的盐、溶剂化物、水合物或前药与一种或多种药学上可接受的辅料的组合。其中“辅料”通常选择本发明所述化合物之外的别的化学成分，例如药学上可接受的药用载体、或其他具有药物效果 的化合物等的混合。药物组合物的目的可以是促进给药给动物的过程，也可以是药物协同作用。
“药用载体”指的是对有机体不引起明显的刺激性和不干扰所给予化合物的生物活性和性质的药物组合物中的非活性成分，例如但不限于：碳酸钙、磷酸钙、各种糖(例如乳糖、甘露醇等)、淀粉、环糊精、硬脂酸镁、纤维素、碳酸镁、丙烯酸聚合物或甲基丙烯酸聚合物、凝胶、水、聚乙二醇、丙二醇、乙二醇、蓖麻油或氢化蓖麻油或多乙氧基氢化蓖麻油、芝麻油、玉米油、花生油等。
前述的药物组合物中，除了包括药学上可接受的载体等外，还可以包括在药(剂)学上常用的辅剂，例如：抗细菌剂、抗真菌剂、抗微生物剂、保质剂、调色剂、增溶剂、增稠剂、表面活性剂、络合剂、蛋白质、氨基酸、脂肪、糖类、维生素、矿物质、微量元素、甜味剂、色素、香精或它们的结合等。
本发明所述的式(I)化合物对RORγt有明显的抑制作用，而RORγt在炎性、代谢性和自身免疫性疾病中有非常重要的作用，抑制RORγt将使得这些疾病得到缓解或有效治疗。
具体实施方式
以下结合实施例用于进一步描述本发明，但这些实施例并非限制着本发明的范围。实施例1：N-(4-乙基苯基)-N-异丁基-4-氧代-2-(四氢-2H-吡喃-4-基)色满-6-磺酰胺化合物EXP 1的制备
Figure PCTCN2017087263-appb-000034
1)化合物2的合成
Figure PCTCN2017087263-appb-000035
将化合物1(10.0g,73.5mmol,1.0eq)在室温下溶于MeCN(200mL)中，加入K2CO3(32.0g,220.5mmol,3.0eq)，室温搅拌三十分钟，再加入MeI(21.0g，147.0mmol，2.0eq)，室温搅拌16小时。LCMS检测反应完全。将溶剂旋干，硅胶拌样，过柱(PE:EA＝40:1),得到化合物2(2.8g,收率：25％)。
TLC:PE/EA＝10:1,UV 254nm
Rf(Compound 1)＝0.6
Rf(Compound 2)＝0.5
2)化合物3的合成
Figure PCTCN2017087263-appb-000036
在单口瓶中加入ClSO3H(30mL,0.46mol,24.6eq),冷却到0℃，再加入化合物2(2.8g，18.7mmol，1.0eq)，搅拌二十分钟，撤去冰水浴，室温反应16小时。TLC点板显示反应完全，有新点生成。将反应液倒入搅拌中的冰水中淬灭，加二氯甲烷萃取，无水硫酸钠干燥，旋干有机相，过柱(PE/EA＝20:1-10:1)，得白色固体化合物3(3.6g，收率：78％)。
TLC:PE/EA＝3:1,UV 254nm
Rf(Compound 2)＝0.8
Rf(Compound 3)＝0.4
3)化合物5的合成
Figure PCTCN2017087263-appb-000037
将化合物3(1.0g，4.32mmol，1.0eq)，化合物4(0.78g，4.44mmol，1.1eq)室温下加入20mL吡啶中，室温下搅拌两小时，TLC显示反应完全。将吡啶旋干，过柱(PE:EA＝20:1-15:1)得到化合物5(1.4g，收率：89％)。
TLC:PE/EA＝3:1,UV 254nm
Rf(Compound 3)＝0.4
Rf(Compound 5)＝0.5
4)化合物6的合成
Figure PCTCN2017087263-appb-000038
将化合物5(0.97g，2.48mmol，1.0eq)溶解于100mL DCM中,冷却到0℃.缓慢滴加BBr3(7.3mL，0.68M in DCM,5.0mmol，2.0eq)。0℃下反应1h.旋干溶剂，过柱(PE:EA＝20:1)得到化合物6(0.33g，收率：33％)。
TLC:PE/EA＝3:1,UV 254nm
Rf(Compound 5)＝0.5
Rf(Compound 6)＝0.7
5)Exp 1的合成
Figure PCTCN2017087263-appb-000039
室温下，将化合物6(170mg，0.45mmol，1.0eq)溶解在MeOH(10mL)中，加入化合物7(62mg，0.54mmol，1.2eq)，吡咯烷(40mg，0.54mmol，1.2eq),80℃下搅拌3小时。TLC显示反应完全，旋干溶剂，prep-HPLC分离制备得到固体化合物
Exp1(70mg,收率:33％).
TLC:PE/EA＝5:1,UV 254nm
Rf(Compound 6)＝0.7
Rf(Compound Exp1)＝0.1
LC-MS:[M+1]＝472.2
1H NMR(400MHz,CDCl3)δ8.13(d,J＝2.0Hz,1H),7.48(dd,J＝8.8,2.4Hz,1H),7.05(d,J＝8.0Hz,2H),6.92(d,J＝8.8Hz,1H),6.89(d,J＝8.4Hz,2H),4.26-4.22(m,1H),4.02-3.98(m,2H),3.41-3.33(m,2H),3.22(d,J＝7.2Hz,2H),2.69(d,J＝7.6Hz,2H),2.57(q,J＝7.6Hz,2H),1.96-1.93(m,1H),1.84-1.80(m,1H),1.55-1.52(m,7H),1.16(t,J＝7.2Hz,3H),0.83(d,J＝6.8Hz,6H).
实施例2：N-(4-乙基苯基)-4羟基-N-异丁基-2-(四氢-2H-吡喃-4-基)色满-6-磺酰胺化合物EXP 2的制备
Figure PCTCN2017087263-appb-000040
室温下，将Exp1(40mg，0.09mmol，1.0eq)溶解在MeOH(5mL)中，加入化合物NaBH4(10mg，0.25mmol，3.0eq),室温下搅拌2小时。TLC显示反应完全，旋干溶剂，prep-HPLC分离制备得到固体化合物Exp 2(21mg,收率:52％).
TLC:PE/EA＝3:1,UV 254nm
Rf(Compound Exp1)＝0.3
Rf(Compound Exp 2)＝0.1
LC-MS:[M+1]＝474.2
1H NMR(400MHz,CDCl3)δ7.60(s,1H),7.27(dd,J＝8.0,2.0Hz,1H),7.05(d,J＝8.0Hz,2H),6.91(d,J＝8.0Hz,2H),6.72(d,J＝8.4Hz,1H),4.84-4.80(m,1H),3.99-3.90(m,3H),3.39-3.33(m,2H),3.22-3.15(m,2H),2.56(q,J＝7.6Hz,2H),2.28-2.23(m,1H),1.91-1.66(m,4H),1.49-1.40(m,4H),1.16(t,J＝7.6Hz,3H),0.84-0.81(m,6H).
实施例3：N-(4-乙基苯基)-4羟基-N-异丁基-4-甲基-2-(四氢-2H-吡喃-4-基)色满-6-磺酰胺化合物EXP 3的制备
Figure PCTCN2017087263-appb-000041
将化合物Exp 1(50mg，0.67mmol，1.0eq)在室温下溶于四氢呋喃(3mL)中，在0℃时，缓慢滴加MeMgBr(1.0ml,1.6mmol,2.5eq),常温搅拌1小时。TLC点板显示反应完全，有新点生成。用饱和氯化铵水溶液(5mL)淬灭，用乙酸乙酯(30mL)萃取三次，合并有机相，用无水硫酸钠干燥，过滤，浓缩得粗品。经prep-HPLC制备分离(流动相：0.1％TFA/CH3CN/H2O)得到白色固体化合物Exp 3(11mg，收率：12％)。
TLC:PE/EA＝5:1,UV 254nm
Rf(Exp 1)＝0.40
Rf(Exp 3)＝0.20
LC-MS:[M+1]＝488
1H NMR(400MHz,CDCl3)δ7.58(s,1H),7.41(dd,J＝8.0,2.4Hz,1H),7.11(d,J＝8.4Hz,2H),6.95(d,J＝8.0Hz,2H),6.82(d,J＝8.4Hz,1H),4.09-4.05(m,2H),3.98-3.94(m,1H),3.43-3.40(m,2H),3.33-3.27(m,1H),3.23-3.17(m,1H),2.63(q,J＝7.6Hz,2H),2.10-2.06(m,1H),1.95-1.85(m,5H),1.50(s,3H),1.25(s,2H),1.22(t,J＝7.6Hz,3H),0.92-0.88(m,
6H).
实施例4：N-(4-乙基苯基)-N-异丁基-4-甲基-2-(四氢-2H-吡喃-4-基)色满-6-磺酰胺化合物EXP 4的制备
Figure PCTCN2017087263-appb-000042
将化合物Exp 3(110mg，0.23mmol，1.0eq)在室温下溶于DCM(5mL)中，加 入Et3SH(1mL，2.3mmol，10.0eq)，在0℃时，滴加BF3***溶液(1mL,2.3mmol,10.0eq),常温搅拌1小时。LCMS显示原料反应完，有产物生成。用饱和氯化铵水溶液(5mL)淬灭，用乙酸乙酯(30mL)萃取三次，合并有机相，用无水硫酸钠干燥，过滤，浓缩得粗品。经机器分离(0.1％TFA/CH3CN/H2O)得到白色固体化合物Exp 4(12mg，收率：11％)。
TLC:PE/EA＝5:1,UV 254nm
Rf(Exp 3)＝0.2
Rf(Exp 4)＝0.4
LC-MS:[M+1]＝472
1H NMR(400MHz,CDCl3)δ7.34(d,J＝8.4Hz,1H),7.29(s,1H),7.11(d,J＝8.0Hz,2H),6.97(d,J＝8.0Hz,2H),6.80(d,J＝8.4Hz,1H),4.06-4.02(m,2H),3.90-3.83(m,2H),3.46-3.40(m,2H),3.28-3.33(m,2H),3.21-3.16(m,1H),2.94-2.89(m,1H),2.62(q,J＝7.6Hz,2H),2.07-2.01(m,1H),1.89-1.86(m,2H),1.62-1.60(m,2H),1.46-1.39(m,2H),1.24(s,1H),1.21(d,J＝7.6Hz,6H),0.90-0.86(m,6H).
实施例5：4-胺基-N-(4-乙基苯基)-N-异丁基-2-(四氢-2H-吡喃-4-基)色满-6-磺酰胺三氟醋酸盐EXP 5的制备
Figure PCTCN2017087263-appb-000043
1)化合物2的制备
将盐酸羟胺(20mg，0.29mmol，2.7eq)溶于5mL的无水乙醇中，室温下加入醋酸钠(50mg，0.61mmol，5.7eq)，室温下搅拌15分钟，然后将Exp 1(50mg，0.11mmol，1.0eq)溶于1.0mL无水乙醇并加入反应液中。室温下搅拌过夜，TLC显示约有30％的原料剩余。补加盐酸羟胺(20mg，0.29mmol，2.7eq)和醋酸钠(50mg，0.61mmol，5.7eq)加入反应液中并在30℃下搅拌5小时，TLC显示原料反应完毕。将反应液旋干后溶于10mL的乙酸乙酯中，用浓度为0.5N的5mL的碳酸钠水溶液洗，再用饱和食盐水洗，无水硫酸钠干燥，旋干后得到白色固体化合物2(50mg，0.10mmol，收率：91％)
TLC:PE/EA＝2:1,UV 254nm
Rf(Exp 1)＝0.3
Rf(Compound 2)＝0.6
2)Exp 5的制备
将化合物2(45mg，0.09mmol，1.0eq)溶于5mL甲醇中，然后加入Raney-Ni(20mg),反应瓶用氮气置换两次后用氢气置换三次。在室温下用氢气球反应过夜。过滤，滤液旋干后用DMSO溶解，然后prep-HPLC制备(流动相：乙腈+水+0.1％三氟乙酸)纯化得到白色固体化合物Exp 5(35mg，0.054mmol,收率：82％)
LC-MS:[M-16]＝456.3
1H NMR(400MHz,DMSO-d6)δ8.53(s,1H),8.36(s,1H),7.95(s,0.5H),7.85(s,0.5H),7.35(d,J＝8.8Hz,0.5H),7.28(d,J＝6.8Hz,0.5H),7.19(d,J＝8.0Hz,2H),7.07-6.87(m,3H),4.71-4.57(m,1H),4.15-4.10(m,1H),3.93(d,J＝8.0Hz,2H),3.25-3.11(m,2H),2.69-2.54(m,3H),2.38-2.32(m,2H),2.05-1.72(m,3H),1.54(br s,1H),1.50-1.31(m,3H),1.17(t,J＝7.6Hz,3H),0.87-0.84(m,6H).
实施例6：N-(4-乙基苯基)-N-异丁基-2-(四氢-2H-吡喃-4-基)色满-6-磺酰胺EXP 6的制备
Figure PCTCN2017087263-appb-000044
将化合物Exp 1(53mg，0.11mmol，1.0eq)加到6mL***中，然后加入2mL浓盐酸，冷却到零度后加入锌粉(588mg，8.99mmol,80eq)。升到室温后在室温下搅拌3小时。过滤，滤液旋干后得到粗品产物。粗品产物用prep-HPLC(流动相：乙腈+水+0.1％三氟乙酸)纯化得到白色固体化合物Exp 6(4mg，0.054mmol,收率：8％)
LC-MS:[M+1]＝458.3
1H NMR(400MHz,MeOD)δ7.23-7.21(m,2H),7.16(d,J＝8.4Hz,2H),6.95(d,J＝8.4Hz,2H),6.82(d,J＝9.2Hz,1H),4.00(d,J＝8.0Hz,2H),3.89-3.85(m,1H),3.47-3.45(m,2H),3.30-3.28(m,2H),2.86-2.71(m,2H),2.64(q,J＝6.8Hz,2H),2.07-2.04(m,1H),1.91-1.88(m,2H),1.78-1.61(m,2H),1.55-1.50(m,3H),1.22(t,J＝7.2Hz,3H),0.89(d,J＝6.8Hz,6H).
实施例7：N-(4-乙基苯基)-N-异丁基-4-甲氧基-2-(四氢-2H-吡喃-4-基)色满-6-磺酰胺EXP 7的制备
Figure PCTCN2017087263-appb-000045
室温下，将Exp 2(80mg，0.17mmol，1.0eq)溶解在THF(5mL)中，加入化合物NaH(13mg，60％in mineral oil,0.34mmol，2.0eq),室温下搅拌0.5小时后再滴加MeI(100mg,0.7mmol,4eq),室温搅拌1.5小时。TLC显示已经反应完全，旋干溶剂,prep-HPLC制备分离(流动相：0.1％TFA/CH3CN/H2O体系)得到固体化合物Exp 7(31mg,收率:37％).
TLC:PE/EA＝1:1,UV 254nm
Rf(Exp 2)＝0.7
Rf(Exp 7)＝0.9
LC-MS:[M+1]＝488.2
1H NMR(400MHz,CDCl3)δ7.60(s,1H),7.23(dd,J＝8.6,2.0Hz,1H),7.05(d,J＝8.0Hz,2H),6.91(d,J＝8.0Hz,2H),6.71(d,J＝8.4Hz,1H),4.45-4.41(m,1H),3.99(d,J＝10.8Hz,2H),3.97-3.87(m,1H),3.40-3.35(m,5H),3.21-3.18(m,2H),2.56(q,J＝7.2Hz,2H),2.30-2.25(m,1H),1.86-1.71(m,7H),1.56-1.46(m,4H),1.16(t,J＝7.6Hz,3H),0.83(d,J＝6.8Hz,6H).
实施例8：N-(2,4-二甲基苯基)-N-异丁基-4-氧代-2-(四氢-2H-吡喃-4-基)色满-6-磺酰胺EXP8的制备
Figure PCTCN2017087263-appb-000046
1)化合物3的制备
Figure PCTCN2017087263-appb-000047
将化合物1(5.0g，41.3mmol，1.0eq)在室温下溶于THF(100mL)中,加入2(2.9g，41.3mmol，1.0eq),室温搅拌1h,在0℃缓慢加入NaBH(OAc)3(12.2g，57.8mmol，1.4eq)，室温搅拌16小时。LCMS检测反应完全。将溶剂旋干，硅胶拌样，过柱(PE:EA＝50:1),得到化合物3(5.0g,收率：68％)。
TLC:PE/EA＝5:1,UV 254nm
Rf(Compound 1)＝0.3
Rf(Compound 3)＝0.7
2)EXP 8的制备
Figure PCTCN2017087263-appb-000048
将化合物4(400mg,1.21mmol,1.0eq)在室温下溶于15mL DCM和3mL MeCN中,再加入化合物3(236mg，1.33mmol，1.1eq)，加入1mL吡啶，室温反应2小时。TLC点板显示反应完全，有新点生成。旋干，加二氯甲烷和水萃取，无水硫酸钠干燥，旋干有机相，刮板(PE/EA＝2:1)，得白色固体化合物5(194mg，收率：34％)。
TLC:PE/EA＝3:1,UV 254nm
Rf(Compound 3)＝0.8
Rf(Compound 4)＝0.3
Rf(EXP 8)＝0.4
LC-MS:[M+1]＝472.6。
实施例9：N-(2,4-二甲基苯基)-4-羟基-N-异丁基-2-(四氢-2H-吡喃-4-基)色满-6-磺酰胺EXP9的制备
Figure PCTCN2017087263-appb-000049
将化合物EXP 8(130mg，0.27mmol，1.0eq)，化合物NaBH4(31.3mg，0.81mmol，3.0eq)室温下加入20mL MeOH中，室温下搅拌两小时，TLC显示反应完全。将MeOH旋干，刮板(PE:EA＝2:1)得到固体化合物EXP 9(63mg，收率：49％)。
TLC:PE/EA＝2:1,UV 254nm
Rf(EXP 8)＝0.6
Rf(EXP 9)＝0.3
1H NMR(400MHz,CDCl3)δ7.67(d,J＝8.0Hz,1H),7.34(d,J＝8.4Hz,1H),7.01(s,1H),6.78-6.74(m,2H),6.45(t,J＝8.4Hz,1H),4.84(br s,1H),4.07-3.88(m,3H),3.44-3.27(m,3H),2.95-2.94(m,1H),2.30-2.27(m,3H),2.22(s,3H),1.97-1.68(m,5H),0.96-0.91(m,3H),0.81-0.78(m,2H),0.73-0.72(m,3H).
实施例10：N-(4-乙基苯基)-N-异丁基-2-(1-甲基哌啶-4-基)-4-氧代-2,3-二氢苯并吡喃-4-酮-6-磺酰胺EXP 10的制备
Figure PCTCN2017087263-appb-000050
参照实施例1的方法，制备获得化合物EXP 10，LC-MS:[M+H]＝485.4。
实施例11：N-(4-乙基苯基)-4-羟基-N-异丁基-2-(1-甲基哌啶-4-基)2,3-二氢苯并吡喃-4-酮-6-磺酰胺EXP 11的制备
Figure PCTCN2017087263-appb-000051
参照实施例2的方法，制备获得化合物EXP 11，LC-MS:[M+H]＝487.3，1H NMR(400MHz,DMSO-d6)δ9.18(br s,1H),7.67(s,1H),7.24(d,J＝8.4Hz,1H),7.18(d,J＝8.0Hz,2H),6.97(d,J＝8.0Hz,2H),6.83(d,J＝8.4Hz,1H),5.75(d,J＝6.4Hz,1H),4.74-4.82(m,1H),4.12-4.20(m,1H),3.43-3.51(m,2H),3.27-3.23(m,2H),3.00-2.89(m,2H),2.77(s,3H),2.60(q,J＝7.6Hz,2H),2.22-2.14(m,1H),2.11-2.03(m,1H),1.93-1.81(m,2H),1.69-1.50(m,3H),1.44-1.36(m,1H),1.17(t,J＝7.6Hz,3H),0.83(d,J＝6.4Hz,6H).
实施例12：N-(4-氟苯基)-N-异丁基-4-氧代-2-(四氢-2H-吡喃-4-基)色满-6-磺酰胺EXP 12的制备
Figure PCTCN2017087263-appb-000052
参照实施例1的方法，制备获得化合物EXP 12，LC-MS:[M+1]＝462.5。
实施例13：N-(4-氟苯基)-4-羟基-N-异丁基-2-(四氢-2H-吡喃-4-基)色满-6-磺酰胺EXP 13的制备
Figure PCTCN2017087263-appb-000053
参照实施例2的方法，制备获得化合物EXP 13，LC-MS:[M+1]＝464.2
1H NMR(400MHz,CDCl3)δ7.69(d,J＝1.2Hz,1H),7.32(dd,J＝8.4Hz,J＝2.0Hz,1H),7.06-6.97(m,4H),6.80(d,J＝8.8Hz,1H),4.93-4.89(m,1H),4.08-3.98(m,3H),3.46-3.40(m, 2H),3.30-3.26(m,2H),2.36-2.32(m,1H),1.92-1.741(m,3H),1.63-1.48(m,3H),0.92-0.89(m,6H).
实施例14：N-异丁基-4-氧代-2-(四氢-2H-吡喃-4-基)-N-(2-(三氟甲基)苄基)色满-6-磺酰胺EXP 14的制备
Figure PCTCN2017087263-appb-000054
参照实施例8的方法，制备了Exp14，LC-MS:[M+1]＝525.6.
实施例15：4-羟基-N-异丁基-2-(四氢-2H-吡喃-4-基)-N-((2-(三氟甲基)苄基)色满-6-磺酰胺EXP 15的制备
Figure PCTCN2017087263-appb-000055
参照实施例9，制备了Exp 15，LC-MS:[M+1]＝528.2
1H NMR(400MHz,CDCl3)δ7.98(d,J＝1.2Hz,1H),7.92(d,J＝7.6Hz,1H),7.65-7.55(m,3H),7.37(t,J＝7.6Hz,1H),6.90(d,J＝8.4Hz,1H),4.99-4.95(m,1H),4.46(s,2H),4.08-4.01(m,2H),3.47-3.41(m,2H),2.94(d,J＝7.2Hz,2H),2.38-2.34(m,1H),1.63-1.46(m,6H),1.50-1.45(m,1H),0.75(d,J＝6.8Hz,6H).
实施例16：N-环丁基-N-(4-乙基苯基)-4-氧代-2-(四氢-2H-吡喃-4-基)色满-6-磺酰胺EXP16的制备
Figure PCTCN2017087263-appb-000056
参照实施例8的方法，制备了Exp16.LC-MS:[M+1]＝470.3
1H NMR(400MHz,CDCl3)δ8.24(d,J＝2.0Hz,1H),7.62(dd,J＝8.8,2.4Hz,1H),7.12(d,J＝8.0Hz,2H),7.00(d,J＝8.8Hz,1H),6.85(d,J＝8.0Hz,2H),4.40-4.37(m,2H),4.07(d,J＝11.6Hz,2H),3.46-3.43(m,2H),2.77(d,J＝1.6Hz,2H),2.62(q,J＝7.6Hz,2H),1.91-1.86(m,6H),1.63-1.57(m,2H),1.55-1.50(m,2H)，1.24(t,J＝7.6Hz,3H).
实施例17：N-环丁基-N-(4-乙基苯基)-4-羟基-2-(四氢-2H-吡喃-4-基)色满-6-磺酰胺EXP17的制备
Figure PCTCN2017087263-appb-000057
参照实施例9，制备了Exp 17，LC-MS:[M+1]＝472.3
1H NMR(400MHz,CDCl3)δ7.72(d,J＝1.2Hz,1H),7.39(dd,J＝8.8,2.0Hz,1H),7.12(d,J＝8.4Hz,2H),6.86(d,J＝8.8Hz,2H),6.80(d,J＝8.4Hz,1H),4.93-4.87(m,1H),4.37-4.31(m,1H),4.07-3.98(m,2H),3.46-3.40(m,2H),2.67-2.61(q,J＝7.6Hz,2H),2.33-2.30(m,1H),1.96-1.74(m,2H),1.65-1.58(m,2H)，1.54-1.50(m,2H)，1.23(t,J＝7.6Hz,3H).
实施例18：N-(4-乙基苯基)-4-氧代-2-(四氢-2H-吡喃-4-基)-N-(2,2,2-三氟乙基)色满-6-磺酰胺EXP 18的制备
Figure PCTCN2017087263-appb-000058
参照实施例8的方法，制备了Exp18，LC-MS:[M+1]＝498.5
实施例19：N-(4-乙基苯基)-4-羟基-2-(四氢-2H-吡喃-4-基)-N-(2,2,2-三氟乙基)色满-6-磺酰胺EXP 19的制备
Figure PCTCN2017087263-appb-000059
参照实施例9的方法，制备了Exp19.
1H NMR(400MHz,CDCl3)δ7.74(s,1H),7.37(d,J＝8.4Hz,1H),7.14(d,J＝8.0Hz,2H),6.98(d,J＝8.0Hz,2H),6.81(d,J＝8.8Hz,1H),5.35(br s,1H),4.91-4.87(m,1H),4.18-3.99(m,5H),3.46-3.40(m,2H),2.64(d,J＝8.0Hz,2H),2.36-2.31(m,1H),2.21(d,J＝7.7Hz,1H),2.03-1.73(m,4H),1.24(t,J＝7.6Hz,3H).
实施例20：N-(4-乙基苯基)-4-氧代-2-(四氢-2H-吡喃-4-基)色满-6-磺酰胺EXP 20的制备
Figure PCTCN2017087263-appb-000060
参照实施例8的方法，制备了Exp20，LC-MS:[M+1]＝416.5.
实施例21：N-(4-乙基苯基)-4-羟基-2-(四氢-2H-吡喃-4-基)色满-6-磺酰胺EXP 21的制备
Figure PCTCN2017087263-appb-000061
参照实施例9的方法，制备了Exp21.
1H NMR(400MHz,CDCl3)δ7.98(s,1H),7.46(d,J＝8.0Hz,1H),7.04(d,J＝8.0Hz,2H),6.98(d,J＝8.0Hz,2H),6.74(d,J＝8.8Hz,1H),4.88-4.86(m,1H),4.09-3.93(m,4H),3.42-3.37(m,2H),2.84(br s,1H),2.55(q,J＝7.6Hz,2H),2.26-2.30(m,1H),1.85-1.75(m,2H),1.54-1.43(m,2H),1.26(s,2H),1.17(t,J＝7.6Hz,3H).
实施例22：N-(2-氟苯基)-N-异丁基-4-氧代-2-(四氢-2H-吡喃-4-基)色满-6-磺酰胺EXP22的制备
Figure PCTCN2017087263-appb-000062
参照实施例8的方法，制备了Exp22.
1H NMR(400MHz,CDCl3)δ8.16(d,J＝2.0Hz,1H),7.60(dd,J＝8.4,2.4Hz,1H),7.27-7.22(m,2H),7.09-7.05(m,1H),6.95-6.91(m,2H),4.28-4.24(m,1H),4.01(d,J＝12.2Hz,2H),3.28(d,J＝7.6Hz,2H),2.69(d,J＝7.6Hz,2H),1.96-1.92(m,1H),1.82(d,J＝14.0Hz,1H),1.64(br s,2H),1.54-1.49(m,2H),0.85(d,J＝6.4Hz,6H).
实施例23：N-(2-氟苯基)-4-羟基-N-异丁基-2-(四氢-2H-吡喃-4-基)色满-6-磺酰胺EXP23的制备
Figure PCTCN2017087263-appb-000063
参照实施例9的方法，制备了Exp23.
1H NMR(400MHz,CDCl3)δ7.71(s,1H),7.36(dd,J＝8.4,2.4Hz,1H),7.22-7.19(m,2H),7.05(t,J＝7.6Hz,1H),6.96(t,J＝9.6Hz,1H),6.74(d,J＝8.8Hz,1H),4.86-4.81(m,1H),4.00-3.91(m,3H),3.39-3.36(m,2H),3.30-3.22(m,2H),2.29-2.24(m,1H),1.88-1.66(m,4H),1.55-1.45(m,4H),0.85-0.83(m,6H).
实施例24：N-(4-氰基-苯基)-N-异丁基-4-氧代-2-(四氢-2H-吡喃-4-基)色满-6-磺酰胺EXP 24的制备
Figure PCTCN2017087263-appb-000064
参照实施例8的方法，制备了Exp24.
1H NMR(400MHz,CDCl3)δ8.16(d,J＝2.0Hz,1H),7.62(d,J＝8.8Hz,2H),7.51(dd,J＝8.8,2.4Hz,1H),7.23(d,J＝8.8Hz,2H),7.01(d,J＝8.8Hz,1H),4.33-4.30(m,1H),4.08(d,J＝12.4Hz,2H),3.46-3.41(m,2H),3.36(d,J＝7.2Hz,2H),2.76(d,J＝7.6Hz,2H),2.04-2.00(m,2H),1.98-1.90(m,2H),1.62-1.55(m,2H),0.90(d,J＝6.4Hz,6H).
实施例25：N-(4-氰基-苯基)-4-羟基-N-异丁基-2-(四氢-2H-吡喃-4-基)色满-6-磺酰胺EXP 25的制备
Figure PCTCN2017087263-appb-000065
参照实施例9的方法，制备了Exp25.
1H NMR(400MHz,CDCl3)δ7.60(s,1H),7.54(d,J＝8.4Hz,2H),7.22-7.7.16(m,3H),6.73(d,J＝8.8Hz,1H),4.85-4.80(m,1H),3.99-3.91(m,3H),3.39-3.35(m,2H),3.26-3.22(m,2H),2.28-2.23(m,1H),2.00(br s,2H),1.89-1.64(m,3H),1.51-1.43(m,2H),0.84-0.82(m,6H).
实施例26：N-((5-(乙基磺酰基)吡啶-2-基)亚甲基)-4-氧代-2-(四氢-2H-吡喃-4-基)色满-6-磺酰胺EXP 26的制备
Figure PCTCN2017087263-appb-000066
参照实施例8的方法，制备了Exp26.
LC-MS:[M+1]＝495.1
1H NMR(400MHz,CD3OD)δ8.76(d,J＝1.6Hz,1H),8.10(dd,J＝8.0,2.0Hz,1H),8.06(d,J＝2.0Hz,1H),7.86(dd,J＝8.4,2.0Hz,1H),7.53(d,J＝8.4Hz,1H),7.06(d,J＝8.4Hz,1H),4.36(s,3H),4.03-4.00(m,2H),3.47-3.45(m,2H),3.23(q,J＝7.4Hz,2H),2.89-2.80(m,1H),2.70-2.68(m,1H),2.03(br s,1H),1.90(d,J＝11.2Hz,1H),1.68-1.47(m,3H),1.18(t,J＝7.6Hz,3H).
实施例27：N-((5-(乙基磺酰基)吡啶-2-基)亚甲基)-4-羟基-2-(四氢-2H-吡喃-4-基)色满-6-磺酰胺EXP 27的制备
Figure PCTCN2017087263-appb-000067
参照实施例9的方法，制备了Exp27.
LC-MS:[M+1]＝497.2
1H NMR(400MHz,DMSO)δ8.85(d,J＝1.6Hz,1H),8.29(t,J＝6.4Hz,1H),8.20(dd,J＝8.4,2.4Hz,1H),7.82(d,J＝1.2Hz,1H),7.61(d,J＝8.0Hz,1H),7.47(dd,J＝8.4,2.0Hz,1H),6.80(d,J＝8.4Hz,1H),4.76-4.72(m,1H),4.19(d,J＝6.4Hz,2H),4.09-4.05(m,1H),3.92-3.88(m,2H),3.39-3.25(m,4H),2.20-2.16(m,1H),1.84(br s,1H),1.76(d,J＝13.2Hz,1H),1.60-1.58(m,2H),1.49-1.22(m,3H),1.11(t,J＝7.2Hz,3H).
实施例28：N-(4-乙基苯基)–N-异丁基-4-氧代-2-((四氢-2H-吡喃-4-基)亚甲基)色满-6-磺酰胺EXP 28的制备
Figure PCTCN2017087263-appb-000068
参照实施例1的方法，制备了Exp28.
LC-MS:[M+H]＝486.4
1H NMR(400MHz,CDCl3)δ8.20(d,J＝2.0Hz,1H),7.55(d,J＝11.2Hz,1H),7.13(d,J＝8.4Hz,2H),7.00-6.95(m,3H),4.70-4.60(m,1H),3.99(d,J＝14.0Hz,2H),3.43(t,J＝12.0Hz,2H),3.29(d,J＝7.6Hz,2H),2.79-2.70(m,2H),2.64(q,J＝7.6Hz,2H),1.98-1.83(m,2H),1.74-1.61(m,3H),1.46-1.34(m,3H),1.23(t,J＝7.6Hz,3H),0.91(d,J＝6.4Hz,6H).
实施例29：N-(4-乙基苯基)-4-羟基-N-异丁基-2-((四氢-2H-吡喃-4-基)亚甲基)色满-6-磺酰胺EXP 29的制备
Figure PCTCN2017087263-appb-000069
参照实施例2的方法，制备了Exp29.
LC-MS:[M+H]＝488.4
1H NMR(400MHz,CDCl3)δ7.67(s,1H),7.34(dd,J＝8.5,2.0Hz,1H),7.12(d,J＝8.0Hz,2H),6.97(d,J＝8.0Hz,2H),6.80(d,J＝8.8Hz,1H),4.91-4.87(m,1H),4.33-4.28(m,1H),3.98(d,J＝13.6Hz,2H),3.47-3.41(m,2H),3.35-3.16(m,2H),2.63(q,J＝7.6Hz,2H),2.32-2.27(m,1H),1.81-1.28(m,10H),1.23(t,J＝7.6Hz,3H),0.92-0.88(m,6H).
实施例30：N-(3-氟苯基)-4-羟基-N-异丁基-2-(四氢-2H-吡喃-4-基)色满-6-磺酰胺EXP 30的制备
Figure PCTCN2017087263-appb-000070
参照实施例2的方法，制备了Exp30.
LC-MS:[M+1]＝464.3
1H NMR(400MHz,CDCl3)δ7.62(d,J＝1.2Hz,1H),7.26-7.21(m,2H),7.22-7.16(m,1H),6.94-6.90(m,1H),6.85(d,J＝7.6Hz,1H),6.73(d,J＝8.8Hz,2H),4.84-4.79(m,1H),3.99-3.91(m,3H),3.39-3.32(m,2H),3.22-3.18(m,2H),2.28-2.23(m,1H),1.85-1.65(m,3H),1.59-1.40(m,4H),0.84-0.82(m,6H).
实施例31：N-(4-乙基苯基)-N-异丁基-2-(1-(甲基磺酰基)哌啶-4-基)-4-氧代色满-6-磺酰胺EXP 31的制备
Figure PCTCN2017087263-appb-000071
参照实施例1的方法，制备了Exp31.
LC-MS:[M+H]＝449.4
1H NMR(400MHz,CDCl3)δ8.20(d,J＝2.4Hz,1H),7.56(dd,J＝8.4,2.0Hz,1H),7.13(d,J＝8.0Hz,2H),7.00(d,J＝8.4Hz,1H),6.96(d,J＝8.4Hz,2H),4.38-4.35(m,1H),3.94(d,J＝11.2Hz,2H),3.29(d,J＝7.6Hz,2H),2.81(s,3H),2.78-2.61(m,6H),2.10(d,J＝12.9Hz,1H),1.86(d,J＝12.1Hz,2H),1.71-1.58(m,3H),1.23(t,J＝7.6Hz,3H),0.91(d,J＝6.8Hz,6H).
实施例32：N-(4-乙基苯基)-4-羟基-N-异丁基-2-(1-(甲基磺酰基)哌啶-4-基)色满-6-磺酰胺EXP 32的制备
Figure PCTCN2017087263-appb-000072
参照实施例2的方法，制备了Exp32.
LC-MS:[M+H]＝551.2
1H NMR(400MHz,CDCl3)δ7.67(s,1H),7.35(dd,J＝8.4,2.0Hz,1H),7.12(d,J＝8.0Hz,2H),6.97(d,J＝8.4Hz,2H),6.80(d,J＝8.4Hz,1H),4.94-4.85(m,1H),4.08-4.01(m,1H),3.92(d,J＝11.4Hz,2H),3.33-3.18(m,2H),2.80(s,3H),2.71-2.59(m,4H),2.36-2.27(m,1H),2.07(d,J＝11.7Hz,1H),1.90-1.75(m,4H),1.68-1.57(m,2H),1.23(t,J＝7.6Hz,3H),0.92-0.88(m,6H).
实施例33：N-(4-乙基苯基)-4-羟基-N-异丁基-2-(哌啶-4-基)色满-6-磺酰胺EXP 33的制备
Figure PCTCN2017087263-appb-000073
参照实施例2的方法，制备了Exp33.
LC-MS:[M+H]＝473.4
1H NMR(400MHz,CDCl3)δ9.53(br s,1H),8.97(br s,1H),7.69(s,1H),7.32(d,J＝8.8Hz,1H),7.13(d,J＝8.4Hz,2H),6.97(d,J＝8.0Hz,2H),6.78(d,J＝8.4Hz,1H),4.95-4.81(m,1H),4.09-3.98(m,1H),3.56-3.38(m,2H),3.32-3.19(m,2H),2.9-2.81(m,2H),2.63(q,J＝7.2Hz,2H),2.33-2.18(m,2H),2.12(d,J＝15.0Hz,2H),1.98-1.88(m,3H),1.61-1.48(m,1H),1.23(t,J＝7.6Hz,3H),0.92-0.88(m,6H).
实施例34：N-(4-乙基苯基)-4氟-N-异丁基-2-(四氢-2H-吡喃-4-基)色满-6-磺酰胺化合物EXP 34的制备
Figure PCTCN2017087263-appb-000074
参照实施例2的方法，制备了Exp34.
LC-MS:[M+1]＝476.2
1H NMR(400MHz,CDCl3)δ7.56(s,1H),7.47(d,J＝8.8Hz,1H),7.13(d,J＝8.0Hz,2H),6.98(d,J＝5.2Hz,2H),6.92(d,J＝8.8Hz,1H),5.5(m,1H),4.08-4.03(m,3H),3.49-3.41(m,2H),3.26(d,J＝7.6Hz,2H),2.66(q,J＝8.0Hz,2H),2.3(m,1H),1.94-1.81(m,3H),1.66-1.51(m,4H),1.23(t,J＝7.6Hz,3H),0.91-0.84(m,6H).
实施例35：(四氢-2H-吡喃-4-基)-N-(2-(三氟甲基)苯基)苯并二氢吡喃-6-磺酰胺化合物EXP 35的制备
Figure PCTCN2017087263-appb-000075
参照实施例2的方法，制备了Exp35.
LC-MS:[M+Na]+＝536.2
1H NMR(400MHz,CDCl3)δ7.83(dd,J＝14.0,2.0Hz,1H),7.72(d,J＝7.6Hz,1H),7.51-7.45(m,3H),7.17-7.13(m,1H),6.85(dd,J＝8.6,1.2Hz,1H),4.94-4.92(m,1H),4.11(d,J＝11.4Hz,2H),4.07-3.97(m,1H),3.50-3.44(m,2H),3.35-3.30(m,1H),3.28-3.02(m,5H),2.35-2.30(m,1H),1.99-1.75(m,3H),1.60-1.53(m,1H),0.90-0.86(m,3H),0.79-0.77(m,3H).
实施例36：2-(3,5-二甲基异恶唑-4-基)-N-(4-乙基苯基)-N-异丁基-4-氧代辛烷-6-磺酰胺化合物EXP 36的制备
Figure PCTCN2017087263-appb-000076
参照实施例1的方法，制备了Exp36
LC-MS:[M+1]＝483.3
1H NMR(400MHz,CDCl3)δ13.15(s,1H),7.87(d,J＝2.0Hz,1H),7.76-7.70(m,2H),7.13-7.60(m,3H),7.02-6.97(m,3H),3.29(d,J＝7.2Hz,2H),2.64-2.50(m,5H),2.37(s,3H),1.29-1.27(m,1H),1.16(t,J＝7.6Hz,3H),0.91(d,J＝6.6Hz,6H).
实施例37：N-(2,4-二氟苯基)-N-异丁基-4-氧代-2-(四氢-2H-吡喃-4-基)苯并二氢吡喃-6-磺酰胺化合物EXP 37的制备
Figure PCTCN2017087263-appb-000077
参照实施例1的方法，制备了Exp37
LC-MS:[M+1]＝480.16
1H NMR(400MHz,DMSO)δ7.88(d,J＝1.2Hz,1H),7.75(dd,J＝8.4,2.0Hz,1H),7.41-7.35(m,1H),7.27(d,J＝8.8Hz,1H),7.25-7.18(m,1H),7.13-7.10(m,1H),4.54-4.50(m,1H),3.94-3.90(m,2H),3.26(d,J＝7.2Hz,4H),2.98-2.88(m,1H),2.77-2.67(m,1H),1.99(br s,1H),1.82(d,J＝12.4Hz,1H),1.58(d,J＝12.4Hz,1H),1.51-1.37(m,3H),0.88(d,J＝6.4Hz,6H).
实施例38：2-(1-(环戊基磺酰基)哌啶-4-基)-N-(4-乙基苯基)-N-异丁基-4-氧代辛烷-6-磺酰胺化合物EXP 38的制备
Figure PCTCN2017087263-appb-000078
参照实施例1的方法，制备了Exp38
1H NMR(400MHz,CD3Cl)δ8.19(d,J＝2.0Hz,1H),7.54(dd,J＝8.4,2.0Hz,1H),7.12(d,J＝8.0Hz,2H),7.01-6.94(m,3H),4.37-4.31(m,1H),3.95(d,J＝12.0Hz,2H),3.44-3.42(m,1H),3.29(d,J＝7.6Hz,1H),2.86-2.74(m,4H),2.64(q,J＝7.2Hz,2H),2.01-1.97(m,5H),1.81-1.75(m,4H),1.64-1.53(m,5H),1.23(t,J＝7.2Hz,1H),0.90(d,J＝6.4Hz,6H).
实施例39：N-环丁基-N-(2,4-二甲基苯基)-4-氧代-2-(四氢-2H-吡喃-4-基)苯并二氢吡喃-6-磺酰胺化合物EXP 39的制备
Figure PCTCN2017087263-appb-000079
参照实施例1的方法，制备了Exp39
LC-MS:[M+1]＝470.19
1H NMR(400MHz,DMSO)δ7.92(dd,J＝8.4,2.4Hz,1H),7.80-7.74(m,1H),7.27(dd,J＝ 8.8,2.0Hz,1H),7.18(s,1H),6.92(d,J＝7.2Hz,1H),6.38-6.36(m,1H),4.59-4.40(m,2H),3.98-3.85(m,2H),3.01-2.88(m,1H),2.74(d,J＝15.0Hz,1H),2.28(s,3H),2.22(s,3H),2.00-1.96(m,1H),1.86-1.83(m,2H),1.74-1.66(m,1H),1.62-1.55(m,3H),1.54-1.37(m,4H),0.94(d,J＝6.8Hz,1H).
实施例40：N-(4-(二甲基氨基)苯基)-N-异丁基-4-氧代-2-(四氢-2H-吡喃-4-基)苯并二氢吡喃-6-磺酰胺化合物EXP 40的制备
Figure PCTCN2017087263-appb-000080
参照实施例1的方法，制备了Exp40
1H NMR(400MHz,CD3Cl)δ8.15(d,J＝2.0Hz,1H),7.50(dd,J＝8.4,2.0Hz,1H),6.91(d,J＝8.4Hz,1H),6.82(d,J＝8.8Hz,2H),6.55(d,J＝9.2Hz,2H),4.27-4.23(m,1H),4.00(d,J＝11.8Hz,2H),3.42-3.32(m,2H),3.19(d,J＝7.2Hz,2H),2.89(s,6H),2.74-2.57(m,2H),1.98-1.91(m,1H),1.87-1.73(m,1H),1.55-1.45(m,4H),0.84(d,J＝6.4,6H).
实施例41：2-(1-(环戊烷羰基)哌啶-4-基)-N-(4-乙基苯基)-N-异丁基-4-氧代辛烷-6-磺酰胺化合物EXP 41的制备
Figure PCTCN2017087263-appb-000081
参照实施例1的方法，制备了Exp41
1H NMR(400MHz,CDCl3)δ8.19(d,J＝2.4 1H),7.54(dd,J＝2.4,8.8Hz 1H),7.12(d,J＝8.0,Hz,2H),6.69(m,3H),4.79(br s,1H),4.33(br s,1H),4.11(br s,1H),3.28(d,J＝7.8,2H), 3.11(br s,1H),2.93(br s,1H),2.91-2.55(m,5H),2.02(m,2H),1.76(m,7H),1.61(m,3H),1.42(m,2H),1.23(t,J＝7.6Hz,3H),0.90-0.84(m,6H).
实施例42：N-异丁基-N-(2-甲基-6-吗啉代吡啶-3-基)-4-氧代-2-(四氢-2H-吡喃-4-基)苯并二氢吡喃-6-磺酰胺化合物EXP 42的制备
Figure PCTCN2017087263-appb-000082
参照实施例1的方法，制备了Exp42
1H NMR(400MHz,CDCl3)δ8.11(dd,J＝6.0,2.4Hz,1H),7.71-7.59(m,1H),7.25(dd,J＝9.4,2.4Hz,1H),7.02(d,J＝8.8Hz,1H),6.53(d,J＝8.8Hz,1H),4.38-4.20(m,1H),4.01(d,J＝11.9Hz,2H),3.78(t,J＝4.8Hz,4H),3.64-3.60(m,4H),3.37-3.30(m,2H),3.27-3.07(m,2H),2.75-2.71(m,2H),2.20(d,J＝4.5Hz,3H),1.99-1.95(m,1H),1.83(d,J＝13.3Hz,1H),1.61-1.43(m,4H),0.86-0.82(m,6H).
实施例43：N-(环丁基甲基)-N-(4-乙基苯基)-4-氧代-2-(四氢-2H-吡喃-4-基)苯并二氢吡喃-6-磺酰胺化合物EXP 43的制备
Figure PCTCN2017087263-appb-000083
参照实施例1的方法，制备了Exp43
1H NMR(400MHz,CDCl3)δ8.25(d,J＝2.0Hz,1H),7.61(dd,J＝8.0,2.4Hz,1H),7.13(d,J＝8.4Hz,2H),7.02(d,J＝8.8Hz,1H),6.93(d,J＝8.4Hz,2H),4.39-4.29(m,1H),4.10d,J＝12.8Hz,2H),3.55(d,J＝7.6Hz,2H),3.51-3.40(m,2H),2.79(d,J＝7.2Hz,2H),2.66(q,J＝7.6Hz,2H),2.37-2.27(m,1H),2.10-1.98(m,1H),1.97-1.87(m,3H),1.87-1.76(m,2H), 1.75-1.63(m,5H),1.25(t,J＝7.6Hz,3H).
实施例44：N-(4-乙基苯基)-N-异丁基-2-(4-甲基四氢-2H-吡喃-4-基)-4-氧代辛烷-6-磺酰胺化合物EXP 44的制备
Figure PCTCN2017087263-appb-000084
参照实施例1的方法，制备了Exp44
1H NMR(400MHz,CDCl3)δ8.13(d,J＝2.0Hz,1H),7.48(dd,J＝8.8,2.0Hz,1H),7.06(d,J＝8.4Hz,2H),6.95-6.88(m,3H),4.13-4.11(m,1H),3.80-3.77(m,2H),3.58(t,J＝11.7Hz,2H),3.22(d,J＝7.2Hz,2H),2.74-2.62(m,1H),2.57(q,J＝7.2Hz,2H),1.80-1.60(m,1H),1.57-1.46(m,4H),1.16(t,J＝7.6Hz,3H),1.07(s,3H),0.84(d,J＝6.4Hz,6H).
实施例45：N-(4-(叔丁基)苯基)-N-异丁基-4-氧代-2-(四氢-2H-吡喃-4-基)色满-6-磺酰胺化合物EXP 45的制备
Figure PCTCN2017087263-appb-000085
参照实施例1的方法，制备了Exp45
1H NMR(400MHz,CDCl3)δ8.12(d,J＝2.4Hz,1H),7.48(dd,J＝8.8,2.4Hz,1H),7.23(d,J＝8.4Hz,2H),6.94-6.89(m,1H),4.28-4.22(m,1H),4.08(d,J＝12.1Hz,2H),3.43-3.33(m,2H),3.22(d,J＝7.6Hz,2H),2.69(d,J＝7.6Hz,2H),1.98-1.92(m,2H),1.84(d,J＝13.6Hz,2H),1.56-1.27(m,4H),1.23(s,9H),0.77(d,J＝6.8Hz,6H).
实施例46：N-(4-乙基苯基)-2-(1-((S)-2-羟基丙酰基)哌啶-4-基)-N-异丁基-4-氧代辛烷-6-磺酰胺化合物EXP 46的制备
Figure PCTCN2017087263-appb-000086
参照实施例1的方法，制备了Exp46
1H NMR(400MHz,CD3Cl)δ8.19(d,J＝1.2Hz,1H),7.55(d,J＝8.4Hz,1H),7.12(d,J＝8.0Hz,2H),7.01-6.94(m,3H),4.75(br s,1H),4.49(br s,1H),4.36-4.33(m,1H),3.84(d,J＝10.4Hz,1H),3.29(d,J＝7.2Hz,2H),3.12-3.07(m,1H),2.78-2.61(m,5H),2.43(br s,3H),2.17(br s,2H),1.84-1.81(m,1H),1.61-1.57(m,1H),1.52-1.46(m,1H),1.35(br s,3H),1.25(t,J＝7.6Hz,3H),0.90(d,J＝6.8Hz,6H).
实施例47：N-苄基-N-(4-乙基苯基)-4-氧代-2-(四氢-2H-吡喃-4-基)苯并二氢吡喃-6-磺酰胺化合物EXP 47的制备
Figure PCTCN2017087263-appb-000087
参照实施例1的方法，制备了Exp47
1H NMR(400MHz,CDCl3)δ8.22(d,J＝2.4Hz,1H),7.59-7.54(m,1H),7.15-7.12(m,5H),6.96(d,J＝8.4Hz,3H),6.82(d,J＝8.4Hz,2H),4.65(s,2H),4.29-4.23(m,1H),4.01(d,J＝10.9Hz,2H),3.42-3.33(m,2H),2.70(d,J＝7.2Hz,2H),2.50(q,J＝7.6Hz,2H),1.84(d,J＝13.0Hz,1H),1.10(t,J＝7.6Hz,3H).
实施例48：N-(4-乙基苯基)-N-异丁基-2-(氧杂环丁烷-3-基)-4-氧代辛烷-6-磺酰胺化合物EXP 48的制备
Figure PCTCN2017087263-appb-000088
参照实施例1的方法，制备了Exp48
LC-MS:[M+1]＝444
1H NMR(400MHz,CDCl3)δ8.15(d,J＝2.0Hz,1H),7.51(dd,J＝8.4,2.4Hz,1H),7.06(d,J＝8.4Hz,2H),6.98(d,J＝8.8Hz,1H),6.89(d,J＝8.4Hz,2H),4.89-4.4.83(m,2H),4.78-4.4.73(m,2H),4.57(t,J＝6.4Hz,1H),3.36-3.31(m,2H),3.23(d,J＝7.6Hz,2H),2.62-2.54(m,3H),1.55-1.47(m,1H),1.16(t,J＝7.6Hz,3H),0.84(d,J＝6.8Hz,6H).
实施例49：N-(4-氟苄基)-4-氧代-2-(四氢-2H-吡喃-4-基)-N-((5-(三氟甲基)呋喃-2-基)甲基)色满-6-磺酰胺化合物EXP 49的制备
Figure PCTCN2017087263-appb-000089
参照实施例1的方法，制备了Exp49
LC-MS:[M-19]＝548.1
1H NMR(400MHz,CDCl3)δ8.17(d,J＝2.4Hz,1H),7.80(dd,J＝8.8,2.4Hz,1H),7.23-7.21(m,2H),7.00-6.94(m,3H),6.52(d,J＝2.0Hz,1H),6.13(d,J＝3.2Hz,1H),4.27-4.19(m,6H),4.03-3.99(m,2H),3.42-3.34(m,2H),2.69-2.66(m,2H),1.97-1.94(m,1H),1.84(d,J＝12.8Hz,1H),1.57-1.53(m,2H).
实施例50：N-(环丙基甲基)-N-(4-乙基苯基)-4-氧代-2-(四氢-2H-吡喃-4-基)苯并二氢吡喃-6-磺酰胺化合物EXP 50的制备
Figure PCTCN2017087263-appb-000090
参照实施例1的方法，制备了Exp50
1H NMR(400MHz,CDCl3)δ8.17(d,J＝2.0Hz,1H),7.55(dd,J＝8.8,2.0Hz,1H),7.06(d,J＝8.4Hz,2H),6.94-6.92(m,3H),4.27-4.22(m,1H),4.00(d,J＝12.0Hz,2H),3.42-3.31(m,4H),2.69(d,J＝7.2Hz,2H),2.58(q,J＝7.6Hz,2H),1.96-1.92(m,1H),1.82(J＝13.2Hz,1H),1.56-1.42(m,4H),1.16(t,J＝7.6Hz,3H),0.85-0.72(m,2H),0.38-0.30(m,2H).
实施例51：N-(4-(1,1,1,3,3,3-六氟-2-羟基丙-2-基)-2-甲基苯基)-N-异丁基-4-氧代-2-(四氢-2H-吡喃-4-基)色满-6-磺酰胺化合物EXP 51的制备
Figure PCTCN2017087263-appb-000091
参照实施例1的方法，制备了Exp51
LC-MS:[M+1]＝624.2
1H NMR(400MHz,CDCl3)δ8.23-8.21(m,1H),7.63-7.52(m,2H),7.40-7.36(m,1H),7.04-7.02(m,1H),6.73(d,J＝9.4Hz,,1H),4.35-4.32(m,1H),4.10-4.06(m,3H),3.48-3.41(m,3H),3.11-3.06(m,1H),2.78(d,J＝8.4Hz,2H),2.465(d,J＝4.1Hz,3H),2.07-2.00(m,2H),1.92-1.89(m,1H),1.66-1.60(m,2H),1.03-1.01(m,3H),0.83(d,J＝6.6Hz,3H).
实施例52：2-(1-(环戊烷羰基)哌啶-4-基)-N-(4-乙基苯基)-N-异丁基-4-氧代辛烷-6-磺酰胺化合物EXP 52的制备
Figure PCTCN2017087263-appb-000092
参照实施例1的方法，制备了Exp52
1H NMR(400MHz,CD3Cl)δ8.19(d,J＝2.0Hz,1H),7.55(dd,J＝8.4,2.0Hz,1H),7.12(d,J＝8.4Hz,2H),7.00-6.94(m,3H),4.78(d,J＝12.8Hz,1H),4.35-4.31(m,1H),4.11(d,J＝12.8Hz,1H),3.29(d,J＝7.6Hz,1H),3.10-3.03(m,1H),2.92-2.90(m,1H),2.77-2.75(m,2H),2.66-2.55(m,3H),2.00(br s,3H),1.82(br s,5H),1.62-1.53(m,3H),1.43-1.38(m,2H),1.22(t,J＝7.6Hz,4H),0.90(d,J＝6.8Hz,6H).
实施例53：N-(苯并[b]噻吩-2-基)-N-异丁基-4-氧代-2-(四氢-2H-吡喃-4-基)苯并二氢吡喃-6-磺酰胺化合物EXP 53的制备
Figure PCTCN2017087263-appb-000093
参照实施例1的方法，制备了Exp53
LC-MS:[M+1]＝500.2
1H NMR(400MHz,CDCl3)δ8.23(d,J＝2.4Hz,1H),7.65-7.59(m,3H),7.28-7.23(m,2H),7.12(s,1H),6.93(d,J＝8.8Hz,1H),4.26-4.23(m,1H),4.02-3.99(m,2H),3.41-3.32(m,3H),2.69(d,J＝8.0Hz,1H),1.97-1.92(m,1H),1.83-1.74(m,2H),1.61-1.44(m,4H),0.90(d,J＝6.4Hz,6H)
实施例54：N-环丁基-N-(2,4-二甲基苯基)-4-氧代-2-((四氢-2H-吡喃-4-基)甲基)色满-6-磺酰胺化合物EXP 54的制备
Figure PCTCN2017087263-appb-000094
参照实施例1的方法，制备了Exp54
1H NMR(400MHz,CD3Cl)δ8.31-8.29(m,1H),7.73-7.71(m,1H),7.12(s,1H),7.03(dd,J＝8.0,2.8Hz,1H),6.85(d,J＝7.2Hz,1H),6.40-6.38(m,1H),4.68(br s,1H),4.56-4.53(m,1H),4.01-3.97(m,2H),3.43(t,J＝11.6Hz,2H),2.75(d,J＝7.6Hz,2H),2.31(s,3H),2.29(s,3H),2.25-2.22(m,1H),1.92-1.84(m,7H),1.48-1.40(m,4H).
实施例55：N-(4-乙基苯基)-2-(3-羟基环丁基)-N-异丁基-4-氧代辛烷-6-磺酰胺化合物EXP 55的制备
Figure PCTCN2017087263-appb-000095
参照实施例1的方法，制备了Exp55
1H NMR(400MHz,CDCl3)δ7.82(d,J＝2.0Hz,1H),7.60(dd,J＝8.4Hz,1.6Hz,1H),7.08(d,J＝8.4Hz,2H),6.99(d,J＝8.8Hz,1H),6.91(d,J＝8.4Hz,2H),6.63(d,J＝14.8Hz,1H),4.24-4.20(m,1H),3.22(d,J＝7.2Hz,2H),2.60-2.51(m,4H),1.88-1.66(m,5H),1.62-1.48(m,2H),1.15(t,J＝7.6Hz,3H),0.85(d,J＝6.8Hz,6H).
实施例56：N-(4-乙基苯基)-N-异丁基-4-氧代-2-(1-(四氢-2H-吡喃-4-基)乙基)色满-6-磺酰胺化合物EXP 56的制备
Figure PCTCN2017087263-appb-000096
参照实施例1的方法，制备了Exp56
LC-MS:[M+H]＝500.3
1H NMR(400MHz,CDCl3)δ8.20(d,J＝2.4Hz,1H),7.55-7.52(m,1H),7.13(d,J＝8.4Hz,2H),7.03-6.93(m,3H),4.64-4.60(m,1H),4.06-3.96(m,2H),3.41(t,J＝10.9Hz,2H),3.29(d,J＝7.3Hz,2H),2.97-2.87(m,1H),2.74-2.64(m,3H),1.70–1.57(m,3H),1.53-1.39(m,2H),1.23(t,J＝7.6Hz,3H),1.11(d,J＝6.9Hz,2H),1.00(t,J＝6.7Hz,1H),0.91(d,J＝6.6Hz,6H).
实施例57：(2-(1-(环戊烷羰基)哌啶-4-基)-N-(4-乙基苯基)-4-羟基-N-异丁基苯并二氢吡喃-6-磺酰胺化合物EXP 57的制备
Figure PCTCN2017087263-appb-000097
参照实施例2的方法，制备了Exp57.
LC-MS:[M+1]＝569.3
1H NMR(400MHz,CDCl3)δ7.66(d,J＝1.6Hz 1H),7.34(dd,J＝8.0,1.2Hz,1H),7.12(d,J＝8.0Hz,2H),6.97(d,J＝8.0Hz,2H),6.79(d,J＝8.4Hz,1H),4.89(br s,1H),4.42(br s,1H),4.02(br s,1H),3.35-3.17(m,2H),2.92(br s,1H),2.81(br s,1H),2.63(q,J＝7.2Hz,2H),2.30(br s,1H),2.01(s,3H),1.79-1.75(m,8H),1.57-1.54(m,5H),1.36(br s,2H),1.23(t,J＝7.6Hz,3H),0.90-0.88(m,6H).
实施例58：N-(4-乙基苯基)-8-(羟基甲基)-N-异丁基-2-(四氢-2H-吡喃-4-基)苯并二氢吡喃-6-磺酰胺化合物EXP 58的制备
Figure PCTCN2017087263-appb-000098
1)乙酸2-溴苯酯(化合物2的制备)
Figure PCTCN2017087263-appb-000099
将化合物1(10g，57.8mmol，1.0eq)溶解到100mL的二氯甲烷中，常温下加入三乙胺(12mL，86.7mmol,1.5eq)和DMAP(0.35g,2.9mmol,0.05eq)。冷却到负5度后滴加乙酰氯(36.48g，63.6mmol,1.1eq)。滴加完毕后在负5度下搅拌10分钟，然后升至室温并搅拌2小时。反应液依次用1N盐酸水溶液(200mL),饱和碳酸氢钠水溶液和饱和食盐水洗涤，无水硫酸钠干燥，旋干后柱层析纯化(纯石油醚到石油醚：乙酸乙酯＝10：1)得到无色油状化合物2(12g，55.81mmol，收率：96％)。
TLC:PE/EA＝10:1,UV 254nm
Rf(Compound 1)＝0.5
Rf(Compound 2)＝0.7
2)1-(3-溴-2-羟基苯基)乙-1-酮(化合物3)的制备
Figure PCTCN2017087263-appb-000100
将化合物2(6.0g，27.91mmol，1.0eq)溶于60mL的1，2-二氯苯中，室温下加入三氯化铝(5.6g,41.86mmol,1.5eq)，然后升温至140度并在此温度下搅拌4小时。冷却到室温后将反应液倒入1N的盐酸水溶液(200mL)中，用乙酸乙酯(2x 50mL)萃取，有机相合并后用饱和食盐水洗，无水硫酸钠干燥后旋干。残留物柱层析纯化(石油醚：乙酸乙酯＝50：1)得到棕色油状固体化合物3(1g，4.65mmol，收率：17％)。
TLC:PE/EA＝10:1,UV 254nm
Rf(Compound 2)＝0.7
Rf(Compound 3)＝0.5
3)8-溴-2-(四氢-2H-吡喃-4-基)苯并二氢吡喃-4-酮(化合物5)的制备
Figure PCTCN2017087263-appb-000101
将化合物3(1.0g，4.65mmol，1.0eq)溶解到15mL的甲醇中，然后加入化合物4(0.64g,5.58mmol,1.2eq)和四氢吡咯(0.49g,6.98mmol,1.5eq)。反应液在70度下搅拌3小时。冷却到室温后将反应液旋干，残留物柱层析纯化(石油醚：乙酸乙酯＝40：1到20：1)得到化合物5(0.8g，2.57mmol，收率：55％)。
TLC:PE/EA＝2:1,UV 254nm
Rf(Compound 3)＝0.9
Rf(Compound 5)＝0.7
4)8-溴-2-(四氢-2H-吡喃-4-基)苯并二氢吡喃-4-醇(化合物6)的制备
Figure PCTCN2017087263-appb-000102
将化合物5(600mg，1.93mmol，1.0eq)溶于10mL的甲醇中，加入硼氢化钠(219mg，5.79mmol，3.0eq)后常温搅拌2小时。将反应液旋干后将残留物中加入20mL的乙酸乙酯和10mL的水，有机相用饱和食盐水洗，无水硫酸钠干燥，旋干后得到白色固体化合物6(600mg，1.91mmol，收率：99％)。
TLC:PE/EA＝1:1,UV 254nm
Rf(Compound 5)＝0.9
Rf(Compound 6)＝0.6
5)8-溴-2-(四氢-2H-吡喃-4-基)苯并二氢吡喃(化合物7)的制备
Figure PCTCN2017087263-appb-000103
将化合物7(600mg，1.92mmol，1.0eq)溶于10mL的二氯甲烷中，冷却到负5度后依次滴加三乙基硅烷(3mL,19.17mmol,10.0eq)和三氟化硼***(2.5mL,19.17mmol,10.0eq)。在负5度下搅拌20分钟后升至室温并在室温下搅拌2小时。反应液用水洗和饱和食盐水洗，无水硫酸钠干燥，旋干后柱层析纯化(石油醚：乙酸乙酯＝5：1)得到白色固体化合物7(530mg，1.78mmol，收率：93％)。
TLC:PE/EA＝2:1,UV 254nm
Rf(Compound 6)＝0.5
Rf(Compound 7)＝0.8
6)2-(四氢-2H-吡喃-4-基)苯并二氢吡喃-8-羧酸甲酯(化合物8)的制备
Figure PCTCN2017087263-appb-000104
将化合物7(300mg，1.0mmol，1.0eq)溶于8mL的N,N-二甲基乙酰胺中，然后室温下依次加入4mL甲醇，三乙胺(556uL,4.0mmol,4.0eq)，1,3-双(二苯基磷烷基)丙烷 (82mg，0.2mmol，0.2eq)和醋酸钯(45mg,0.2mmol,0.2eq)，反应液在1个大气压的一氧化碳气氛下升至80度下搅拌过夜。冷却到室温后反应液中加入20mL的乙酸乙酯，有机相用水洗，饱和食盐水洗，无水硫酸钠干燥，旋干后柱层析纯化(石油醚：乙酸乙酯＝2：1)得到白色固体化合物8(270mg，0.98mmol，收率：98％)。
TLC:PE/EA＝2:1,UV 254nm
Rf(Compound 6)＝0.8
Rf(Compound 7)＝0.7
7)6-(氯磺酰基)-2-(四氢-2H-吡喃-4-基)苯并二氢吡喃-8-羧酸甲酯(化合物9)的制备
Figure PCTCN2017087263-appb-000105
将2mL的氯磺酸冷却到零度，然后加入化合物8(100mg，0.36mmol，1.0eq)，加完后升至室温并搅拌1小时。TLC显示原料8反应完毕。将反应液缓慢倒入冰水中，用10mL的乙酸乙酯萃取，有机相用水洗，饱和食盐水洗，无水硫酸钠干燥，旋干后柱层析纯化(石油醚：乙酸乙酯＝10：1到5：1)得到白色固体化合物9(110mg，0.29mmol，收率：81％)。
TLC:PE/EA＝2:1,UV 254nm
Rf(Compound 8)＝0.7
Rf(Compound 9)＝0.6
8)6-(N-(4-乙基苯基)-N-异丁基氨磺酰基)-2-(四氢-2H-吡喃-4-基)苯并二氢吡喃-8-羧酸甲酯(化合物11)的制备
Figure PCTCN2017087263-appb-000106
将化合物9(80mg，0.21mmol，1.0eq)溶解到2mL的吡啶中，加入化合物10(57mg，0.32mmol，1.5eq)后室温搅拌过夜。将20mL的乙酸乙酯加到反应液中，混合液用2N的盐酸水溶液(50mL)洗，分出有机相，有机相用水洗，饱和食盐水洗，无水硫酸钠干燥，旋干后柱层析纯化(石油醚：乙酸乙酯＝10：1到5：1)得到白色固体化合物11(70mg，0.13mmol，收率：65％)。
TLC:PE/EA＝2:1,UV 254nm
Rf(Compound 9)＝0.6
Rf(Compound 11)＝0.7
9)N-(4-乙基苯基)-8-(羟基甲基)-N-异丁基-2-(四氢-2H-吡喃-4-基)苯并二氢吡喃-6-磺酰胺化合物EXP 58的制备
Figure PCTCN2017087263-appb-000107
将化合物11(50mg，0.097mmol，1.0eq)溶解到3mL的THF中，加入三乙基硼氢化锂(1.0M的THF溶液，389uL，4.0eq)后室温下搅拌5小时。将20mL的乙酸乙酯加到反应液中，混合液用水洗，饱和食盐水洗，无水硫酸钠干燥，旋干后prep-HPLC(流动相：0.1％TFA/乙腈/水)纯化得到白色固体化合物EXP 58(7mg，0.014mmol，收率：15％)。
LC-MS:[M+23]＝510.2
1H NMR(400MHz,CDCl3)δ7.35(s,1H),7.20(s,1H),7.13(d,J＝8.0Hz,2H),6.99(d,J＝8.0Hz,2H),4.73-4.59(m,1H),4.09(d,J＝11.6Hz,2H),3.96-3.85(m,1H),3.49-3.43(m,2H),3.26(d,J＝7.6Hz,2H),2.84-2.72(m,4H),2.64(q,J＝7.2Hz,2H),2.07(d,J＝13.6Hz,1H),1.89(d,J＝10.1Hz,2H),1.78-1.75(m,1H),1.63-1.53(m,3H),1.23(t,J＝7.6Hz,3H),0.90(d,J＝6.6Hz,6H).
实施例59：N-环丁基-N-(2,4-二甲基苯基)-4-羟基-2-(四氢-2H-吡喃-4-基)苯并二氢吡喃-6-磺酰胺化合物EXP 59的制备
Figure PCTCN2017087263-appb-000108
参照实施例2的方法，制备了Exp59
LC-MS:[M+1]＝472.21
1H NMR(400MHz,CDCl3)δ7.75(d,J＝12.8Hz,1H),7.43-7.39(m,1H),7.04(s,1H),6.77(t,J＝8.4Hz,2H),6.34(d,J＝5.6Hz,1H),4.87-4.85(m,1H),4.51-4.36(m,1H),3.99-3.90(m,3H),3.38-3.35(m,2H),2.23-2.20(m,7H),1.95-1.64(m,7H),1.46-1.43(m,6H).
实施例60：N-(4-(二甲基氨基)苯基)-4-羟基-N-异丁基-2-(四氢-2H-吡喃-4-基)苯并二氢吡喃-6-磺酰胺化合物EXP 60的制备
Figure PCTCN2017087263-appb-000109
参照实施例2的方法，制备了Exp60
1H NMR(400MHz,CD3Cl)δ7.44(d,J＝10.0Hz,1H),7.31(s,1H),7.22(d,J＝8.8Hz,2H),7.12(d,J＝8.4Hz,2H),6.82(d,J＝8.8Hz,1H),4.74-4.69(m,1H),4.05(d,J＝11.2Hz,2H),3.95-3.86(m,1H),3.46-3.34(m,6H),3.18-3.13(m,2H),3.12(s,6H),2.31-2.25(m,1H),1.81-1.64(m,2H),1.52-1.42(m,2H),0.87-0.81(m,6H).
实施例61：N-(环丁基甲基)-N-(4-乙基苯基)-4-羟基-2-(四氢-2H-吡喃-4-基)苯并二氢吡喃-6-磺酰胺化合物EXP 61的制备
Figure PCTCN2017087263-appb-000110
参照实施例2的方法，制备了Exp61
1H NMR(400MHz,CDCl3)δ7.64(d,J＝1.2Hz,1H),7.31(dd,J＝8.4,2.0Hz,1H),7.04(d,J＝8.4Hz,2H),6.85(d,J＝8.4Hz,2H),6.74(d,J＝8.8Hz,1H),4.87-4.80(m,1H),4.01-3.98(m,2H),3.96-3.90(m,1H),3.48-3.36(m,4H),2.56(q,J＝7.6Hz,2H),2.29-2.20(m,2H),1.96(br s,2H),1.77-1.68(m,4H),1.65-1.48(m,6H),1.16(t,J＝7.6Hz,3H).
实施例62：N-(2,4-二氟苯基)-4-羟基-N-异丁基-2-(四氢-2H-吡喃-4-基)苯并二氢吡喃-6-磺酰胺化合物EXP 62的制备
Figure PCTCN2017087263-appb-000111
参照实施例2的方法，制备了Exp62
LC-MS:[M+1]＝482.17
1H NMR(400MHz,CDCl3)δ7.72(s,1H),7.36(d,J＝9.2Hz,1H),6.79-6.70(m,4H),4.85-4.83(m,1H),4.01-3.94(m,3H),3.39-3.36(m,2H),3.25-3.22(m,2H),2.31-2.23(m,1H),2.10(s,1H),1.71-1.65(m,3H),1.54-1.37(m,4H),0.85-0.82(m,6H).
实施例63：N-(4-(1,1,1,3,3,3-六氟-2-羟基丙-2-基)-2-甲基苯基)-4-羟基-N-异丁基-2-(四氢-2H-吡喃-4-基)色满-6-磺酰胺化合物EXP 63的制备
Figure PCTCN2017087263-appb-000112
参照实施例2的方法，制备了Exp63
LC-MS:[M+1]＝626.3
实施例64：N-苄基-N-(4-乙基苯基)-4-羟基-2-(四氢-2H-吡喃-4-基)苯并二氢吡喃-6-磺酰胺化合物EXP 64的制备
Figure PCTCN2017087263-appb-000113
参照实施例2的方法，制备了Exp64
1H NMR(400MHz,CDCl3)δ7.76(d,J＝1.6Hz,1H),7.43(dd,J＝8.4,2.0Hz,1H),7.24-7.18(m,5H),7.03(d,J＝8.4Hz,2H),6.92(d,J＝8.4Hz,2H),6.84(d,J＝8.4Hz,1H),4.95-4.88(m,1H),4.75-4.65(m,2H),4.06-3.98(m,3H),3.48-3.41(m,2H),2.56(q,J＝7.2Hz,2H),2.37-2.31(m,1H),1.91-1.73(m,4H),1.58-1.52(m,2H),1.17(t,J＝7.6Hz,3H).
实施例65：N-(苯并[b]噻吩-2-基)-4-羟基-N-异丁基-2-(四氢-2H-吡喃-4-基)苯并二氢吡喃-6-磺酰胺化合物EXP 65的制备
Figure PCTCN2017087263-appb-000114
参照实施例2的方法，制备了Exp65
LC-MS:[M+1]＝502.3
1H NMR(400MHz,CDCl3)δ7.73(d,J＝2.0Hz,1H),7.64-7.59(m,2H),7.38(dd,J＝8.4,2.0Hz,1H),7.29-7.21(m,2H),7.10(s,1H),6.73(d,J＝8.4Hz,1H),4.82-4.78(m,1H),4.01-3.91(m,3H),3.41-3.24(m,4H),2.27-2.22(m,1H),1.84-1.64(m,4H),1.55-1.42(m,3H),1.19(s,1H),0.90-0.88(m,6H).
实施例66：N-(4-乙基苯基)-4-羟基-N-异丁基-2-(1-(四氢-2H-吡喃-4-基)乙基)色满-6-磺酰胺化合物EXP 66的制备
Figure PCTCN2017087263-appb-000115
参照实施例2的方法，制备了Exp66
LC-MS:[M+H]＝502.3
1H NMR(400MHz,CDCl3)δ7.68(d,J＝1.6Hz,1H),7.33(dd,J＝8.6,2.2Hz,1H),7.13(d,J＝8.2Hz,2H),6.98(dd,J＝8.4,2.1Hz,2H),6.80(dd,J＝8.6,6.8Hz,1H),4.90(br s,1H),4.32(d,J＝13.2Hz,1H),4.01(br s,2H),3.41(t,J＝11.8Hz,2H),3.33-3.20(m,2H),2.64(q,J＝7.6Hz,2H),2.30-2.17(m,1H),1.98-1.90(m,1H),1.89-1.75(m,2H),1.75-1.59(m,3H),1.57-1.47(m,3H),1.23(t,J＝7.6Hz,3H),1.03-0.96(m,3H),0.96-0.89(m,6H).
实施例67：6-((6-乙基-3-甲基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-(四氢-2H-吡喃-4-基)苯并二氢吡喃-4-醇化合物EXP67的制备
Figure PCTCN2017087263-appb-000116
1)3-氯-N-(4-乙基苯基)丙酰胺(化合物3)的制备
Figure PCTCN2017087263-appb-000117
在一个100mL的三口烧瓶中，将化合物1(2.0g，16.5mmol，1.0eq),K2CO3(3.4g，24.7mmol，1.5eq)溶于H2O(40mL)和acetone(20mL)中，氩气保护下在0℃下搅拌30min。加入3-氯丙酰氯(2.7g,21.5mmol,1.3eq)，室温下搅拌16小时。将反应液倒入冰水中淬灭，用布氏漏斗抽滤，固体用水洗涤2次，最后用正己烷洗涤3次。用油泵抽干后得到白色固体化合物3(2.7g，收率：77％)。
2)6-乙基-3,4-二氢喹啉-2(1H)-酮(化合物4)的制备
Figure PCTCN2017087263-appb-000118
将化合物3(0.8g，3.8mmol，1.0eq)在120℃下搅拌融化，用氩气保护。然后少量分批加入AlCl3(0.6g，4.5mmol，1.2eq)，在此温下搅拌3h。TLC检测有新点出现。冷却到室温后加水稀释，用EA萃取，无水硫酸钠干燥，旋干过柱(PE/EA＝20:1～5:1)得到化合物4(0.1g，收率：15％)。
TLC:PE/EA＝5:1,UV 254nm
Rf(Compound 3)＝0.8
Rf(Compound 4)＝0.5
3)6-乙基-1-(4-甲氧基苄基)-3,4-二氢喹啉-2(1H)-酮(化合物5)的制备
Figure PCTCN2017087263-appb-000119
将化合物4(0.6g，3.4mmol，1.0eq)溶于DMF(2mL)准备待用，在0℃下将NaH(60％in mineral oil，0.176g，4.4mmol，1.3eq)加入3mL的DMF中，氩气保护下搅拌5min。加入化合物4的DMF溶液后在零度下搅拌30min。加入PMBCl(0.8g，5.1mmol，1.5eq)，然后升到室温并在室温下反应3h，TLC显示反应完毕。将反应液倒入冰水中，用乙酸乙酯萃取，无水Na2SO4干燥，过柱(PE:EA＝25：1～10：1),得到黄色固体化合物5(0.2g，收率：20％)
TLC:PE/EA＝5:1,UV 254nm
Rf(Compound 4)＝0.5
Rf(Compound 5)＝0.6
4)6-乙基-1-(4-甲氧基苄基)-3-甲基-3,4-二氢喹啉-2(1H)-酮(化合物6)的制备
Figure PCTCN2017087263-appb-000120
将LHMDS(1M/L，0.40mL,1.1eq)加入到THF(2mL)中，氮气保护并在0℃下搅拌5min。加入化合物5(0.1g，0.34mmol，1.0eq)的3mL THF溶液后在0℃下搅拌30min，将反应液冷却至-78℃。加入CH3I(72.3mg，0.51mmol，1.5eq)，使混合物恢复至室温并搅拌过夜。TLC显示有新点出现。加水稀释，用DCM萃取，Na2SO4干燥，过柱(PE:EA＝30:1～10:1)，得到化合物6(68mg，收率：66％)
TLC:PE/EA＝5:1,UV 254nm
Rf(Compound 5)＝0.6
Rf(Compound 6)＝0.8
5)6-乙基-3-甲基-3,4-二氢喹啉-2(1H)-酮(化合物7)的制备
Figure PCTCN2017087263-appb-000121
将化合物6(0.2g，0.6mmol，1.0eq)溶于TFA(5mL)中，然后在80度下搅拌3h，TLC显示没有原料剩余。加入5mL的饱和Na2CO3水溶液，乙酸乙酯萃取，干燥，浓缩，旋干后得到化合物7(0.1g，收率：87％)。
TLC:PE/EA＝5:1,UV 254nm
Rf(Compound 6)＝0.8
Rf(Compound 7)＝0.5
6)6-乙基-3-甲基-1,2,3,4-四氢喹啉(化合物8)的制备
Figure PCTCN2017087263-appb-000122
将化合物7(25mg，0.13mmol，1.0eq)溶于THF(2mL)中，降温至零度后加入BH3/THF(1.0M，0.4mL，3.1eq)溶液，然后零度下搅拌30min。将体系升温至80度并搅拌3h，TLC显示没有原料剩余。加入2mL的甲醇和2mL的2N盐酸水溶液，将反应体系调节PH＝7后用EA萃取，有机相用饱和氯化钠洗，无水硫酸钠干燥。浓缩后得到化合物8(18mg，收率：79％)。
TLC:PE/EA＝5:1,UV 254nm
Rf(Compound 7)＝0.5
Rf(Compound 8)＝0.8
7)6-((6-乙基-3-甲基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-(四氢-2H-吡喃-4-基)苯并二氢吡喃-4-酮(化合物10)的制备
Figure PCTCN2017087263-appb-000123
将化合物8(30mg，0.17mmol，1.0eq),化合物9(61.5mg,0.19mmol,1.1eq)混合后加入2mL吡啶。室温搅拌2h，TLC显示化合物8反应完全。加入10mL EA，用2N HCl洗反应液。有机相用饱和食盐水洗，无水硫酸钠干燥，旋干后用pre-HPLC(流动相：0.1％三氟乙酸/乙腈/水)纯化得到白色固体化合物10(6mg,收率：7％)
LC-MS:[M+1]＝470.3
1H NMR(400MHz,CDCl3)δ8.25-8.23(m,1H),7.66-7.62(m,2H),7.05-6.91(m,2H),6.82(s,1H),4.28(q,J＝7.2Hz,1H),4.14(d,J＝13.2Hz,1H),4.05(d,J＝11.9Hz,2H),3.49-3.37(m,2H),3.12-3.00(m,1H),2.73(d,J＝8.0Hz,2H),2.65-2.51(m,3H),2.19-2.07(m,1H),2.03-1.96(m,1H),1.86(d,J＝14.0Hz,1H),1.81-1.77(m,1H),1.59-1.57(m,1H),1.56-1.52(m,1H),1.31-1.26(m,1H),1.19(t,J＝7.6Hz,3H),0.96(d,J＝6.6Hz,3H).
8)6-((6-乙基-3-甲基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-(四氢-2H-吡喃-4-基)苯并二氢吡喃-4-醇化合物EXP67的制备
Figure PCTCN2017087263-appb-000124
将化合物10(70mg，0.19mmol，1.0eq)溶解到2mL的甲醇中,加入NaBH4(23mg，0.6mmol，3.2eq)后在室温下搅拌2h，TLC显示化合物10反应完全。pre-HPLC(流动相：流动相：0.1％三氟乙酸/乙腈/水)纯化后得到白色固体化合物Exp 67(6mg,收率：9％)
LC-MS:[M+1]＝472.3
1H NMR(400MHz,CDCl3)δ7.72(d,J＝11.5Hz,1H),7.67-7.64(m,1H),7.42-7.40(m,1H), 7.00(d,J＝8.4Hz,1H),6.81(s,1H),6.76(dd,J＝8.4,1.2Hz,1H),4.87-4.83(m,1H),4.17-4.02(m,3H),3.98-3.94(m,1H),3.45-3.40(m,2H),3.05-2.99(m,1H),2.56(q,J＝7.6Hz,3H),2.33-2.28(m,1H),2.15-2.02(m,1H),1.86(t,J＝11.1Hz,2H),1.79-1.69(m,2H),1.64-1.47(m,3H),1.19(t,J＝7.6Hz,3H),0.99-0.89(m,3H).
实施例68：4-(环己氧基)-N-(4-乙基苯基)-N-异丁基-2-(四氢-2H-吡喃-4-基)苯并二氢吡喃-6-磺酰胺化合物EXP68的制备
Figure PCTCN2017087263-appb-000125
将化合物1(40mg，0.084mmol，1.0eq)加入2mL DCM中，然后加入化合物2(84mg，0.84mmol，10.0eq)。将反应体系降温至-50℃后加入BF3.Et2O(17mg，0.12mmol，1.4eq)自然升温到室温后搅拌4h。用prep-HPLC(流动相：0.1％三氟乙酸/乙腈/水))纯化得到白色固体化合物Exp 68(6mg，收率：13％)。
LC-MS:[M+1]＝556.3
1H NMR(400MHz,CDCl3)δ7.62-7.31(m,2H),7.13(d,J＝8.0Hz,2H),6.99(d,J＝8.0Hz,2H),6.86-6.75(m,1H),4.63-4.44(m,1H),4.17-3.94(m,3H),3.49-3.44(m,4H),3.36-3.22(m,2H),2.63(q,J＝7.6Hz,2H),2.30-2.07(m,1H),1.89-1.53(m,13H),1.36-1.21(m,6H),0.89(d,J＝5.2Hz,6H).
实施例69：N-(6-氟-2,3-二氢-1H-茚-1-基)-4-羟基-N-异丁基-2-(四氢-2H-吡喃-4-基)苯并二氢吡喃-6-磺酰胺化合物EXP69的制备
Figure PCTCN2017087263-appb-000126
1)6-氟-N-异丁基-2,3-二氢-1H-茚-1-胺(化合物3)的制备
Figure PCTCN2017087263-appb-000127
将化合物1(1.0g,6.67mmol,1.0eq)溶于无水甲醇(10mL)和无水四氢呋喃(30mL)中。室温下，加入化合物2(1.46g,20.0mmol,3.0eq)和NaBH(CN)3(0.837g,13.3mmol,2.0eq)。65℃加热反应16h，LCMS和TLC监测反应完毕。冷却到室温，用NaHCO3淬灭，浓缩，EA萃取，无水硫酸钠干燥，旋干过柱(石油醚：乙酸乙酯＝20:1～10:1)得到化合物3(730m g,收率:52％)
TLC:PE/EA＝5:1,UV 254nm
Rf(Compound 1)＝0.8
Rf(Compound 2)＝0.4
2)N-(6-氟-2,3-二氢-1H-茚-1-基)-N-异丁基-4-氧代-2-(四氢-2H-吡喃-4-基)苯并二氢吡喃-6-磺酰胺(化合物5)的制备
Figure PCTCN2017087263-appb-000128
将化合物4(400mg,1.21mmol,1.0eq)和吡啶(191mg,2.42mmol,2.0eq)在室温下溶于二氯甲烷(20mL)中，加入化合物3(277mg,1.33mmol,1.1eq)。搅拌反应16小时，LCMS显示原料反应完，有产物生成。用稀盐酸(1M)洗涤，二氯甲烷萃取，干燥，浓缩，柱层析，得化合物淡黄色5(400mg,收率：67％)。
3)N-(6-氟-2,3-二氢-1H-茚-1-基)-4-羟基-N-异丁基-2-(四氢-2H-吡喃-4-基)苯并二氢吡喃-6-磺酰胺化合物EXP69的制备
Figure PCTCN2017087263-appb-000129
将化合物5(150mg，0.333mmol，1.0eq)和NaBH4(15.1mg，0.340mmol，1.2eq)在室温下溶于甲醇(10mL)中，搅拌1小时。TLC点板显示反应完全，有新点生成。加入饱和NH4Cl水溶液(5mL)淬灭反应，浓缩，乙酸乙酯萃取，分液，有机相用无水硫酸钠干燥，过滤，浓缩得粗品。Prep-HPLC(流动相：0.1％TFA/CH3CN/H2O)得白色固体化合物EXP69(50mg，收率：33％)。
TLC:PE/EA＝1:1,UV 254nm
Rf(Compound 5)＝0.40
Rf(Compound 69)＝0.30
LC-MS:[M+Na]＝526.2
1H NMR(400MHz,CDCl3)δ7.98(d,J＝7.6Hz,1H),7.65(d,J＝8.4Hz,1H),7.11(t,J＝8.4Hz,1H),6.90(J＝8.4Hz,2H),6.60(t,J＝8.4Hz,1H),5.41(t,J＝8.4Hz,1H)),4.98-4.97(m,1H),4.11(d,J＝5.2Hz,2H),4.04-4.00(m,1H),3.48(t,J＝8.4Hz,2H),3.35(br s,1H),2.70-2.29(m,4H),2.36-2.34(m,1H),2.27-2.19(m,1H),1.96-1.80(m,4H),1.67-1.56(m,4H),0.82-0.74(m,6H).
实施例70：N-(4-乙基苯基)-4-羟基-N-(氧杂环丁烷-3-基)-2-(四氢-2H-吡喃-4-基)苯并二氢吡喃-6-磺酰胺化合物EXP70的制备
Figure PCTCN2017087263-appb-000130
1)N-(4-乙基苯基)氧杂环丁烷-3-胺(化合物3)的制备
Figure PCTCN2017087263-appb-000131
将化合物1(500mg，4.13mmol，1.0eq)在室温下溶于6mL甲醇中,加入化合物2(298mg，4.13mmol，1.0eq),室温搅拌1小时,在0℃缓慢加入NaBH(OAc)3(876mg，4.13mmol，1.0eq)，室温搅拌半小时。TLC板检测反应完全。将溶剂旋干，拌样，过柱(PE:EA＝30:1),得到化合物3(110mg,收率：10％)。
TLC:PE/EA＝5:1,UV 254nm
Rf(Compound 1)＝0.1
Rf(Compound 3)＝0.4
2)N-(4-乙基苯基)-N-(氧杂环丁烷-3-基)-4-氧代-2-(四氢-2H-吡喃-4-基)苯并二氢吡喃-6-磺酰胺(化合物5)的制备
Figure PCTCN2017087263-appb-000132
将化合物3(187mg，0.56mmol，1.0eq)在室温下溶于10mL吡啶中,加入化合物4(100mg，0.56mmol，1.0eq),室温搅拌4小时，LC-MS显示大部分是产品，然后旋干溶于DMF去制备纯化，得到化合物KFP-010-149(80mg)。(制备流动相：0.1％TFA/H2O/CH3CN)。
1H NMR(400MHz,CD3Cl)δ8.04(d,J＝2.4Hz,1H),7.35(dd,J＝8.4,2.4Hz,1H),7.05(d,J＝8.0Hz,2H),6.90(d,J＝8.8Hz,1H),6.76(d,J＝8.4Hz,2H),4.84-4.76(m,1H),4.58-4.51(m,4H),4.28-4.23(m,1H),4.04-3.98(m,2H),3.42-3.33(m,2H),2.69(d,J＝8.4Hz,2H),2.56(q,J＝7.2Hz,2H),1.98-1.92(m,1H),1.58-1.46(m,4H),1.16(t,J＝7.6Hz,3H).
3)N-(4-乙基苯基)-4-羟基-N-(氧杂环丁烷-3-基)-2-(四氢-2H-吡喃-4-基)苯并二氢吡喃-6-磺酰胺化合物EXP70的制备
Figure PCTCN2017087263-appb-000133
将化合物5(70mg，0.15mmol，1.0eq)在室温下溶于10mL甲醇中,加入化合物NaBH4(12mg，0.3mmol，2.0eq),室温搅拌1小时，LC-MS显示大部分是产品，然后旋干溶于DMF去制备纯化，得到化合物EXP 70(28mg)。(制备流动相：0.1％TFA/H2O/CH3CN)。
1H NMR(400MHz,CDCl3)δ7.59(d,J＝1.2Hz,1H),7.27-7.24(m,1H),7.14(d,J＝8.4Hz,2H),6.85(d,J＝8.4Hz,2H),6.81(d,J＝8.8Hz,1H),4.92-4.81(m,2H),4.67-4.63(m,2H),4.60(d,J＝7.2Hz,2H),4.12-4.05(m,2H),4.05-3.99(m,1H),3.49-3.41(m,2H),2.65(q,J＝7.6Hz,2H),2.40-2.32(m,1H),1.87-1.73(m,2H),1.63-1.50(m,4H),1.25(t,J＝7.6Hz,3H).
实施例71 RORγt抑制剂荧光素酶报告基因实验
实验材料和仪器：
Figure PCTCN2017087263-appb-000134
Figure PCTCN2017087263-appb-000135
其中SR1001为RORγt的反向激动剂，作为阳性参照物，其结构为：
Figure PCTCN2017087263-appb-000136
实验步骤：
1、第一天细胞种板。293T贴壁细胞加1mL胰酶消化5min左右，用移液器吸取已消化好的细胞，转移至15mL离心管中，1000rpm，5min离心。弃旧培养基，用新鲜培养基重悬细胞并稀释至所需密度。
2、细胞计数。按细胞密度1.5万个/孔，配制细胞悬液。种板，每孔100μL细胞。为了防止边缘效应，96孔细胞培养板只种板中间的60个孔，四周36个孔用每孔100μL PBS补齐。37℃，5％CO2培养箱培养细胞。
3、细胞种板后24小时方做细胞瞬时转染实验。配制瞬转质粒(即Gal4-RORγ-LBD：25ng/孔；PgL4.3-luc：25ng/孔)、转染试剂(脂质体2000浓度是DNA的3倍)。
4、待转染试剂稀释后孵育5min，将转染试剂和质粒混合孵育20min，然后每孔加10μL。瞬时转染5h以上即可加小分子化合物(SR1001或Exp1-Exp34的化合物)。
5、根据需要，先将待检测化合物用含10％胎牛血清的DMEM细胞培养基3倍比稀释(100～0.195μM)，然后将细胞培养板中的已有培养基吸出，之后加入已配制好的待检测化合物及新鲜培养基。
6、然后放入37℃，5％CO2培养箱培养细胞。大约24h后将细胞取出，镜下观察细胞生长情况，将细胞培养板拿出细胞间。然后做荧光素酶双报告基因检测实验。
7、首先将细胞培养基吸弃，然后加入大约100μL PBS洗残留培养基。将母液5×的细胞裂解液稀释成1×后，每孔加20μL，然后振荡大约20min将细胞裂解。
8、将细胞转入白色不透光96孔检测板。然后使用En Spire Alpha 2390均相发光免疫检测***测试实验结果：加已配置好的萤火虫荧光素底物检测化合物干扰后的细胞活性。
9、抑制活性的计算：
Figure PCTCN2017087263-appb-000137
10、实验结果：
化合物 RORγt活性半数抑制浓度(IC50)
Exp 1 ++
Exp 2 ++++
Exp 3 ++++
Exp 4 +++
Exp 5 +
Exp 6 +++
Exp 7 ++
Exp 8 +++
Exp 9 ++++
Exp 10 +
Exp 11 +
Exp 12 ++++
Exp 13 ++++
Exp 14 ++
Exp 15 ++++
Exp 16 +++
Exp 17 ++++
Exp 18 ++++
Exp 19 +++
Exp 20 ++
Exp 21 ++
Exp 22 +
Exp 23 +++
Exp 24 ++
Exp 25 +++
Exp 26 NA
Exp 27 NA
Exp 28 ++++
Exp 29 +++
Exp 30 +++
Exp 31 ++
Exp 32 ++++
Exp 33 +
Exp 34 NA
Exp 35 ++++
Exp 36 +
Exp 37 +++
Exp 38 +
Exp 39 ++++
Exp 40 +++
Exp 41 +
Exp 42 +++
Exp 43 +++
Exp 44 +++
Exp 45 +++
Exp 46 +
Exp 47 +++
Exp 48 ++
Exp 49 +
Exp 50 ++++
Exp 51 ++++
Exp 52 +
Exp 53 ++
Exp 54 ++
Exp 55 ++
Exp 56 +++
Exp 57 +
Exp 58 ++++
Exp 59 ++++
Exp 60 ++++
Exp 61 ++++
Exp 62 +++
Exp 63 ++++
Exp 64 +++
Exp 65 ++++
Exp 66 ++++
Exp 67 NA
Exp 68 +
Exp 69 +++
Exp 70 ++
SR1001 21510
++++表示IC50<50nM；+++表示IC50范围为50～200nM；++表示IC50范围为200～1000nM；+表示IC50>1000nM；NA表示未检测。
实施例72 RORγt结合实验
1.试剂和耗材：
Figure PCTCN2017087263-appb-000138
Figure PCTCN2017087263-appb-000139
2.化合物管理：
2.1化合物储存：将化合物溶解在DMSO中，制成10mM储液。
2.2化合物保存：所有溶解在DMSO中的化合物，短期内储存在干燥器中，室温不超过3个月。长期则保存于-20℃。
2.3准备化合物：
a)所有的化合物用DMSO进行3倍梯度稀释，10个稀释梯度，起始浓度为500uM。
b)阳性对照化合物用DMSO进行3倍梯度稀释，10个稀释梯度，起始浓度为25uM。
c)准备50x的阳性对照(25uM的阳性对照化合物)和50x的阴性对照(100％DMSO)。
d)将化合物板子封闭并震荡5分钟。
3.实验过程：
3.1制备反应buffer：将DTT和KF溶解在1x buffer D中。终浓度：DTT 5mM，KF50mM。
3.2检测化合物:
a)在buffer中准备2x梯度稀释的化合物(见步骤2.3)。
b)在384孔的反应板子中加入10ul 2x梯度稀释的化合物(见步骤a)。
c)用冷冻的buffer制备2x的反应物：RORγ-LBD(40nM),SRC(100nM),anti-GST Eu(1:200)和链酶青霉素-D2(25nM)。
d)在384孔反应板子(见步骤b)中加入10ul 2x反应物(见步骤c)。
e)将384孔反应板离心，1000g，1min。
f)室温避光孵育1小时。
g)检测板子：波长665nm和615nm；仪器：多标记微孔板检测仪。
4.数据分析
4.1相对比率(RR):计算每个孔的相对比例[(665nm响应值/615nm响应值-空白背景响应值)*1000]。
4.2百分抑制率(％Inhibition)的计算如下：
Figure PCTCN2017087263-appb-000140
4.3计算化合物的IC50和量效曲线:通过计算得到的化合物的抑制率和化合物浓度的log值，利用Graphpad 5.0，得到化合物的IC50和量效曲线。
4.4检查报告：
4.4.1一个实验员完成报告，另一个实验员再次检查报告，以确保数据的准确性。
4.4.1.1数据从检测仪器中导出并手动进行分析。
4.4.1.2将比率转化为百分抑制率。利用Graphpad5.0软件和百分抑制率第一次计算出化合物的IC50。
4.4.1.3用比率计算化合物的IC50，用本次的IC50检查数据的准确性。
4.4.2确定所有化合物的名称是否正确。
4.5数据标准：Z factor>0.5；S/B>3；
阳性对照化合物的IC50在历史平均数值的3倍范围内。
5.数据结果:
化合物 RORγt活性半数抑制浓度(IC50)
Exp 1 17nM
Exp 2 2.6nM
Exp 6 25nM
Exp 32 6.6nM
Exp 35 13nM
Exp 39 12nM
Exp 50 4.1nM
Exp 51 5.2nM
Exp 58 1.4nM
Exp 60 2.7nM
Exp 61 0.5nM
SR1001 255nM
通过上述实验结果可以看出，式(I)化合物对RORγt有明显的抑制作用，而RORγt在炎性、代谢性和自身免疫性疾病中有非常重要的作用，抑制RORγt将使得这些疾病得到缓解或有效治疗。特别是RORγt抑制剂用于治疗呼吸***疾病(例如哮喘、COPD)、自身免疫性疾病(如类风湿性关节炎、银屑病、溃疡性结肠炎、克罗恩氏病)的用途被深入研究和认可。

Claims (25)

  1. 结构如式(I)所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药：
    Figure PCTCN2017087263-appb-100001
    其中，
    R1、R2各自独立的选自氢、卤素、羟基、氨基、C1-C6烷基、C1-C6烷基胺基、C1-C6烷氧基、C3-C8环烷基氧基，或者R1、R2合并为氧代基；
    R4选自氢、任意取代的C1-C6烷基、任意取代的C3-C8环烷基、任意取代的C2-C8杂环烷基、任意取代的-CH2C3-C8环烷基、任意取代的C6-C10芳基或任意取代的C2-C10杂芳基，取代基选自氢、卤素、羟基、氨基、C1-C6烷基、C1-C6卤代烷基或C3-C8环烷基；
    R5选自任意取代的C6-C10芳基、任意取代的-CH2C6-C10芳基、任意取代的C2-C10杂芳基或任意取代的-CH2C2-C10杂芳基，取代基选自氢、卤素、氰基、C1-C6烷基、氨基、C1-C3烷基胺基、C2-C8杂环烷基、C1-C2烷基C4-C8杂环烷基、C3-C8环烷基、C1-C6烷氧基、C1-C6卤代烷基、羟基C1-C6卤代烷基或-S(O2)C1-C6烷基；
    R6选自氢、卤素、羟基、氨基、任意取代的C1-C6烷基，取代基选自氢、卤素、羟基、氨基或C1-C6烷基；
    R3为基团-(CHR7)s-(Y)t-(CHR8)u-R9；
    R7、R8独立选自氢、C1-C6烷基、羟基；
    Y选自C1-C6烷基、NH或O；
    R9选自任意取代的C2-C8杂环烷基、任意取代的C3-C8环烷基、任意取代的C6-C10芳基或任意取代的C2-C10杂芳基，取代基选自H、C1-C6烷基、卤素取代的C1-C6烷基、羟基取代的C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基、-S(O2)C1-C6烷基、-S(O2)(CH2)mC3-C8环烷基、-S(O2)(CH2)m C2-C8杂环烷基、-C(O)C1-C6烷基、-C(O)(CH2)mC3-C8环烷基、-C(O)(CH2)m C2-C8杂环烷基、C2-C10杂芳基、C6-C10芳基、羟基或卤素；
    m选自0、1、2；
    s、t、u独立地选自0、1、2；
    X选自O、NR10、CR10；
    R10选自氢、C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基；
    n选自0、1。
  2. 根据权利要求1中所述的式(I)化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药，其特征在于，所述R5选自任意取代的以下基团：苯环、吡啶环、苯并噻吩、嘧啶环、哒嗪环、吡嗪环、喹啉、异喹啉、吡咯环、吡唑环、咪唑环、噻吩环、噻唑环、呋喃环或噁唑环；取代基选自氢、卤素、氰基、C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基、C1-C6烷氧基、C1-C6卤代烷基、C1-C3烷基胺基或-S(O2)C1-C6烷基。
  3. 根据权利要求2中所述的式(I)化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药，其特征在于所述R5选自任意取代的苯环、任意取代的苯并噻吩或任意取代的吡啶环；取代基选自氢、卤素、氰基、C1-C6烷基、C2-C8杂环烷基、C1-C6烷氧基、C1-C6卤代烷基、C1-C3烷基胺基或-S(O2)C1-C6烷基。
  4. 根据权利要求1中所述的式(I)化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药，其特征在于，所述R9选自任意取代的以下基团：氧杂环丙烷、氧杂环丁烷、环丁烷、异噁唑、四氢呋喃、四氢-2H-吡喃、氮杂环丁烷、吡咯烷、哌啶、吗啉、吡啶、吗啉-3-酮或硫代吗啉1,1-二氧化物；取代基选自H、C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基、-S(O2)C1-C6烷基、-S(O2)(CH2)mC3-C8环烷基、-S(O2)(CH2)m C2-C8杂环烷基、-C(O)C1-C6烷基、-C(O)(CH2)mC3-C8环烷基、-C(O)(CH2)m C2-C8杂环烷基、C2-C10杂芳基、C6-C10芳基、羟基取代的C1-C6烷基、羟基或卤素。
  5. 根据权利要求4中所述的式(I)化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药，其特征在于，所述R3为-CH2R9或-R9；R9选自任意取代的以下基团：氧杂环丙烷、氧杂环丁烷、环丁烷、异噁唑、四氢呋喃、四氢-2H-吡喃、氮杂环丁烷、吡咯烷、哌啶、吗啉、吡啶、吗啉-3-酮或硫代吗啉1,1-二氧化物；取代基选自H、C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基、-S(O2)C1-C6烷基、-S(O2)(CH2)mC3-C8环烷基、-S(O2)(CH2)m C2-C8杂环烷基、-C(O)C1-C6烷基、-C(O)(CH2)mC3-C8环烷基、-C(O)(CH2)m C2-C8杂环烷基、C2-C10杂芳基、C6-C10芳基、羟基取代的C1-C6烷基、羟基或卤素。
  6. 根据权利要求5中所述的式(I)化合物或其立体异构体、互变异构体或其药学上 可接受的盐或其溶剂合物或者前药，其特征在于，所述R9选自任意取代的以下基团：氧杂环丁烷、环丁烷、异噁唑、四氢呋喃、四氢-2H-吡喃、吡咯烷、哌啶、吗啉、吡啶；取代基选自H、C1-C6烷基、卤素取代的C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基、-S(O2)C1-C6烷基、-S(O2)(CH2)mC3-C8环烷基、-S(O2)(CH2)m C2-C8杂环烷基、-C(O)C1-C6烷基、-C(O)(CH2)mC3-C8环烷基、-C(O)(CH2)m C2-C8杂环烷基、羟基取代的C1-C6烷基、羟基或卤素。
  7. 根据权利要求1中所述的式(I)化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药，其特征在于，其中X选自O、NH或CH2。
  8. 根据权利要求7中所述的式(I)化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药，其特征在于，其中X为O或NH。
  9. 根据权利要求1中所述的式(I)化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药，其特征在于，R1、R2各自独立的选自氢、羟基、卤素、氨基、C1-3烷基、C1-C3烷氧基、C3-C6环烷基氧基或者R1、R2合并为氧代基。
  10. 根据权利要求1中所述的式(I)化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药，其特征在于，R4选自氢、任意取代的C1-C6烷基、任意取代的C3-C8环烷基、任意取代的C2-C6杂环烷基、任意取代的-CH2C3-C6环烷基、任意取代的C6-C10芳基或任意取代的C2-C8杂芳基，取代基选自氢、卤素、羟基、氨基、C1-C6烷基或C3-C6环烷基。
  11. 根据权利要求1中所述的式(I)化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药，其特征在于，R6选自氢、卤素、任意取代的C1-C6烷基，取代基选自氢、卤素、羟基、氨基或C1-C6烷基；
  12. 权利要求1中所述的式(I)化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药，其特征在于，其中：
    X为O；
    n为0或1；
    R1、R2各自独立的选自氢、羟基、卤素、氨基、C1-C3烷基、C1-C3烷氧基，或者R1、R2合并为氧代基；
    R4选自氢、任意取代的C1-C6烷基、任意取代的C3-C6环烷基、任意取代的C4-C8杂环烷基、任意取代的-CH2C3-C8环烷基或任意取代的C6-C10芳基，取代基选自氢、卤素、 羟基、氨基、C1-C3烷基或C3-C8环烷基；
    R5选自任意取代的苯环、任意取代的苯并噻吩或任意取代的吡啶环；取代基选自氢、卤素、氰基、C1-C3烷基、C1-C3烷氧基、C1-C3卤代烷基、C1-C3烷基胺基或-S(O2)C1-C3烷基；
    R6选自氢、卤素、任意取代的C1-C6烷基，取代基选自氢、卤素、羟基、氨基或C1-C6烷基；
    R3为-CH2R9或-R9；R9选自任意取代的以下基团：氧杂环丁烷、环丁烷、四氢呋喃、四氢-2H-吡喃、吡咯烷、哌啶、吗啉、吡啶；取代基选自H、C1-C3烷基、卤素取代的C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基、-S(O2)C1-C3烷基、羟基或卤素。
  13. 结构如式Ia-Ij任一结构所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药：
    Figure PCTCN2017087263-appb-100002
    其中：R3、R4、R5、R6和n的定义如权利要求1中所述。
  14. 根据权利要求13所述的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药，其特征在于，其中：
    R3选自基团-(CHR7)s-(Y)t-(CHR8)u-R9；
    R7、R8独立选自氢、C1-C6烷基、羟基；
    Y选自C1-C6烷基、NH或O；
    s、t、u独立地选自0、1、2；
    R9选自任意取代的以下基团：氧杂环丙烷、氧杂环丁烷、环丁烷、异噁唑、四氢呋喃、四氢-2H-吡喃、氮杂环丁烷、吡咯烷、哌啶、吗啉、吡啶、吗啉-3-酮或硫代吗啉1,1-二氧化物；取代基选自H、C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基、-S(O2)C1-C6烷基、-S(O2)(CH2)mC3-C8环烷基、-S(O2)(CH2)m C2-C8杂环烷基、-C(O)C1-C6烷基、-C(O)(CH2)mC3-C8环烷基、-C(O)(CH2)m C2-C8杂环烷基、C2-C10杂芳基、C6-C10芳基、羟基取代的C1-C6烷基、羟基或卤素；
    R4选自氢、任意取代的C1-C6烷基、任意取代的C3-C8环烷基、任意取代的C2-C6杂环烷基、任意取代的-CH2C3-C8环烷基、任意取代的C6-C10芳基或任意取代的C2-C8杂芳基，取代基选自氢、卤素、羟基、氨基、C1-C6烷基、C3-C6环烷基或C3-C6环烷基；
    R5选自任意取代的以下基团：苯环、吡啶环、苯并噻吩、嘧啶环、哒嗪环、吡嗪环、喹啉、异喹啉、吡咯环、吡唑环、咪唑环、噻吩环、噻唑环、呋喃环或噁唑环；取代基选自氢、卤素、氰基、C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基、C1-C6烷氧基、C1-C6卤代烷基、C1-C3烷基胺基或-S(O2)C1-C6烷基；
    R6选自氢、卤素、任意取代的C1-C6烷基，取代基选自氢、卤素、羟基、氨基或C1-C6烷基。
  15. 结构如式Ia-Ie、Ih、Ii或Ij所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药：
    Figure PCTCN2017087263-appb-100003
    Figure PCTCN2017087263-appb-100004
    其中，R3、R4、R5、R6和n的定义如权利要求1所述。
  16. 结构如式Ia-Ie或Ij任一所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药：
    Figure PCTCN2017087263-appb-100005
    其中：R3、R4、R5、R6和n的定义如权利要求14所述。
  17. 根据权利要求16所述的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药，其特征在于，其中：
    R5选自任意取代的苯环、任意取代的苯并噻吩或任意取代的吡啶环；取代基选自氢、卤素、氰基、C1-C6烷基、C1-C6烷氧基、C1-C6卤代烷基、C1-C3烷基胺基或-S(O2)C1-C6烷基；
    R3为-CH2R9或-R9；R9选自任意取代的以下基团：氧杂环丁烷、环丁烷、四氢呋喃、四氢-2H-吡喃、氮杂环丁烷、吡咯烷、哌啶、吗啉、吡啶；取代基选自H、C1-C6烷基、卤素取代的C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基、-S(O2)C1-C6烷基、羟基或卤素。
  18. 根据权利要求17所述的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药，其特征在于，其中：R9选自任意取代的四氢-2H-吡喃、任意取代的哌啶、任意取代的氧杂环丁烷或任意取代的环丁烷；取代基选自H、C1-C6烷基、C2-C8杂环烷基、C3-C8环烷基、-S(O2)C1-C6烷基、羟基或卤素。
  19. 根据权利要求1所述的式(I)化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药，其特征在于，所述化合物选自：
    Figure PCTCN2017087263-appb-100006
    Figure PCTCN2017087263-appb-100007
    Figure PCTCN2017087263-appb-100008
  20. 权利要求1所述式(I)化合物的制备方法，其特征在于，所述方法选自路线1、路线2或路线3：
    路线1：
    Figure PCTCN2017087263-appb-100009
    路线2：
    Figure PCTCN2017087263-appb-100010
    路线3：
    Figure PCTCN2017087263-appb-100011
    其中，R1、R2、R3、R4、R5、R6、X和n的定义如权利要求1中所述。
  21. 一种药物组合物，其特征在于，其包括一种或多种权利要求1-19中任一项所述化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药，和一种或多种药学上可接受的辅料。
  22. 权利要求1-19中任一项所述的化合物或立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药，其在用于制备治疗RORγ介导的疾病的药物中的应 用。
  23. 根据权利要求22所述的应用，其特征在于所述疾病为炎性、代谢性或自身免疫性疾病。
  24. 权利要求23所述的应用，其特征在于所述炎性、代谢性或自身免疫性疾病为哮喘、慢性阻塞性肺病、支气管炎、过敏性鼻炎、异位性皮肤炎、囊性纤维化、肺同种异体移植排斥、多发性硬化症、类风湿性关节炎、青少年类风湿性关节炎、骨关节炎、强直性脊柱炎、***性红斑狼疮、银屑病、桥本氏病、胰腺炎、自身免疫性糖尿病、自身免疫性眼病、溃疡性结肠炎、克罗恩氏病、炎性肠病、炎性肠综合征、斯耶格伦氏综合征、视神经炎、I型糖尿病、视神经脊髓炎、重症肌无力、葡萄膜炎、格林-巴利综合征、银屑病关节炎、格雷氏病或巩膜炎。
  25. 如权利要求24所述的应用，其特征在于，所述疾病为哮喘、类风湿性关节炎、银屑病、溃疡性结肠炎或克罗恩氏病。
PCT/CN2017/087263 2016-12-21 2017-06-06 一类色满-6-磺酰胺RORγ调节剂及其用途 WO2018113201A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201611195147.6 2016-12-21
CN201611195147.6A CN108218845B (zh) 2016-12-21 2016-12-21 一类色满-6-磺酰胺RORγ调节剂及其用途

Publications (1)

Publication Number Publication Date
WO2018113201A1 true WO2018113201A1 (zh) 2018-06-28

Family

ID=62624351

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/087263 WO2018113201A1 (zh) 2016-12-21 2017-06-06 一类色满-6-磺酰胺RORγ调节剂及其用途

Country Status (2)

Country Link
CN (1) CN108218845B (zh)
WO (1) WO2018113201A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109574970A (zh) * 2018-12-27 2019-04-05 上海毕得医药技术有限公司 一种5-溴苯并二氢吡喃的合成方法
CN112107583A (zh) * 2020-07-31 2020-12-22 东南大学 一种色满-6-磺酰胺RORγ调节剂的A晶型化合物的组合物及其制备方法和应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110734437B (zh) * 2018-07-19 2022-04-08 南京烁慧医药科技有限公司 吡唑并嘧啶化合物和药物组合物及其应用
CN115974647A (zh) * 2022-12-05 2023-04-18 江苏宏邦化工科技有限公司 以四氢-4-甲基-2-苯基-2h-吡喃-4-醇为原料制备苯乐戊醇的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032475A1 (en) * 1997-12-19 1999-07-01 Bayer Corporation Novel sulfonamide substituted chroman derivatives useful as beta-3 adrenoreceptor agonists
WO2016097392A1 (fr) * 2014-12-19 2016-06-23 Galderma Research & Development Dérivés tétrahydroquinolines sulfonamides en tant qu'agonistes inverses du récepteur gamma orphelin associé aux rétinoïdes ror gamma (t)
WO2016185342A1 (en) * 2015-05-15 2016-11-24 Aurigene Discovery Technologies Limited Substituted tetrahydroquinolinone compounds as ror gamma modulators

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105272904B (zh) * 2014-07-18 2019-04-09 中国科学院广州生物医药与健康研究院 N-苯基酰胺类化合物及其应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032475A1 (en) * 1997-12-19 1999-07-01 Bayer Corporation Novel sulfonamide substituted chroman derivatives useful as beta-3 adrenoreceptor agonists
WO2016097392A1 (fr) * 2014-12-19 2016-06-23 Galderma Research & Development Dérivés tétrahydroquinolines sulfonamides en tant qu'agonistes inverses du récepteur gamma orphelin associé aux rétinoïdes ror gamma (t)
WO2016097394A1 (fr) * 2014-12-19 2016-06-23 Galderma Research & Development Dérivés sulfonamides bicycliques en tant qu'agonistes inverses du récepteur gamma orphelin associé aux rétinoïdes ror gamma (t)
WO2016185342A1 (en) * 2015-05-15 2016-11-24 Aurigene Discovery Technologies Limited Substituted tetrahydroquinolinone compounds as ror gamma modulators

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109574970A (zh) * 2018-12-27 2019-04-05 上海毕得医药技术有限公司 一种5-溴苯并二氢吡喃的合成方法
CN112107583A (zh) * 2020-07-31 2020-12-22 东南大学 一种色满-6-磺酰胺RORγ调节剂的A晶型化合物的组合物及其制备方法和应用

Also Published As

Publication number Publication date
CN108218845B (zh) 2022-11-29
CN108218845A (zh) 2018-06-29

Similar Documents

Publication Publication Date Title
AU2019204244B2 (en) Cyclopropylamines as lsd1 inhibitors
US9604980B2 (en) Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors
TWI631097B (zh) 作爲ｓ１ｐ調節劑及／或ａｔｘ調節劑之化合物
JP2020023529A6 (ja) Ｌｓｄ１阻害剤としてのシクロプロピルアミン類
TW201839000A (zh) 作為a2a抑制劑的硫胺甲酸酯衍生物以及用於癌症治療的方法
ES2583528T3 (es) Compuesto de pirazoloquinolina
PT1370552E (pt) Inibidores de rho-quinase
WO2018113201A1 (zh) 一类色满-6-磺酰胺RORγ调节剂及其用途
CN112312904A (zh) 螺环化合物
CA2830882A1 (en) Substituted fused tricyclic compounds, compositions and medicinal applications thereof
JP2017525677A (ja) 治療用化合物及びその使用方法
ES2784398T3 (es) Compuestos heterocíclicos de 3,3-difluoropiperidina carbamato como antagonistas del receptor de NMDA NR2B
BR112020019399A2 (pt) Compostos macrocíclicos como inibidores de trk quinases
CN116583502A (zh) 二环-杂环衍生物及其作为食欲素-2受体激动剂的用途
AU2013292782A1 (en) Fused triazole derivatives as gamma secretase modulators
ES2396126T3 (es) Compuesto de 3-fenilpirazol[5,1-b]tiazol
TW202245753A (zh) 用於治療疾病之類似物
TW202033520A (zh) 用作fgfr4抑制劑的稠環衍生物
KR102656524B1 (ko) 연골형성을 유도하기 위한 화합물 및 조성물
TW202214603A (zh) 一種噠嗪類衍生物游離鹼晶型及其製備方法和應用
CA2938459A1 (en) Antibacterial compounds
WO2021027647A1 (zh) 桥杂环基取代的嘧啶类化合物及其制备方法和医药用途
KR101820541B1 (ko) 8-옥소디히드로퓨린 유도체
EA027177B1 (ru) Макролидные производные, их получение и их терапевтическое использование
CN116783183A (zh) 作为vhl抑制剂用于治疗贫血和癌症的1-(2-(4-环丙基-1h-1,2,3-***-1-基)乙酰基)-4-羟基-n-(苄基)吡咯烷-2-甲酰胺衍生物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17884739

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17884739

Country of ref document: EP

Kind code of ref document: A1